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ABSTRACT 
 
 
Biomaterial implantation gives rises to an inflammatory response, starting with an acute 
inflammatory response mediated by innate immune cells, namely macrophages and their 
mediators. If the inflammatory response is not well resolved, leading to a chronic 
inflammatory response and material encapsulation, the biological function of the implanted 
biomaterial is compromised. So, it is fundamental to understand how macrophages will 
recognize and respond to a specific biomaterial. 
 
For the development of this doctoral dissertation work, we hypothesized that modulating 
the macrophage response to biomaterials, using an immunomodulatory material that will be 
able to shift macrophage polarization towards a M2 anti-inflammatory, pro-reparative 
phenotype we could improve implant tissue integration and tissue repair. So, herein we 
aimed to: (i) understand the role of NOD-like receptor family pyrin domain containing 
3 (NLRP3) inflammasome in the macrophage response to macroscopic 3D chitosan (Ch) 
scaffolds with different degrees of acetylation (DA); (ii) develop an immunomodulatory 
biomaterial using Resolvin D1 (RvD1) incorporated in Ch scaffolds to modulate 
inflammation through M2 macrophage polarization; (iii) assess in an in vivo model of bone 
tissue injury the ability of the developed material to improve bone healing, using a rat model 
of femoral bone defect.  
 
To accomplish our aims, we started by investigating how 3D Ch scaffolds affect 
inflammasome activation. Opposite to what is described, we found that Ch scaffolds per se 
were not able to activate NLRP3 inflammasome neither in mouse or human macrophages. 
Importantly, Ch scaffolds with different DA promoted a general decrease of interleukin (IL)-
1b release, NLRP3 inflammasome oligomers and cell death after NLRP3 inflammasome 
activation, in both cell types. Finally, we observed that 3D Ch scaffolds impaired the priming 
step of inflammasome activation, decreasing the pro-IL-1b protein expression in mouse 
macrophages and NLRP3 protein expression in human macrophages. 
 
The role of macrophages on the outcome of tissue repair, lead us to develop an 
immunomodulatory biomaterial capable to modulate the inflammatory response through M2 
macrophage polarization. To achieve this goal, we incorporated RvD1, an endogenous pro-
resolving mediator with essential roles in the resolution of the inflammatory response, in 3D 
Ch scaffolds. A general decrease of inflammatory cells recruited to the implanted site and 
also to the implant itself was observed with Ch + RvD1 lyophilized. More notably, the Ch + 
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RvD1 lyophilized was able to increase the percentage of M2 macrophages and decrease 
the percentage of M1 macrophages leading to an improvement of M2:M1 ratio that has 
been pointed as a good prognosis for tissue repair. Importantly, a general decrease of pro-
inflammatory cytokines in the inflammatory exudates was also verified with Ch + RvD1 
lyophilized, corroborating the phenotypic change observed in macrophages by the analysis 
of specific cell markers.  
 
Afterwards we verified in vivo the ability of the developed material to improve bone repair 
in a model of bone injury. We observed a slightly increase in new bone formation (BV/TV), 
a significant increase in bone trabecular thickness (Tb.Th) and collagen (Coll) type I. It is 
important to mention that an increment of Tb.Th and Coll type I is indicator of bone quality 
and strength. These outcomes advocated that RvD1 has a positive effect on bone healing. 
 
In order to obtain a sustained release of RVD1 and also to increase its activity through time, 
solid lipids nanoparticles (SLNs) were used as the delivery system. RvD1-loaded SLNs 
were successfully developed and tested to assess its capacity to decrease the pro-
inflammatory cytokines (IL-6 and tumour necrosis factor (TNF)-a) in human macrophages 
stimulated with lipopolysaccharide (LPS). The results demonstrated that RvD1-loaded 
SLNs presented an anti-inflammatory effect and are non-toxic to macrophages.  
 
The work developed in the scope of this thesis contributed to further dissect the role of 
NLRP3 inflammasome in macrophage response to macroscopic materials. Particularly, we 
showed that 3D Ch scaffolds per se were not able to induce NLRP3 inflammasome 
activation, which is an important aspect in the context of tissue repair. Additionally, we were 
able to develop an immunomodulatory material, that promote the shift from M1 (pro-
inflammatory) macrophage phenotype to a M2 (anti-inflammatory, pro-reparative) 
macrophage phenotype. Although the material did not enhance substantially bone healing, 
we were able to improve the formation of new bone of high quality. Consequently, we 
started to develop a new strategy to increase the half-life and the release time of RvD1. The 
promising results indicated that RvD1-loaded SLNs could be used to promote bone healing.  
 
Taken together, the results obtained will impact the development of new strategies and new 
targets to modulate inflammatory response to biomaterials, and thus improve 
biomaterial/tissue integration and tissue repair. 
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RESUMO 
 
 
O processo de implantação de um biomaterial dá origem a uma resposta inflamatória, que 
se inicia com uma resposta aguda, mediada por células do sistema imune inato, 
nomeadamente macrófagos e mediadores inflamatórios produzidos por estas células. 
Quando a resposta inflamatória persiste, leva a uma resposta crónica e ao encapsulamento 
do material e consequentemente a sua função biológica é comprometida. É por isso 
fundamental perceber como é que os macrófagos irão reconhecer e responder a um 
determinado material.  
 
Deste modo, o trabalho desenvolvido nesta tese de Doutoramento foi sustentado na 
hipótese de que modulando a resposta dos macrófagos a biomateriais, usando um material 
imunomodulador, eficiente na alteração da polarização dos macrófagos para um fenótipo 
do tipo M2, anti-inflamatório e pro-reparativo, poderíamos melhorar a integração dos 
materiais implantados e ao mesmo tempo favorecer a reparação de tecidos. Neste 
contexto, os seguintes objetivos foram definidos: (i) investigar o papel do inflamasoma 
NLRP3 na resposta dos macrófagos a esponjas 3D de quitosano com diferentes graus de 
acetilação; (ii) desenvolver um material capaz de modelar a resposta imune, incorporando 
Resolvina D1 (RvD1) nas esponjas de quitosano a fim de obter uma modulação da 
inflamação  através da polarização dos macrófagos para um perfil do tipo M2; (iii) avaliar 
num modelo animal de lesão óssea, a capacidade do material desenvolvido favorecer a 
reparação óssea. 
 
Para atingir os objetivos propostos, começou-se por investigar de que forma as esponjas 
3D de quitosano influenciam a ativação do inflamasoma NLRP3. Contrariamente ao que 
está descrito, verificamos que as esponjas de quitosano por si só, não são capazes de 
ativar o inflamasoma NLRP3 em macrófagos quer de ratinho quer de humanos. É 
importante destacar que as esponjas de quitosano com diferentes graus de acetilação, 
promoveram um decréscimo generalizado da interleucina (IL)-1b; da formação de 
oligomeros do inflamasoma NLRP3 e morte celular após ativação do NLRP3. Finalmente, 
observamos que as esponjas de quitosano afetam o primeiro sinal de ativação do 
inflamasoma, diminuindo a expressão da proteína pro-IL-1b em macrófagos de ratinho e a 
expressão da proteína NLRP3 em macrófagos humanos. 
  
O papel decisivo dos macrófagos na reparação de tecidos, levou-nos a desenvolver um 
biomaterial imunomodulador capaz de modular a resposta inflamatória através da 
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polarização dos macrófagos para um fenótipo tipicamente M2. Para atingir este objetivo, 
incorporamos RvD1, um mediador endógeno com funções cruciais na resolução da 
resposta inflamatória, em esponjas 3D de quitosano. Foi observada uma diminuição geral 
de células inflamatórias não só recrutadas para o local do implante, mas também a 
colonizar o implante de Ch + RvD1 liofilizada. verificou-se ainda que este material foi capaz 
de aumentar a percentagem de macrófagos M2 e diminuir a percentagem de macrófagos 
M1 levando a um aumento da relação M2:M1, que é considerado indicador de um bom 
prognóstico para a reparação de tecidos. É importante notar que uma diminuição geral das 
citocinas pró-inflamatórias nos exsudatos inflamatórios também foi verificada com o Ch + 
RvD1 liofilizada, corroborando a alteração fenotípica observada nos macrófagos pela 
análise de marcadores celulares específicos. 
 
Em seguida, verificamos num modelo in vivo de lesão óssea a capacidade do material 
desenvolvido contribuir para uma melhoria na reparação óssea. Observamos que o 
material foi capaz de induzir um ligeiro aumento na formação de novo osso (BV / TV), um 
aumento significativo na espessura trabecular (Tb.Th) e no colagénio tipo I. É importante 
mencionar que um aumento de Tb.Th e colagénio tipo I é um indicador de qualidade e força 
do tecido ósseo. Estes resultados demonstram que a RvD1 tem um efeito positivo na 
reparação óssea.  
 
Para obter uma libertação mais sustentada de RvD1 e também para aumentar a atividade 
ao longo do tempo, decidimos usar nanopartículas lipídicas sólidas (NLSs) como sistema 
de entrega de RvD1. NLSs carregadas com RvD1 foram desenvolvidas com sucesso e 
testadas para avaliar a sua capacidade em diminuir citocinas pró-inflamatórias (IL-6 e TNF-
a) em macrófagos humanos estimulados com LPS. Verificou-se que as NLSs com RvD1 
têm um efeito anti-inflamatório e não são tóxicas. 
 
Globalmente, o trabalho desenvolvido no âmbito desta tese contribuiu para melhorar o 
conhecimento do papel do inflamasoma NLRP3 na resposta de macrófagos a materiais 
macroscópicos. Demonstramos que as esponjas 3D de quitosano, por si só, não foram 
capazes de induzir a ativação do inflamasoma NLRP3, sendo uma característica 
importante no contexto da reparação de tecidos. Além disso, conseguimos desenvolver um 
material imunomodulador, que promove a mudança do fenótipo M1 (pró-inflamatório) para 
um fenótipo M2 (anti-inflamatório, pró-reparativo). Embora o material não tenha melhorado 
substancialmente a reparação óssea, fomos capazes de induzir a formação de novo osso 
de elevada qualidade. Consequentemente, começamos a desenvolver uma nova 
estratégia para aumentar a atividade e o tempo de libertação da RvD1, os resultados 
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alcançados até ao momento são bastante promissores, indicando que as NLSs carregadas 
com RvD1 poderão ser usadas para promover a reparação óssea. 
 
Em suma, os resultados obtidos terão impacto no desenvolvimento de novas estratégias 
para modular a resposta inflamatória a biomateriais, melhorando assim a integração do 
biomaterial bem como a reparação do tecido em questão. 
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GENERAL INTRODUCTION 
 
1. Biomaterials – Concepts and Developments 
 
Biomaterials are used in several different clinical applications, from implants and prosthesis 
(e.g., hip implants and artificial heart valves) to tissue regeneration and drug delivery. Since 
the decade of 1960, millions of patients have their quality of life improved through the use 
of biomaterials or biomedical devices. Biomaterial development has greatly change over 
time and nowadays biomaterials can be classified according to their evolution in “first”, 
“second” and “third” generation. The first generation of materials was developed between 
1960 and 1970 to be used in the human body. The major goal of the first developed 
biomaterials was to “achieve a suitable combination of physical properties to match those 
of the replaced tissue with a minimal toxic response in the host” [1]. The principal feature of 
these materials was the biological “inertness” with a minimal interaction between the 
“bioinert” implant and host tissues [1]. In the 1980s Professor Bonfield and his research 
group have focused their research efforts in the development of a new generation of 
biomaterials. This work led to an innovative composite material, named as Hapex™, a 
combination of a polymeric matrix of polyethylene and dispersed bioactive phase of 
hydroxyapatite (HA) [2]. A second generation of biomaterials had been developed with the 
purpose of being “bioactive”. These new developed materials would elicit a controlled 
reaction within the host [3, 4]. After that, different compositions of bioactive glasses, 
ceramics, glass-ceramic, polymers and composites were developed. The clinical success 
of “bionert” and bioactive implants has been fundamental to the medical needs with the 
population ageing. However, between one third to half of the applied prostheses tend to fail 
within 10-25 years, requiring that patients have a revision surgery [5, 6]. So, the challenge 
for the twenty-first century, was the development of a third-generation of biomaterials that 
were able to stimulate specific cellular responses at the molecular level [7, 8]. Third-
generation of biomaterials are being designed to activate genes stimulating the tissue 
repair. Two alternative approaches of repair could be used: (i) tissue engineering that uses 
progenitor cells seeded and differentiated in resorbable scaffolds. Tissue engineered 
constructs are then implanted in the host to replace damage tissues and (ii) in situ tissue 
regeneration that uses biomaterials in the form of powders, solutions, or microparticles to 
stimulate local tissue repair through the release at controlled rates of biochemical products, 
such as growth factors. The release of these biochemical products will activate and 
stimulate local cells that in turn will produce other factors, stimulating generations of growing 
cells [7, 8]. The main benefit of both approaches is the genetic control of tissue repair 
processes [7-9]. 
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Biomaterials are a growing industry and it was reported that the world market is expected 
to reach 149,17 billion USD per year by 2021 with an expected compound annual growth 
rate of 16% [10]. In the last decades the definition of biomaterials has been intensely 
refined. Professor Williams in 1986 defined a biomaterial as “… a substance that has been 
engineered to take form which, alone or as part of a complex system, is used to direct, by 
control of interactions with components of living systems, the course of any therapeutic or 
diagnostic procedure” [11]. More recently a group of world experts in the biomaterials field 
establish a new definition. A biomaterial is now defined as “a material designed to take a 
form which can direct, through interactions with living systems, the course of any therapeutic 
or diagnostic procedure” [12].  
Over the last years, we have perceived a change in the concept of an ideal biomaterial. 
Instead of being a passive material design to diminish host responses, biomaterials are now 
developed to trigger desired immunological responses and therefore enable its integration 
and subsequent tissue repair [15]. It is now accepted that a successful biomaterial 
implantation can be achieved by controlling the activation of the immune system. With this 
concept a new area of research is emerging, the “Regenerative Immunology”. Can the 
“immunomodulatory biomaterials” became the fourth-generation of biomaterials? 
 
 
2. Inflammatory response to Biomaterials 
 
The inflammatory response to implanted biomaterials has been deeply investigated over 
the last years. James Anderson has provided us several landmark papers concerning the 
biological responses to biomaterials [13-15].  
 
The inflammatory response can be defined as an acute response to tissue injury directed 
at limiting damage to the body, and it is started through the detection of signals of acute 
damage or changes of the steady state [16]. The process of biomaterial implantation results 
in damage to tissues or organs of the host. This injury together with changes in the 
homeostatic mechanisms will lead to an inflammatory response to the implanted biomaterial 
[14, 17]. A series of events are initiated upon the implantation process, beginning with an 
acute inflammatory response that in some circumstances may lead to a chronic 
inflammatory response, a foreign-body reaction, and the deposition of a collagenous fibrous 
capsule around the implant. The efficacy of biomedical devices can be affected by the 
extent and duration of the inflammatory process, having a direct impact on biomaterial 
stability and compatibility [14, 15]. The tissue response to biomaterials is commonly 
described as a sequence of events that are started by the biomaterial implantation 
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procedure, additionally to its presence [14, 15]. We will briefly review these responses 
starting with (i) blood-material interactions; (ii) release of danger signals by injured cells; (iii) 
acute inflammation; (iv) chronic inflammation; (v) foreign body reaction. 
 
(i) Blood-material interactions: The inflammatory response is always initiated due 
to injury caused in connective tissue. Shortly after injury, changes in vascular flow and 
permeability occur, followed by the exudation of fluid, proteins and blood cells from the 
vascular system into the affected tissues [18]. Almost immediately proteins adsorb to the 
biomaterial surface [19, 20]. This layer of adsorbed proteins (type of proteins, concentration 
and conformation upon adsorption) will define the initiation of the coagulation cascade, 
complement system, platelets and immune cells leading to the formation of a transitional 
fibrin matrix at the implant site (Fig. 1A) [21]. 
 
(ii) Release of danger signals by injured cells: Following tissue injury, danger 
signals the ‘‘alarmins” are promptly released by cells undergoing necrosis. Alarmins are the 
endogenous equivalent of pathogen-associated molecular patterns (PAMPs) including for 
example heat shock proteins, ATP and uric acid. Alarmins are capable of recruit and 
activate different immune cells such as macrophages and dendritic cells (DCs), being 
recognized trough pattern recognition receptors (PRRs) such as toll-like receptors (TLRs), 
scavenger receptors and purinergic receptors [22-24], and thus promoting inflammation [25, 
26]. As a consequence of biomaterial implantation, alarmins will be released by injured cells 
at the implant site due to the surgical procedure (Fig. 1A) [27]. 
 
(iii) Acute inflammation: This step of the inflammatory response is of relative short 
duration and is mainly characterized by the rapid recruitment of polymorphonuclear 
leukocytes (PMNs) to the implant site through the release of chemoattractants by activated 
platelets and endothelial cells. The PMNs will then initiate a phagocytic response together 
with the secretion of proteolytic enzymes and reactive oxygen species (ROS). Due to size 
disparity, phagocytosis will most likely not occur and the destructive agents released by 
these cells may corrode the material surface (Fig. 1B). Several chemokines such as 
monocyte chemotactic protein (MCP-1) and macrophage inflammatory protein (MIP-1b), 
that are chemoattractants and activators of monocytes, macrophages, immature DCs and 
lymphocytes, will be secreted by activated PMNs. Commonly, PMNs will disappear from 
the implant site in the first two days after biomaterial implantation, [17, 26, 28, 29]. 
 
(iv) Chronic inflammation: When the inflammatory stimuli persist, a chronic 
inflammation will progress, being the macrophage one of the central cell type of this phase 
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of the inflammatory response. Macrophages release a great number of biological active 
inflammatory mediators such as tumor necrosis factor-a (TNF-a), interleukin (IL)-8, IL-1b, 
MCP-1 and MIP-1b among others (Fig. 1C). Macrophages are considered as having a 
fundamental role in wound healing and tissue repair since they exhibit extraordinary 
plasticity and in response to environmental cues can change their physiology, inducing 
distinct cell populations with different functions. This has originated the division of macro- 
phages into two major extreme phenotypes (M1 and M2). The classically activated, pro-
inflammatory, cytotoxic macrophage phenotype, labelled as M1, promotes pathogen killing 
and is related with classic signs of active inflammation, mostly with chronic inflammation. 
The alternatively activated, anti-inflammatory macrophage phenotype, labelled as M2, 
supports immunoregulation tissue repair and remodeling [30-34]. 
 
(v) Foreign body reaction: Since macrophages can only phagocytose particles up 
to 5 mm, when the particle size is larger, they will fuse and form foreign body giant cells 
(FBGCs) (Fig. 1B). It is described in the literature that after fusing in FBGCs, macrophages 
show a decrease in the phagocytic activity together with an enhanced degradative capacity 
due to the release of reactive species, thus creating a highly degradative environment at 
the biomaterial surface [17, 35, 36]. Macrophages and FBGCs can be found at the 
implanted biomaterial surface for the lifetime of the implant. There is a fibrous encapsulation 
around the biomaterial due to fibroblast recruiting factors secreted by FBGCs resulting in 
its activation and collagen (Coll) deposition. This fibrous capsule will impair the implant 
function because it will be isolated from the local tissue environment [15, 37, 38]. 
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Figure 1. The inflammasome in the immune response to an implanted biomaterial. (A) Biomaterial 
implantation: The process of implantation of a biomaterial causes injury to cells. Danger signals released from 
injured cells (such as alarmins, High mobility group protein B1 (HMGB1), ATP and UTP) results in the 
recruitment and activation of PMNs, monocytes and resident macrophages, via PRRs engagement. Well-known 
damage associated molecular patterns (DAMPs) include ATP, nucleic acids, heat shock protein (HSP), 
monosodium urate, HMGB1 and inflammatory cytokines. The adsorption of blood proteins to material surface 
will further recruit immune cells. (B) Acute inflammatory response to biomaterials: Immune cells secrete 
proteolytic enzymes and ROS that will degrade the biomaterial surface and extracellular matrix (ECM) 
components. Endogenous danger signals are usually released from stressed or necrotic cells and also damaged 
ECM during acute inflammation. (C) Inflammasome activation: Activation of NOD-like receptor containing Pyrin 
Domain 3 (NLRP3) inflammasome, composed of NLRP3, associated speck like protein containing a caspase 
recruitment domain (ASC), and pro-caspase-1, is regulated by two-step signals: The first signal (signal 1) can 
be danger signals released from injured tissues and immune cells that will enhance the expression of 
inflammasome components and target proteins via activation of nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-kB). The second ‘‘activation” signal (signal 2) promotes the assembly of inflammasome 
components, that involves three major mechanisms, including generation of ROS, lysosomal damage 
(phagocytosis of biomaterial degradation products), and the potassium efflux. Inflammasome assembly leads 
to caspase-1 activation that in turn cleaves the pro-forms of cytokines IL-1b and IL-18 as well as gasdermin D 
that induce the pyroptotic inflammatory cell death. The perpetuation of the inflammatory cascade culminates 
either in resolution of inflammation, return to homeostasis and tissue healing or in chronic inflammation and 
biomaterial encapsulation. 
 
 
2.1. Key role of Macrophages 
 
Macrophages display remarkable plasticity, changing their physiology in response to 
environmental cues [31]. Macrophages are strategically positioned throughout the body 
(PMNs) to the implant site through the release of chemoat-
trac ants by activated platelets and endothelial cells. The
PMNs will then initiate a phagocytic response together with
the secretion of proteolytic enzymes and reactive oxygen
species (ROS). Due to size disparity, phagocytosis will most
likely not occur and the destructive agents released by these
cells may corrode the aterial surface (Fig. 1B). Several
chemokines such as monocyte chemotactic protein (MCP-
1) and macrophage inflammatory protein (MIP-1b), that
are chemoattractants and activators of monocytes, macro-
phages, immature DCs and lymphocytes, will be secreted
by activated PMNs. Commonly, PMNs will disappear from
the implant site in the first two days after biomaterial
implantation, [4,19,21,22].
(iv) Chronic inflammation: When the inflammatory stimuli per-
sist, a chronic inflammation will progress, being the macro-
phage one of the central cell type of this phase of the
inflammatory response. Macrophages release a great num-
ber of biological active inflammatory mediators such as
tumour necrosis factor-a (TNF-a), interleukin (IL)-8, IL-1b,
MCP-1 and MIP-1b among others (Fig. 1C). Macrophages
are considered as having a fundamental role in wound heal-
ing and tissue repair since they exhibit ext aordinary plas-
ticity and in response to environmental cues can change
their physiology, inducing distinct cell populations with dif-
ferent functions. This has originated the division of macro-
phages into two major extreme phenotypes (M1 and M2).
The classically activated, pro-inflammatory, cytotoxic
macrophage ph notype, labelled as M1, promotes pathogen
killing and is related with classic signs of active inflamma-
tion, mostly with chronic inflammation. The alternatively
activated, anti-inflammatory macrophage phenotype,
labelled as M2, supports immunoregulation tissue repair
and r modelling [23-27].
(v) Foreign body reaction: Since macrophages can only phagocy-
tose particles up to 5 mm, when the particle size is larger
they will fuse and form foreign body giant cells (FBGCs)
(Fig. 1B). It is described in the literature that after fusing in
FBGCs, macrophages show a decrease in the phagocytic
activity together with an enhanced degradative capacity
due to the release of r active species, thus creating a highly
degradative environment at the biomaterial surface
[4,28,29]. Macrophages and FBGCs can be found t the
implanted biomaterial surface for the lifetime of the
implant. There is a fibrous encapsulation around the bioma-
terial due to fibroblast recruiting factors secreted by FBGCs
resulting in its activation and collagen deposition. This
fibrous capsule will i pair the implant function because it
will be isolated from the local tissue environment [3,30,31].
2.2. Resolution of inflammation
Inflammation is a crucial step in an efficient host defence. It is a
response to pathogen invasion and also to tissue injury. However,
Fig. 1. The inflammasome in the immune response to an implanted biomaterial. (A) Biomaterial implantation: The process of implantation of a biomaterial causes injury to
cells. Danger signals released from injured cells (such as alarmins, HMGB1, ATP and UTP) results in the recruitment and activation of polymorphonuclear leukocytes (PMNs),
monocytes and resident macrophages, via pattern recognition receptor (PRRs) engagement. Well-known damage associated molecular patterns (DAMPs) include ATP, nucleic
acids, HSP, monosodium urate, HMGB1 and inflammatory cytokines. The adsorption of blood proteins to material surface will further recruit immune cells. (B) Acute
inflammatory response to biomaterials: Immune cells secrete proteolytic enzymes and reactive oxygen species (ROS) that will degrade the biomaterial surface and ECM
components. Endogenous danger signals are usually released from stressed or necrotic cells and also damaged ECM during acute inflammation. (C) Inflammasome activation:
Activation of NLRP3 inflammasome, composed of NLRP3, ASC, and pro-caspase-1, is regulated by two-step signals: The first signal (signal 1) can be danger signals released
from injured tissues and immune cells that will enhance the expression of inflammasome components and target proteins via activation of NF-jB. The second ‘‘activation”
signal (signal 2) promotes the assembly of inflammasome components, that involves three major mechanisms, including generation of ROS, lysosomal damage (phagocytosis
of biomaterial degradation products), and the potassium efflux. Inflammasome assembly leads to caspase-1 activation that in turn cleaves the pro-forms of cytokines IL-1b
and IL-18 as well as gasdermin D that induce the pyroptotic inflammatory cell death. The perpetuation of the inflammatory cascade culminates either in resolution of
inflammati n, return to homeostasis and tissue healing or in chronic inflammation and biomaterial encapsulation.
D.P. Vasconcelos et al. / Acta Biomaterialia xxx (2018) xxx–xxx 3
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tissues, scavenging debris and dead cells. These cells play a decisive role in tissue repair, 
secreting cytokines and chemokines that directly impact inflammatory processes and tissue 
repair [39-41]. Élie Metchnikoff, more than 100 years ago, proposed that the key to immunity 
is “stimulate the phagocytes” [42]. Since there, immunologists have been occupied in 
understanding the role of macrophages in host defense. Macrophages mature and are 
activated in response to environmental stimulus acquiring specialized and distinct functional 
phenotypes. Similar to Th cell nomenclature system, a division has been proposed for 
macrophage activation: classic vs alternative, M1 and M2, respectively. In response to 
interferons (IFNs) and TLRs, macrophages undergo M1 (classical) and in response to IL-
4/IL-13 signaling undergo M2 (alternative) activation (alternative) [43, 44]. These states 
correlate to the Th1 – Th2 polarization of T cells [44-46]. The M1 macrophages are 
characterized by the production of high levels of pro-inflammatory cytokines, reactive 
nitrogen and oxygen species and strong antimicrobial and tumoricidal activity. On the other 
hand, the M2 phenotype is considered to be involved in the promotion of tissue remodeling, 
tumor progression and to have immunoregulatory functions [43]. 
 
Tissue repair after injury is a critical biological process that is essential to the survival of all 
organisms [47]. After tissue injury, due to infection, toxic or mechanical action, an 
inflammatory response is initiated in response to DAMPs from dead or dying cells or PAMPs 
from invading organisms [48]. These danger signals induce a complex inflammatory 
response that is characterized by the recruitment, proliferation, and activation of 
neutrophils, macrophages, natural killer cells, B cells, T cells, fibroblasts, epithelial cells, 
endothelial cells, and stem cells, that together orchestrate tissue repair [49]. Once wound-
healing is well organized, the inflammatory response resolves rapidly, and normal tissue 
architecture is restored, but if tissue repair becomes dysregulated, can lead to fibrosis or 
scaring, that could impair tissue function. Wound-healing is a tightly regulated process and 
is driven by the interactions between immune cells and other cell types such as fibroblasts 
and myofibroblasts as well the temporary plasticity of immune cells [50]. The initial cellular 
response after injury is highly influenced by cytokines, chemokines, MMPs, and other 
inflammatory mediators, released by tissue resident macrophages. Several studies showed 
an impairment in tissue repair when macrophages are depleted in an early phase of wound 
healing [51-53]. 
 
Due to their plasticity [31], during wound healing macrophages switch from an inflammatory 
phenotype, to a tissue repair to a resolving phenotype, having a critical role in the regulation 
of all phases of repair or fibrosis [54]. M1 macrophages arrive early at the injury site and 
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are responsible for the recruitment of effector cells and for the initiation of an effective 
defense to pathogens and the clearance of tissue debris [55]. Chronic M1 macrophages 
delay tissue repair [56]. In a well balance wound healing, inflammatory macrophages (M1) 
switch to an anti-inflammatory, homeostatic wound healing macrophages (M2). M2 
macrophages guarantee that the tissue-damaging inflammatory response is suppressed, 
and normal tissue architecture is restored. If the process is not well controlled, persistent 
inflammation can lead to fibrosis [39, 54, 56].  
 
Macrophages represent a major target in regenerative medicine. Strategies to modulate 
macrophages suggest the capacity of a better control of wound healing and tissue repair 
and regeneration. Biomaterials either lager scale or in the form of nanoparticles, soluble 
factors or even specific cell types could be used to modulate macrophage-mediated repair 
response.  
 
 
3. Resolution of Inflammation 
 
Inflammation is a crucial step in an efficient host defense. It is a response to pathogen 
invasion and also to tissue injury. However, to re-establish tissue homeostasis it is 
necessary to resolve the inflammatory response, in order to prevent increased tissue injury 
and to minimize the development of chronic inflammation, therefore enabling tissue repair 
and regeneration [57-59]. 
 
The resolution of inflammation and the recovery of homeostasis was for many years 
considered to be a passive process. It was thought that local inflammatory stimuli would 
just fade or ‘‘burn out” with time, allowing tissues to drain, repair and return to normal 
function. It is today accepted that resolution of inflammation is an active process that is 
highly regulated. Specialized immunoresolvents have been recently described as having a 
fundamental role, together with anti-inflammatory cytokines as IL-10, in the termination of 
inflammation triggering pathways that signal the termination of the acute phase of the 
inflammatory response. These mediators include a group of endogenous molecules: 
resolvins, lipoxins, protectins and maresins, collectively coined as specialized pro-resolving 
mediators (SPMs) [60-62]. 
 
In the initial phase of inflammation, lipid mediators such as eicosanoids including 
prostaglandins and leukotrienes, synthesized from membrane-released arachidonic acid of 
activated cells, have a central role as local mediators in the advance of an inflammatory 
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condition, inducing an effective chemotactic response of leukocytes whose activation is 
associated to the local release of pro-inflammatory cytokines. A high increase in the 
production of inflammatory mediators such as prostaglandins and leukotrienes is 
associated with an advance from acute to chronic inflammation. In a second phase, an 
active shift in the type of mediators leads to the production of immunoresolvents initiating 
the resolution of inflammation. Transcellular metabolism of arachidonic acid by 
lipoxygenase/lipoxygenase interaction pathways gives rise to SPMs [63, 64]. These 
endogenous lipid pro-resolution mediators are generated through complex pathways being 
the (i) lipoxins derived from endogenous fatty acids (arachidonic acid), while (ii) resolvins, 
(iii) protectins and (iv) maresins are derived from dietary fatty acids, specifically omega-3 
fatty-acids [65]. 
 
(i) Lipoxins (lipoxygenase interaction products) are considered to be effective stop 
signals for PMNs, limiting their recruitment to sites of inflammation through the reduction of 
vascular permeability and stimulating the return to homeostasis; they also induce 
nonphlogistic recruitment of macrophages that are required for wound healing and for the 
uptake of apoptotic PMNs [66-68]. 
 
(ii) Resolvins (resolution-phase interaction products) induce several functions in the 
resolution of inflammation such as the regulation of cytokines and reactive oxygen species; 
the prevention of PMNs infiltration; the increase phagocytosis of apoptotic PMNs that will 
clear the lesion and lower the magnitude of the response and thus promote tissue 
regeneration [66, 69]. 
 
(iii) Protectins (the term was introduced due to the general anti-inflammatory and 
protective actions) reduce PMNs recruitment and reinforce the clearance of apoptotic PMNs 
by macrophages [70]. 
 
(iv) Maresins (macrophage mediators in resolving inflammation) were described as 
being produced by macrophages that have homeostatic functions, these mediators also 
support the removal of apoptotic PMNs by macrophages contributing to the re-establishing 
of tissue homeostasis [71, 72]. 
 
General evidences of resolution are the general decrease of pro-inflammatory cytokines, 
phagocytosis of apoptotic PMNs and clearance of the inflammatory debris. SPMs stimulate 
re-epithelialization, wound healing, and tissue regeneration reducing the pro-inflammatory 
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chemical mediators. Chronic inflammation and fibrosis will occur if inflammatory resolution 
fails [73]. 
 
 
4. The new trend in biomaterial development 
 
For many years, it was accepted that the key for long term durability and function of an 
implanted biomaterial was its ability to elicit a minimal inflammatory response, since it was 
considered to be an adverse reaction. Within the last years, this paradigm of the host-
biomaterial response has been intensely refined [74]. During several decades biomaterial 
engineering was dedicated on the development of passive biomaterials to minimize the host 
response, but it has now been understood that allowing specific biological responses is 
beneficial for both biomaterial integration and performance [75]. In view of this, biomaterials 
development has change from ‘‘immune-evasive” to ‘‘immune-interactive” biomaterials to 
allow the modulation of the inflammatory response improving healing and regeneration [76]. 
 
It has now became clear that the immune system is fundamental in orchestrating and 
defining the nature of the repair response [58, 77], and that without injury and ensuing 
inflammation, regeneration or repair does not occur [78]. The coordination between 
inflammation and its resolution is required for successful tissue repair and regeneration [59]. 
Nowadays, there is growing evidence that the immune response supports repair and 
provides local tissue protection [79]. The link amongst repair and immune response is 
complex and both positive and negative roles are described. The result of the tissue healing 
process can change from incomplete healing and repair that may cause scarring or fibrosis, 
to complete restoration of the tissue functions being this significantly affected by the immune 
response [58]. 
 
John Hunter, a famous Scottish surgeon, in 1794, wrote that ‘‘inflammation in itself is not to 
be considered as a disease, but as a salutary operation consequent to some violence or 
some disease” [80]. Hunter’s rational is rather interesting taking in consideration the recent 
findings of inflammation being crucial in tissue repair and regeneration. 
 
An impressive number of immune mediators cooperate in every step of the tissue healing 
process. For example, the macrophage response is crucial for an effective tissue 
remodeling following biomaterial implantation, since macrophages are rather important in 
the process of tissue healing [81], and if macrophage infiltration is prevented, healing is 
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severely impaired [36]. Therefore, modulating the immune system response, namely 
specific immune cell types, is a valid strategy to support tissue regeneration [82]. 
Recovery of tissue integrity and return to homeostasis following injury is a central property 
of all organisms and the immune system is of key importance in defining the quality of the 
repair process [16, 83]. Recently, new and unexpected roles of immune cells have been 
described in the promotion of a local environment favorable for effective cell replacement 
and restoration of tissue integrity. Hence, an in-depth knowledge of the mechanisms 
controlling the inflammatory response and how it is related with the healing process, will be 
an important milestone in tissue repair [18, 19]. 
 
The challenge nowadays, is to develop capable biomaterial and delivery systems to 
regulate tissue healing through immune-mediated mechanisms. The next generation of 
regenerative approaches may progress from typical ‘‘biomaterial-, stem cell-, or growth 
factor-centric approaches” to an ‘‘immune-centric” approach, following the modulation of 
the immune system as a way of stimulating repair of tissues and organs [82]. 
 
 
4.1. Immunomodulatory biomaterials 
 
Traditionally, the immune system has been viewed by biomedical engineers as an enemy 
to the adequate design of biomaterials, as a coordinator of the host response that decreases 
the duration and function of implants. However, interest is increasingly growing on 
engineering biomaterials to wisely control the immune system by enhancing or suppressing 
immune reactions [84]. 
 
The emergence of tissue engineering and regenerative medicine has motivated the 
development of novel biomaterials with additional and precise functions, such as the ability 
to change inflammatory and innate immune response [85]. 
 
The conception of biomaterials that are able to modulate the immune system response is a 
developing field that is evolving together with advances in immunology. There is solid hope 
on the potential of biomaterials to elicit appropriate immune responses through the 
modulation of immune cell function, the so called immunomodulatory biomaterials [86]. 
 
The use of biomaterials to change immune responses is creating interesting new 
approaches in different research areas such as cancer immunotherapy, vaccination, 
establishing tolerance in organ transplantation and treatment of autoimmune disorders [84]. 
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However, in this thesis we will focus on the repair of damage tissues using immune-
mediated strategies that is emerging as an innovative approach. Engineering biomaterials 
to control the immune system may encourage the development of therapies that stimulate 
pro-regenerative immune responses, leading to an improved tissue repair [87]. 
 
These so-called immunomodulatory biomaterials should ideally influence immune cell 
function promoting tissue healing and the integration of the implant while supporting its 
function [88]. Different strategies are used in biomaterial-based immunomodulation such as 
(i) tuning of the chemical properties of biomaterials; (ii) changing the physical properties of 
the materials (iii) incorporation of bioactive molecules either anti-inflammatory drugs or pro-
resolution mediators or growth factors; (iv) biomaterials based on decellularized 
extracellular matrix (ECM) and (v) cell therapy methods either by including immune cells or 
by inducing their recruitment [76]. 
 
The studies described in the literature attempting to modulate immune responses are mostly 
focused on the macrophage, namely in macrophage polarization (Fig. 2). This is because 
macrophages are highly plastic cells [43, 89] that play a decisive role in inflammation and 
also in the coordination of tissue repair, fibrosis and tissue regeneration [39]. 
 
The development of structures that either mimic or use components or decellularized ECM 
will allow the establishment of a microenvironment favorable for healing and repair [90]. 
Brown et al. [91] have demonstrated that there is an association between early macrophage 
response to implanted ECM scaffold materials and the result of tissue remodeling probably 
associated with M1 vs. M2 macrophage response, being increased ratios of M2:M1 
macrophages associated with positive remodeling outcomes (Fig. 2). Franz et al. [81] have 
investigated different artificial ECM derivatives and suggest that these materials could be 
used as coatings for biomaterials allowing the modulation of macrophage functions during 
the healing response, since they were able to in vitro impair the polarization of human M1 
macrophages. 
 
The delivery of bioactive molecules such as cytokines or pro-resolution mediators has 
provided rather interesting results. Gower et al. [85] were able to modulate leukocyte 
infiltration and phenotype after a poly(lactide-co-glycolide) (PLG) scaffold implantation 
using a gene-therapy approach consisting in the localized delivery of IL-10, decreasing the 
leukocyte inflammatory response. Spiller et al. [92] designed a scaffold that allowed the 
sequential delivery of interferon-gamma (IFN-g) followed by IL-4, in order to promote the 
transition of M1 to M2 macrophages. Chen et al. [93] have used the same rationale and 
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developed a system of double hydrogel layers on titania nanotubes (TNT) to achieve a 
controlled release of IL-4 and IFN-g. We have developed an immunomodulatory strategy 
based on the local delivery of SPMs, namely lipoxin A4 and resolvin D1, and we were able 
to in vivo shift the macrophage phenotypic profile towards a M2 reparative response [94, 
95]. 
 
Exploring the physicochemical properties of biomaterials has also led to some promising 
outcomes. Shayan et al. [96] have used nanopatterned bulk metallic glasses to modulate 
murine macrophage polarization and concluded that nanopatterned surfaces lead to a more 
constructive tissue repair with higher vascularization and increased M2 to M1 ratio, when 
compared to flat surfaces. Wang et al.[97] have produced macroporous electrospun poly-
caprolactone scaffolds with different fiber size and concluded that macrophages cultured 
on thicker-fiber scaffolds tended to polarize into M2 phenotype, whereas those cultured on 
thinner-fiber scaffolds expressed mainly M1 phenotype. Lee et al. [98] have performed a 
chemical surface modification in a titanium implants using the divalent cations calcium and 
strontium and were able to up-regulate M2 macrophage phenotype expression. Li et al. [99] 
have developed titanium implants doped with magnesium with the objective of assessing 
the macrophage response both in vitro and in vivo and were able to induce a higher 
percentage of M2 macrophages and higher concentrations of the anti-inflammatory 
cytokines IL-4 and IL-10. 
 
The next generation of biomaterials will be developed upon knowledge of the biology of 
inflammation and healing and will regulate biological responses with precision [75]. It is 
essential to understand which cells and/or mediators of the immune system can be used to 
actively stimulate regeneration [100]. Material science has also a great deal to offer to the 
field of immunology through the design of different biomaterial-based immunomodulatory 
approaches. 
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Figure 2. Modulation of macrophage interaction with biomaterials. Implantation of a biomaterial triggers an 
acute inflammatory response, resulting in the recruitment of polymorphonuclear leukocytes (PMNs) and 
macrophages that will initially polarize to M1 pro-inflammatory macrophages. Afterwards, the 
immunomodulatory biomaterial will release anti-inflammatory agents (such as cytokines or specialized pro-
resolving mediators (SPMs)) leading to changes in the macrophage polarization towards a M2 pro-healing 
phenotype, promoting implant integration and tissue healing. 
 
 
5. Inflammasomes 
5.1. What is the inflammasome? 
 
As explained before, inflammation is initiated on the recognition of signs of acute damage 
or disturbances of the steady state and mainly mediated by the production of soluble factors 
like cytokines. The innate immune system has several PRRs that upon activation induce 
the production of different pro-inflammatory cytokines. PRRs can be subdivided into two 
major classes based in their subcellular location: TLRs and C-type lectin receptors (CLRs) 
are transmembrane proteins; while the RIG-I-like receptors (RLRs) and the NOD-like 
receptors (NLRs), reside in the intracellular compartments. These receptors recognize and 
activate in response, for example, to distinct PAMPs and also host-derived signals produced 
during tissue damage or homeostasis disturbances called damage-associated molecular 
patterns (DAMPs) [101, 102]. 
on engineering biomaterials to wisely control the immune system
by enhancing or suppressing immune reactions [58].
The emergence of tissue engineering and regenerative medicine
has motivated the development of novel biomaterials with addi-
tional and precise functions, such as the ability to change inflam-
matory and innate immune response [59].
The conception of biomaterials that are able to modulate the
immune system response is a developing field that is evolving
together with advances in immunology. There is solid hope on
the potential of biomaterials to elicit appropriate immune
responses through the modulation of immune cell function, the
so called immunomodulatory biomaterials [60].
The use of biomaterials to change immune responses is creating
interesting new approaches in different research areas such as can-
cer immunotherapy, vaccination, establishing tolerance in organ
transplantation and treatment of autoimmune disorders [58].
However, in this review we will focus on the repair of damage tis-
sues using immune-mediated strategies that is emerging as an
innovative approach. Engineering biomaterials to control the
immune system may encourage the development of therapies that
stimulate pro-regenerative immune responses, leading to an
improved tissue repair [61].
These so-called immunomodulatory biomaterials should ideally
influence immune cell function promoting tissue healing and the
integration of the implant while supporting its function [62]. Dif-
ferent strategies are used in biomaterial-based immunomodula-
tion such as (i) tuning of the chemical properties of biomaterials;
(ii) changing the physical properties of the materials (iii) incorpo-
ration of bioactive molecules either anti-inflammatory drugs or
pro-resolution mediators or growth factors; (iv) biomaterials based
on decellularized extracellular matrix (ECM) and (v) cell therapy
methods either by including immune cells or by inducing their
recruitment [51].
The studies described in the literature attempting to modulate
immune responses are mostly focused on the macrophage, namely
in macrophage polarization (Fig. 2). This is because macrophages
are highly plastic cells [63,64] that play a decisive role in inflam-
mation and also in the coordination of tissue repair, fibrosis and
tissue regeneration [65].
The development of structures that either mimic or use compo-
nents or decellularized ECM will allow the establishment of a
microenvironment favourable for healing and repair [66]. Brown
et al. [67] have demonstrated that there is an association between
early macrophage response to implanted ECM scaffold materials
and the result of tissue remodelling probably associated with M1
vs. M2 macrophage response, being increased ratios of M2:M1
macrophages associated with positive remodelling outcomes
(Fig. 2). Franz et al. [56] have investigated different artificial ECM
derivatives and suggest that these materials could be used as coat-
ings for biomaterials allowing the modulation of macrophage func-
tions during the healing response, since they were able to in vitro
impair the polarization of human M1 macrophages.
The delivery of bioactive molecules such as cytokines or pro-
resolution mediators has provided rather interesting results.
Gower et al. [59] were able to modulate leukocyte infiltration
and phenotype after a poly(lactide-co-glycolide) (PLG) scaffold
implantation using a gene-therapy approach consisting in the
localized delivery of IL-10, decreasing the leukocyte inflammatory
response. Spiller et al. [68] designed a scaffold that allowed the
sequential delivery of interferon-gamma (IFN-c) followed by IL-4,
in order to promote the transition of M1 to M2 macrophages. Chen
et al. [69] have used the same rationale and developed a system of
Fig. 2. Modulation of macrophage interaction with biomaterials. Implantation of a biomaterial triggers an acute inflammatory response, resulting in the recruitment of
polymorphonuclear leukocy es (PMNs) and macroph ges that will initially polarize to M1 pro-inflammatory m crophages. Afterwards, the immunomodulatory biomaterial
will release anti-inflammatory agents (such as cytokines or specialized pro-resolving mediators (SPMs)) leading to changes in the macrophage polarization towards a M2 pro-
he ling phenotype, promoting implant integration and issue healing.
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The concept of inflammasome was introduced in the beginning of this century by Jϋrg 
Tschopp. The term inflammasome was coined to describe an intracellular multiprotein 
complex that perceives pathogenic microorganisms and sterile stressors, being responsible 
for the activation of the highly pro-inflammatory cytokines IL-1b and IL-18 [103]. 
Inflammasome is derived from the word inflammation – to reflect the function of this complex 
- and the suffix ‘‘some” from the Greek ‘‘soma” that means body, which is generally used to 
define several molecular complexes such as liposome or ribosome [104]. 
 
The inflammasome complex (Fig. 3) consists of a cytosolic sensor that could be a PRR of 
the NLRs or AIM2-like receptors (ARLs) families, in some cases includes an adaptor protein 
called apoptosis-associated speck like protein containing a caspase recruitment domain 
(ASC), and an effector protein that in the canonical inflammasomes is caspase-1 [105]. 
ASC is a bipartite molecule that contains both an N-terminal Pyrin domain (PYD) and a C-
terminal caspase activation and recruitment domain (CARD), enabling it to bridge the 
inflammasome sensor with PYD domain (NLRs or ALRs) and the effector pro-caspase-1. 
Additionally, to NLRs and ALRs, other proteins with a PYD domain could also assemble 
ASC to form inflammasomes, such as the protein Pyrin [106]. 
 
Different PRRs have been identified to form inflammasomes, including NLRP1, NLRP3, 
NLRC4 or AIM2, among others. In some conditions the combined activation of two 
inflammasomes could contribute to the inflammatory response [107-109]. The assembly of 
these PRRs in pentameric or heptameric structures oligomerize ASC in filaments and these 
ASC filaments recruit caspase-1 leading to the formation of the inflammasome. The 
inflammasome complex oligomerize in response to a varied set of inflammation-inducing 
stimuli including PAMPs and DAMPs and are appreciated as an important sensing system 
that allows the host to mount an effective immune response [110]. This response is 
mediated by the activation of caspase-1 within the inflammasome, a response that induces 
by one hand the cleavage of pro-IL-1b and pro-IL-18 into their mature biological active forms 
and a special type of cell death termed pyroptosis upon cleavage of gasdermin D. 
Pyroptosis is executed by the formation of pores in the plasma membrane by the insertion 
of the resulting N-terminus fragment of gasdermin D and the leakage of intracellular content 
including mature IL-1b and IL-18 cytokines (Fig. 4).  
The NOD like receptor containing pyrin domain 3 (NLRP3) inflammasome (previously 
known as cryopyrin or NALP3) is presently the most fully characterized inflammasome and 
consists of the NLRP3 scaffold, the ASC adaptor protein and caspase-1, together with the 
accessory protein, NIMA – related kinases (NEK7) that maintain NLRP3 oligomer in active 
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state [111, 112]. The NLRP3 inflammasome is primarily expressed in monocytes, 
macrophages, granulocytes, dendritic cells, and also in epithelial cells and osteoblast, being 
its expression in myeloid cells highly inducible [113]. This inflammasome is initially primed 
in response to diverse signals (Fig. 4, priming ‘‘signal 1”), including de novo translation 
driven by nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and post-
transcriptional modifications, including phosphorylation, dephosphorylation, 
deubiquitination, nitrosylation and ribosylation [114]. Upon NLRP3 priming, diverse 
endogenous host-derived activators (such as extracellular ATP, uric acid crystals or 
hyaluronan), environmental-derived molecules (such as asbestos and silica particles) and 
several PAMPs are recognized by myeloid cells and induces the oligomerization of NLRP3 
[102, 115, 116]. This second activator signal (Fig. 4, activation for complex formation ‘‘signal 
2”) is transduced by various mechanisms such as ROS production or lysosomal damage, 
being a key common step the intracellular potassium efflux [113, 117, 118]. Therefore, the 
NLRP3 inflammasome recognize an optimal intracellular milieu [119]. 
Furthermore, different mutations in NLRP3 results in a protein conformation with increase 
ability to oligomerize and induce spontaneous activation of the NLRP3 inflammasome in 
the absence or with a low threshold of activators. These mutations lead to autoinflammatory 
syndromes in humans known as Cryopyrin-associated periodic syndromes (CAPS), 
characterized by recurrent inflammatory flares [120]. 
 
 
 
Figure 3. NLRP3 Inflammasome assembly. (1) NLRP3 recruits procaspase-1 through ASC to form the 
inflammasome. (2) Within the inflammasome, procaspase-1 undergoes autocatalytic processing, resulting in 
active caspase-1 which in turn cleaves the pro-IL-1b and pro-IL-18 into the mature and active form (3). NLR: 
NOD-like receptor; PYD: pyrin domain; LRR: leucine-rich repeat; NATCH: central nucleotide domain; ASC: 
apoptosis-associated speck-like protein containing a caspase recruitment domain (CARD). Adapted from [121]. 
 
 
 
 
double hydrogel layers on titania nanotubes (TNT) to achieve a
controlled release of IL-4 and IFN-c. We have developed an
immunomodulatory strategy based on the local delivery of SPMs,
namely lipoxin A4 and resolvin D1, and we were able to in vivo
shift the macrophage phenotypic profile towards a M2 reparative
response [70,71].
Exploring the physicochemical properties of biomaterials has
also led to some promising outcomes. Shayan et al. [72] have used
nanopatterned bulk metallic glasses to modulate murine macro-
phage polarization and concluded that nanopatterned surfaces
lead to a more constructive tissue repair with higher vasculariza-
tion and increased M2 to M1 ratio, when compared to flat surfaces.
Wang et al. [73] have produced macroporous electrospun poly-
caprolactone scaffolds with different fiber size and concluded that
macrophages cultured on thicker-fiber scaffolds tended to polarize
into M2 phenotype, whereas those cultured on thinner-fiber scaf-
folds expressed mainly M1 phenotype. Lee et al. [74] have per-
formed a chemical surface modification in a titanium implants
using the divalent cations calcium and strontium and were able
to up-regulate M2 macrophage phenotype expression. Li et al.
[75] have developed titanium implants doped with magnesium
with the objective of assessing the macrophage response both
in vitro and in vivo nd w re able to induce a higher percentage
of M2 macrophages and higher concentrations of the anti-
inflammatory cytokines IL-4 and IL-10.
The next generation of biomaterials will be developed upon
knowledge of the biology of inflammation and healing and will
regulate biological responses with precision [50]. It is essential to
understand which cells and/or mediators of the immune system
can be used to actively stimulate regeneration [5]. Material science
has also a great deal to offer to the field of immu ology through
the design of different biomaterial-based immunomodulatory
approaches.
3. The inflammasome
3.1. What is the inflammasome?
As explained before, inflammation is initiated on the recogni-
tion of signs of acute damage or disturbances of the steady state
and mainly mediated by the production of soluble factors like cyto-
kines. The innate immune system has several PRRs that upon acti-
vation induce the production of different pro-inflammatory
cytokines. PRRs can be subdivided into two major classes based
in their subcellular location: TLRs and C-type lectin receptors
(CLRs) are transmembrane proteins; while the RIG-I-like receptors
(RLRs) and the NOD-like receptors (NLRs), reside in the intracellu-
lar compartments. These receptors recognize and activate in
response, for example, to distinct PAMPs and also host-derived sig-
nals produced during tissue damage or homeostasis disturbances
called damage-associated molecular patterns (DAMPs) [76,77].
The concept of inflammasome was introduced in the beginning
of this century by Jϋrg Tschopp. The term inflammasome was
coined to describe an intracellular multiprotein complex that per-
ceives pathogenic microorganisms and sterile stressors, being
responsible for t e activation of the highly pro-inflammatory
cytokines IL-1b and IL-18 [78]. Inflammasome is derived from
the word inflammation – to reflect the function of this complex -
and the suffix ‘‘some” from the Greek ‘‘soma” that means body,
which is generally used to define s veral molecular complexes
such as liposome or ribosome [6].
The inflammasome complex (Fig. 3) consists of a cytosolic sen-
sor that could be a PRR of the NLRs or AIM2-like receptors (ARLs)
families, in some cases includes an adaptor protein called
apoptosis-associated speck like protein containing a caspase
recruitment domain (ASC), and an effector protein that in the
canonical inflammasomes is caspase-1 [79]. ASC is a bipartite
molecule that cont ins both an N-terminal Pyrin domain (PYD)
and a C-terminal caspase activation and recruitment domain
(CARD), enabling it to bridge the inflammasome sensor with PYD
domain (NLRs or ALRs) and the effector pro-caspase-1. Additionally
to NLRs and ALRs, other proteins with a PYD domain could also
assemble ASC to form inflammasomes, such as the protein Pyrin
[80].
Different PRRs have been identified to form inflammasomes,
including NLRP1, NLRP3, NLRC4 or AIM2, a ong others. In some
conditions the combined activation of two inflammasomes could
contribute to the inflammatory response [81–83]. Th assembly
of these PRRs in pentameric or heptameric structures oligomerize
ASC in filaments and these ASC filaments recruit caspase-1 leading
to the formation of the inflammasome. The inflammasome com-
plex oligomerize in response to a varied set of inflammation-
inducing stimuli including PAMPs and DAMPs and are appreciated
as an important sensing system that allows the host to mount an
effective immu e response [84]. This response is mediated by the
activation of caspase-1 within the inflammasome, a response that
induces by one hand the cleavage of pro-IL-1b and pro-IL-18 into
their mature biological active forms and a special type of cell death
termed pyroptosis upon cleavage of gasdermin D. Pyroptosis is
executed by the formation of pores in the plasma membrane by
the insertion of the resulting N-terminus fragment of gasdermin
D and the leakage of intracellular content including mature IL-1b
and IL-18 cytokines (Fig. 4).
The NLRP3 inflammasome (previously known as cryopyrin or
NALP3) is presently the most fully characterized inflammasome
Fig. 3. NLRP3 Inflammasome assembly. (1) NLRP3 recruits procaspase-1 through ASC to form the inflammasome. (2) Within the inflammasome, procaspase-1 undergoes
autocatalytic processing, resulting in active caspase-1 which in turn cleaves the pro-IL-1b and pro-IL-18 into the mature and active form (3). NLR: nucleotide-binding domain,
leucine-rich repeat containing; PYD: pyrin domain; LRR: leucine-rich repeat; NATCH: nucleotide-binding domain; ASC: apoptosis-associated speck-like protein containing a
caspase recruitment domain (CARD). . Adapted from [128]
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5.2. The importance of the inflammasome in the innate immune response 
 
Our knowledge on the molecular mechanisms underlying the different functions of the 
innate immune system has significantly advanced in the past decade, in particular the 
activity of the inflammasome in leading innate immune responses, being now considered a 
central platform for a correct innate immune response [115] and recognized as one of the 
cornerstones of the intracellular surveillance system [122]. 
 
The innate immune system is capable to distinguish non-pathogenic or commensals from 
pathogenic microbes, but the mechanisms behind this feature is still unknown. Matzinger et 
al. [123], to explain these unanswered questions of the ‘‘self-from-nonself model”, proposed 
a different hypothesis, ‘‘the danger hypothesis”. This model suggests that an efficient 
immune response will be triggered through an antigen presentation in the context of a 
danger signal and not only by the foreignness of the antigen. Interestingly, an increasing 
number of studies disclose an important function of the inflammasome in the sensing of a 
controversial signal: danger [104]. The discovery that the NLRP3 inflammasome can be 
activated by host-derived molecules supports the idea that the innate immune system 
senses endogenous indicators of cellular danger or stress [115], as in the sterile immune 
response to allografts [124]. 
 
In addition, the effective activity of the inflammasome in guiding innate immune responses 
is clearly revealed by some heritable and acquired diseases in which the dysregulation of 
the NLRP3 inflammasome activity due to mutations that affect its structure is observed, and 
also by the success with which many of these diseases can be treated using IL-1b receptors 
or an antagonist [115, 120]. 
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Figure 4. Inflammasome activation. The exposure to PAMPs or DAMPs, leads to TLRs stimulation causing 
NF-kB activation. NF-kB will then promote the transcription of NLRP3, proIL-1b, and proIL-18 that remain 
inactive in the cytoplasm. This signal (‘‘Signal 1”) is a priming event. For NLRP3 inflammasome activation a 
second signal is required (‘‘Signal 2”) leading to the oligomerization of inactive NLRP3, ASC, and procaspase-
1. This protein complex will then convert procaspase-1 to caspase-1, which leads to the production and 
secretion of the mature IL-1b and IL-18. Different mediators have been described as the second step of 
inflammasome activation: Extracellular ATP can induce K+/potassium efflux through a purinergic P2X7-
dependent pore; PAMPs and DAMPs trigger the generation of ROS; Phagocytosed environmental irritants or 
biomaterials (nanoparticles or biomaterial degradation products) may lead to lysosomal rupture and release of 
their contents. All the above described factors induce NLRP3 inflammasome assembly and activation.  
 
 
5.3. The inflammasome in the inflammatory response to biomaterials 
Different host-derived molecules that are revealing of tissue injury will activate the NLRP3 
inflammasome; these molecules include extracellular ATP, high mobility group protein B1 
(HMGB1), different types of crystals, as uric acid or cholesterol and hyaluronan [115, 125]. 
The implantation process of a biomaterial causes injury to the cells and will consequently 
release danger signals that could activate the NLRP3 inflammasome (Fig. 1). 
and consists of the NLRP3 scaffold, the ASC adaptor protein and
caspase-1, together with the accessory protein NEK7 that maintain
NLRP3 oligomer in active state [85,86]. The NLRP3 inflammasome
is primarily expressed in monocytes, macrophages, granulocytes,
dendritic cells, and also in epithelial cells and osteoblast, being
its expression in myeloid cells highly inducible [87]. This inflam-
masome is initially primed in response to diverse signals (Fig. 4,
priming ‘‘signal 1”), including de novo translation driven by nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-jB) and
post-transcriptional modifications, including phosphorylation,
dephosphorylation, deubiquitination, nitrosylation and ribosyla-
tion [88]. Upon NLRP3 priming, diverse endogenous host-derived
activators (such as extracellular ATP, uric acid crystals or hyaluro-
nan), environmental-derived molecules (such as asbestos and silica
particles) and sev al PAMP are recognized by myeloid cells and
induces the oligomerization of NLRP3 [77,89,90]. This second acti-
vator signal (Fig. 4, activation for complex f rmation ‘‘signal 2”) is
transduced by various mechanisms such as ROS production or
lysosomal damage, being a key common step the intracellular
potassium efflux [87,91,92]. Therefore, the NLRP3 inflammasome
recognise an optimal intracellular milieu [93].
Furthermore, different mutations in NLRP3 results in a protein
conformation with increase ability to oligomerize and induce
spontaneous activation of the NLRP3 inflammasome in the absence
or with a low threshold of activators. These mutations lead to
autoinflammatory syndromes in humans known as Cryopyrin-
associated periodic syndromes (CAPS), characterized by recurrent
inflammatory flares [94].
3.2. The importance of the inflammasome in the innate immune
response
Our knowledge on the molecular mechanisms underlying the
different functions of the innate immune system has significantly
advanced in the past decade, in particular the activity of the
infl mmasome in leading innate immune responses, being now
considered a central platform for a correct innate immune
response [89], and recognized as one of the cornerstones of the
intracellular surveillance system [95].
The innate immune system is capable to distinguish non-
pathogenic or commensals from pathogenic microbes, but the
mechanisms behind this feature is still unknown. Matzinger and
colleagues [96], to explain these unanswered questions of the
‘‘self-from-nonself model”, proposed a different hypothesis, ‘‘the
danger hypothesis”. This model suggests that an efficient immune
response will be triggered through an antigen presentation in the
context of a danger signal and not only by the foreignness of the
antigen. Interestingly, an increasing number of studies disclose
Fig. 4. Inflammasome activation. The exposure to pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs), leads to Toll-like
receptors (TLRs) stimulation causing NF-jB activation. NF-jB will then promote the transcription of NLRP3, proIL-1b, and proIL-18 that remain inactive in the cytoplasm. This
signal (‘‘Signal 1”) is a priming event. For NLRP3 inflammasome activation a second signal is required (‘‘Signal 2”) leading to the oligomerization of inactive NLRP3, apoptosis-
associated speck-like protein (ASC), and procaspase-1. This protein complex will then convert procaspase-1 to caspase-1, which leads to the production and secretion of the
mature IL-1b and IL-18. Different mediators have been described as the second step of inflammasome activation: Extracellular ATP can induce K+/potassium efflux through a
purinergic P2X7-dependent pore; PAMPs and DAMPs trigger the generation of ROS; Phagocytosed environmental irritants or biomaterials (nanoparticles or biomaterial
degradation products) may lead to lysosomal rupture and release of their contents. All the above described factors induce NLRP3 inflammasome assembly and activation.
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The activation of inflammasomes by implanted biomaterials is still poorly understood and 
requires a more in-depth investigation (Table 1). There are already studies in the literature 
exploring the activation of inflammasomes by gold nanoshells [126], silver nanoparticles 
[127] and chitin/chitosan [128] based in the quantification of IL-1b production as a measure 
of inflammasome activation. Malik et al. [129] have performed a more detailed study and 
demonstrated the involvement of the inflammasome in interactions between cells and 
biomaterials and in the progress of the foreign body response using NLRP3, ASC, NLRC4 
and caspase-1 deficient mice. They have observed that microspheres of poly(methyl 
metacrylate) (PMMA) can stimulate the NLRP3 inflammasome and cause the formation of 
an inflammatory exudate that depends on the inflammasome components NLRP3, ASC 
and caspase-1, and lead to the formation of active caspase-1 and secretion of IL-1b. 
Reisetter et al. [130] have demonstrated with in vitro studies using macrophages that 
exposure to carbon black nanoparticles lead to inflammasome activation assessed by the 
cleavage of caspase-1 to its active form and subsequent IL-1b release. Lunov et al. [131] 
have shown in vitro that amino-functionalized polystyrene nanoparticles (PS-NH2), but not 
carboxyl-(PS-COOH) or non-functionalized particles, trigger NLRP3 inflammasome 
assembly and downstream release of pro-inflammatory IL-1b by human macrophages. 
Gómes et al. [132] have investigated in vitro the activation of the NLRP3 inflammasome by 
silica nanoparticles (SiNPs) and reported that SiNPs lead to the production of pro-
inflammatory cytokines with the participation of NLRP3 inflammasome components. 
Caicedo et al. [133] studied the role of shape and size of Cobalt-Chromium-Molybdenum 
(CoCrMo) alloy particles on human macrophage phagocytosis and inflammasome 
activation and found that larger and irregular particles induce higher macrophage IL-1b 
production due to inflammasome activation. 
 
The NLRP3 inflammasome has been implicated in the biological response to wear debris 
resulting from joint replacements (Fig. 5). The normal usage of joint replacements inevitably 
results in the generation of wear debris and the biological response to these particles is 
complex and often drives the process towards periprosthetic tissue destruction and implant 
loosening. Wear debris act as danger signals in tissues around loose implants and are 
recognized as such or after phagocytosis by several PRRs. This will induce the activation 
of the NLRP3 inflammasome pathway leading to the activation of the pro-inflammatory 
cytokine precursors pro- IL-1b and pro-IL-18 by caspase-1, these pro-inflammatory media- 
tors present in the joint fluid will lead to the recruitment, differentiation and maturation of 
osteoclasts precursors and thus, bone resorption will predominate over osteogenesis at the 
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bone- implant interface eventually leading to the loosening of the implant [133-136]. Burton 
et al. [137] investigated both in vitro and in vivo the contribution of the NLRP3 
inflammasome in peri-implant osteolysis using perturbations of caspase-1 and 
inflammasome components. They recognize the NLRP3 inflammasome as an important 
mediator of wear-induced osteolysis and as a potential beneficial target for the treatment of 
periprosthetic osteolysis. 
 
Continued investigation into how biomaterials activate the inflammasome is therefore of 
great interest [138]. Biomaterial recognition by inflammasomes [127, 128, 139] comprises 
key pathways, that can be targeted to improve biomaterial-tissue integration and 
subsequent tissue repair [129]. 
 
 
 
Figure 5. Wear particles released from loose implants lead to inflammasome activation. Wear particles 
are recognized as such or after phagocytosis (lysosomal rupture), by PRRs including TLRs and NLRs leading 
to the assembly of NLRP3 inflammasome. Once assembled the NLRP3 inflammasome cleaves pro-IL-1b into 
the active IL-1b. Secreted IL-1b can promote the maturation of osteoclasts into bone-resorbing cells increasing 
bone resorption and consequently impairing implant function. 
 
A very interesting study of liver regeneration using NLRP3-KO
mice revealed that deficiency of NLRP3 signalling impairs liver
regeneration. The activation of inflammasomes in the liver was
induced after 70% partial hepatectomy. The liver-to-body weight
ratio was significantly decreased in NALP3-KO mice when com-
pared to WT mice after partial hepatectomy, and the expression
of pro-inflammatory cytokines (IL-1b, TNF-a, and IL-6) was
decreased in the remnant liver of NALP3-KO mice compared to
WT mice. In addition, treatment with ATP increased the liver-to-
body weight ratio in WT mice. These results indicate that NALP3
signalling is required for the induction of an inflammatory
response and the improvement of liver regeneration after partial
hepatectomy [116].
Taken together, these results directly link inflammation to pro-
tective and regenerative processes being the inflammasome now
considered as an attractive target to control tissue regeneration
[117]. Thus, the understanding of the signalling that is elicited by
inflammasome can be employed to improve healing [7].
There is extensive interest in the discovery of effective
approaches that selectively inhibit the NLRP3 inflammasome path-
way because this inflammasome is involved in a wide range of
important processes from inflammation to tissue repair [118-
122]. Therefore, modulation of NLRP3 activity is an important tar-
get to develop effective strategies for biomaterial integration
which represents a rather important challenge in the biomedical
research and clinical medicine [123,124].
4. Concluding remarks and future perspectives
Recently, research effort is being placed in the development of
state-of-the-art tissue engineering procedures and biomedical
implants directed to the improvement or even restoration of the
function of diseased tissues or organs. However, the adverse
immune reactions to biomaterials that often interfere with healing
are one of the main challenges to clinical success. The outcome of
tissue engineering therapies and medical implants can be signifi-
cantly ameliorated through biomaterial-based immunomodulation
strategies [51,125].
The engineering of biomaterials that not only fulfil all the
needed requirements of the past but that can also modulate the
immune system, both innate and adaptive responses, is now a
major goal of several studies. The use of biomaterials that stimu-
late the establishment of a pro-regenerative microenvironment at
the implantation site is clearly an emerging field of research. In this
context, biomaterials are considered as key modulators of the
immune response and thus can have important effects in tissue
regeneration and repair. It is our view that immunomodulatory
biomaterials can have a profound impact on patient care if success
in modulating wound healing and tissue regeneration is achieved
[126].
Discoveries emerging from investigating inflammasome biology
promise insights into key pathways regulating immunity, inflam-
mation and homeostasis. Therefore, successful modulation of the
inflammasome activity may become a milestone in bioengineering.
Given the evidence that NLRP3 inflammasome is involved in a ser-
ies of processes from inflammation to tissue repair, there is exten-
sive interest in the discovery of effective approaches that
selectively inhibit the NLRP3 inflammasome pathway [84,127].
There is still poor information on the role of the inflammasome
in the biological response to large scale biomaterials because up to
now studies regarding inflammasome activation were mostly per-
formed using nano- or micro-particles. Clearly, a good number of
tissue engineering approaches involve the implantation of macro-
scopic scaffolds or devices, thus further research into how these
materials activate the inflammasome is of great interest.
Additional studies in this area will be a significant step for
developing effective and novel strategies in regenerative medicine.
The utmost advanced solutions will rise from a close collaboration
between scientist of different areas of research as tissue engineer-
ing, regenerative medicine, materials science and immunology. The
regenerative immunology is an emerging and rather promising
field of research.
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Table 1. Selected studies of the inflammasome role in the inflammatory response to biomaterials. 
 
 
Biomaterial Applicability Pathways Inflammasome Cell/Immune Response 
Gold 
nanoshell-enabled 
photothermal therapy 
(NEPTT) 
Cancer therapies 
Release of ATP, ADP and uric 
acid from tumor cells treated by 
NEPTT 
NLRP3 
 Induce the production of IL-1b [126] 
Silica Cosmetic; food and medical products 
ROS production; Endosomal 
rupture; Leakage of cathepsin B 
 
NLRP3 
 
Recruitment of inflammatory cells; IL-1b secretion 
[140-143] 
 
Quantum Dots Diagnostic and Therapeutic tools Mitochondrial (mtROS) production 
NLRP3 
 Hepatocyte pyroptosis, liver inflammation [144] 
Hydroxyapatite (HA) Bioceramics in orthopaedics surgery 
K+ efflux; ROS generation; 
lysosomal damage 
NLRP3 
 
Stimulate the secretion of the pro-inflammatory 
cytokines-IL-1b and IL-18 [145]; 
 
Microspheres of poly 
(methyl methacrylate) 
(PMMA) and Silicone 
discs 
Wide variety of applications for 
biomedical research and life 
sciences 
Clustering of lipid rafts resulting 
in nonspecific cytosolic 
aggregation of ITAM and 
activation of a Syk kinase 
pathway 
ASC, Caspase 1 
and AIM2 
Foreign Body response (Coll production; 
Leukocyte recruitment)  129];[146] 
Mesoporous silica 
micro-rod (MSR) 
scaffold modified with 
PEG, PEG-RGD and 
PEG-RDG groups 
Biomaterial scaffold-based 
vaccines 
ROS production; Endosomal 
rupture 
NLRP3 
 
MSR stimulated IL-1β production in vitro and 
played a key role in regulating immune cell 
infiltration in vivo [147] 
 
Aluminium 
 
Adjuvants in human and animal 
vaccines 
Membrane disruption with 
resultant K+ efflux 
 
NLRP3 
 
IL-1b and IL-18 production [148] 
 
Calcium 
supplemented -
Biphasic calcium 
phosphate (BCP/Ca) 
particles 
Bone repair Inhibition of ATP/P2X7R interactions 
NLRP3 
 
 
Down-modulated, IL-1β and IL-18 synthesis [149] 
Chitosan and Chitin Regenerative medicine Lysosomal rupture, K(+) efflux, ROS NLRP3 
Higher doses of chitosan activated the 
inflammasome pathway, leading to an increase IL-
1b and PGE2 release [128, 139, 150] 
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5.4. The inflammasome as a bridge between inflammation and regeneration 
 
The immune system is of primary importance in orchestrating a correct repair process [58, 
59], and since inflammasomes are involved in the innate immune response, it is expected 
that they have a key role in tissue repair/regeneration. The activation of the inflammasome 
and thus of caspase-1 has surprising consequences: it not only induces the inflammatory 
response through the activation and secretion of pro-inflammatory cytokines, but it also has 
an important role in the regulation of the extracellular levels of specific proteins, such as 
basic fibroblast growth factor (FGF-2), that are clearly involved in the processes of tissue 
repair and cytoprotection [151]. 
 
There are already some evidences described in the literature on the role of inflammasomes 
in tissue repair/regeneration. Recent studies using a murine skin wound repair model have 
interestingly establish a clear bridge between inflammation and tissue repair through the 
NLRP3 pathway. Weinheimer-Haus et al. [152] used a murine wound repair model in mice 
deficient in NLRP3 and caspase-1 and observed that these animals exhibited a reduced 
inflammatory response at day 5 following wounding with reduced levels of the pro-
inflammatory cytokines IL-1b and TNF-a together with reduced neutrophil and macrophage 
accumulation when compared to wild-type (WT) animals. It was also observed in the 
knockout (KO) mice a delay in wound healing when compared with WT mice. To assess 
whether loss of IL-1b in wounds of NLRP3-KO mice was responsible for the defects 
observed in wound healing the authors performed a rescue experiment in NLRP3-KO mice 
treating the wounds with recombinant IL-1b and concluded that treatment IL-1b exhibited a 
trend of accelerated re-epithelialization. Taken together, these findings indicate that the 
NLRP3 inflammasome contributes to the early inflammatory phase following skin wounding 
and is important for efficient healing. Ito et al. [153] used WT and NALP3-KO and ASC-KO 
mice, and the overall conclusion of the study was that wound repair in mice was significantly 
impaired in NALP3 and ASC-KO mice when compared to the WT. The authors concluded 
that the genetic deficiency of NALP3 decreased the expression of pro-inflammatory 
cytokines together with a reduced inflammatory response at the skin wound site, resulting 
in impairment of wound repair, being similar results obtained using an inhibitor of NALP3. 
In addition, this study revealed that topical treatment with adenosine triphosphate (ATP), 
which is a ligand of NALP3, up-regulated the expression of pro-inflammatory cytokines at 
the wound site and accelerated wound healing in the WT mice. The authors demonstrated 
that the NALP3 pathway activation is involved in wound repair via upregulation of the 
inflammatory response, and the topical use of ATP promoted skin wound closure through 
the upregulation of the inflammatory response in the early wound-healing stage. 
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A very interesting study of liver regeneration using NLRP3-KO mice revealed that deficiency 
of NLRP3 signaling impairs liver regeneration. The activation of inflammasomes in the liver 
was induced after 70% partial hepatectomy. The liver-to-body weight ratio was significantly 
decreased in NALP3-KO mice when compared to WT mice after partial hepatectomy, and 
the expression of pro-inflammatory cytokines (IL-1b, TNF-a, and IL-6) was decreased in the 
remnant liver of NALP3-KO mice compared to WT mice. In addition, treatment with ATP 
increased the liver-to-body weight ratio in WT mice. These results indicate that NALP3 
signaling is required for the induction of an inflammatory response and the improvement of 
liver regeneration after partial hepatectomy [154]. 
 
Taken together, these results directly link inflammation to protective and regenerative 
processes being the inflammasome now considered as an attractive target to control tissue 
regeneration [155]. Thus, the understanding of the signaling that is elicited by 
inflammasome can be employed to improve healing [156]. 
 
There is extensive interest in the discovery of effective approaches that selectively inhibit 
the NLRP3 inflammasome pathway because this inflammasome is involved in a wide range 
of important processes from inflammation to tissue repair [157-161]. Therefore, modulation 
of nlrp3 activity is an important target to develop effective strategies for biomaterial 
integration which represents a rather important challenge in the biomedical research and 
clinical medicine [162, 163]. 
 
 
6. Chitosan  
 
Chitosan (Ch), is a linear polysaccharide, obtained by deacetylation of chitin and is 
composed of (1à4)-2-acetamido-2-deoxy-b-D-glucan (D-Glucosamine) units, and it is the 
most widely used natural polymer after Coll. Chitin or poly (b-(1à4)-N-acetyl-D-
glucosamine) is synthetized by living organisms, being the structural component of the 
shells of crustaceous, cell walls of fungi and exoskeletons of insects. However, due to poor 
solubility of chitin, practical applications are extremely reduced. The degree of deacetylation 
(DDA) of Ch, is related with the number of amino groups along the chain and it is calculated 
as the ratio of D-glucosamine to the sum of D-glucosamine and N-acetyl D-glucosamine. 
Chitosan should contain at least 60% of D-glucosamine residues (DDA of 60%), usually 
DDA fluctuates between 60% and 100% and its molecular weight (MW) from 300 to 1000 
kDA [164]. Instead of DDA, some authors use the degree of acetylation (DA) to characterize 
Ch-based products, which represents the proportion of N-acetyl-D-glucosamine units with 
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respect to the total number of units. The DA allows to define the two terms chitin and Ch. 
So, in the case of Ch, DA is considered to be below 50% [165]. The DDA or DA is a structural 
parameter which influences physicochemical properties such as the MW [166] and also the 
biological properties, such as biodegradation by lysozyme [167], wound-healing properties 
[168] and immune response [169]. 
 
The amino groups in Ch chain differentiate Ch from chitin, offering to the polymer several 
peculiar properties. The amino groups of the D-glucosamine could be protonated making 
the Ch soluble in acidic solutions [170]. The amino groups along the Ch structure allow 
particular interactions with proteins, cells and living organisms. Due to its unique 
characteristics, as it is nontoxic, mucoadhesive, biocompatible and biodegradable, Ch has 
been used to several biomedical applications, such as drug delivery, gene therapy [171], 
vaccine adjuvants [172] and tissue engineering [173], with a variety of shapes and sizes. 
To date, 23.739 articles related to term Ch are indexed by Pubmed, and 8 Ch-based 
products that are currently under clinical trials with the status “recruiting/active, not 
recruiting” (Table 2), can be found at https://www.ncbi.nlm.nih.gov/pubmed/ and 
https://clinicaltrials.gov, respectively, demonstrating that it is a very active area which will 
yield many promising biomedical applications. 
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Table 2. List of clinical studies containing the search term “chitosan” according to clinicaltrial.gov (accessed 15.01.2019). 
 
Study Title Conditions Interventions Location Phase  
Study of Chitosan for pharmacologic 
manipulation of AGE (Advanced Glycation 
Endproducts) levels in prostate cancer patients 
Prostate cancer Drug: Chitosan 
United States of America 
(NCT03712371) 
Phase 1 
Phase 2 
 
Chitosan nerve tube for primary repair of 
traumatic sensory nerve lesions of the hand 
Traumatic lesion of 
sensory nerves of the 
hand 
Device Chitosan nerve tube in addition 
to gold standard therapy 
Procedure: Gold standard primary 
microsurgical repair 
Germany 
(NCT02372669) 
Not 
applicable 
 
Chitosan nanoparticles, chlorhexidine 
gluconate, as intra canal medicaments in 
primary teeth 
Necrotic pulp 
Drug: Chitosan nanoparticles gel 
Drug: Chitosan gel 
Drug: Chlorhexidine gluconate 
Egypt 
(NCT03588351) 
Not 
applicable 
 
The effect of peri-implant surgery and 
chairside supportive post-surgical peri-implant 
therapy 
Periimplantitis 
Peri-implant mucositis 
Device: Chitosan brush 
Data not available 
(NCT03421717 
Not 
applicable 
 
Treatment of Mild to Moderate Peri-implantitis 
Using an Oscillating Chitosan Device Peri-Implantitis 
Device: Labrida BioClean 
Other: Titanium curettes 
Norway 
(NCT03373448) 
Not 
applicable 
 
Functional Chewing Gum in Reduction of 
Gingival Inflammation Gengivitis 
Device: Functional Chitosan Chewing 
 
 Gum Device: Control Chewing Gum 
 
 Behavioral: Oral hygiene measures 
United States of America 
(NCT0323762) 
Not 
applicable 
 
Dental Extractions in Patients Under Dual 
Antiplatelet Therapy 
Blood coagulation 
disorders 
Device: HemCon Dental Dressing 
 
Device: Oxidized Cellulose Gauze 
Brazil 
(NCT02918045) 
Not 
applicable 
 
Dental extractions in patients under dual 
antiplatelet therapy 
Blood coagulation 
disorders 
Device: HemCom dental dressing 
 
Device: Oxidized cellulose gauze 
Brazil 
(NCT02918045) 
Not 
applicable 
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Table 2 (continuation)     
 
Study Title Conditions Interventions Location Phase  
RAVE: Radial Artery Vascular Complication 
and Resource Utilization 
 
Angiogram 
Percutaneous 
Coronary 
Intervention 
Device: SoftSeal®-STF hemostatic pad 
Device: VascBand™Hemostat 
US 
(NCT03522077) 
Phase 4 
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6.1. Immunomodulatory properties of Ch 
 
Modulating the immune system using immunomodulatory biomaterials may support the 
development of therapies that promote both systemic and local pro-regenerative immune 
responses, ultimately stimulating tissue repair. Chitosan exhibits different 
immunostimulatory behaviors, depending on their physical and chemical properties (such 
as molecular weight and DDA or DA). Chitosan products could lead immune cells to release 
pro– or anti-inflammatory mediators. The release of these different mediators can have a 
substantial impact on the performance of the different biomedical devices where Ch is used. 
Biodegradable Ch particles have been shown to promote the release of pro-inflammatory 
cytokines, IL-1b, TNF-a and chemokines associated with M1 macrophage phenotype [150, 
174, 175]. Castro et al. showed that Ch/poly(g-glutamic acid) nanoparticles with a DA of 
11% (i.e., 89% glucosamine and 11% N-acetyl glucosamine) were able to modulate 
macrophage phenotype from a M2 macrophage polarization towards a M1 macrophage 
pro-inflammatory profile, decreasing the expression of CD163 and promoting the release of 
IL-12p40 and TNF-a [176]. We described that 3D Ch scaffolds with a DA of 15% induce a 
typical M1 macrophage response, leading to an increase of M1 surface markers (CCR7+) 
and pro-inflammatory cytokines (IL-6 and TNF-a), in an in vivo study [169]. On the other 
hand, Ch can also induce the release of anti-inflammatory cytokines, leading to an anti-
inflammatory M2 macrophage phenotype [169, 174, 177, 178]. We showed in an in vivo 
model of inflammation that Ch 3D scaffolds with a lower DA (5%, i.e., 96% glucosamine 
and 4% N-acetyl glucosamine) induce a M2 macrophage phenotype, increasing the 
expression of the M2 marker CD206 and the release of anti-inflammatory cytokines, such 
as IL-4 [169]. Oliveira et al. demonstrated in vitro that 2D Ch films with a DA of 11% lead to 
an anti-inflammatory macrophage polarization, increasing the release of IL-10 and TGF-b1 
and a pro-inflammatory dendritic cell stimulation, rising IL-1b and TNF-a [177]. 
 
Immune-modulating properties of Ch have been deeply studied for several years [179], 
however only recently intracellular pathways start to be clarified. The intracellular pathways 
associated to activation of immune cells by Ch-based products are the pathways that 
involve cGas-STING and NLRP3 inflammasome activation [139, 150, 172]. These results 
were observed following macrophage exposure to Ch with different DA and MW. NLRP3 
activation and c-Gas-Sting pathways were recently linked in the context of macrophage 
infection by intracellular pathogens. Thus, macrophages use the same mechanisms to 
respond to Ch particle and intracellular pathogen uptake [180]. 
Chapter I – General Introduction 
 29 
It is thus difficult to characterize Ch-based products as inducers of a pro- or anti-
inflammatory response since both can have positive or negative effects depending on the 
type and severity degree of inflammation and also the conditions that needs to be resolved. 
Assessing the immunological effects of the chemical and physical properties of Ch in an in 
vivo context it is crucial to fully exploit the potential of this polymeric biomaterial in 
regenerative medicine. 
 
 
6.2. Chitosan applications in tissue repair 
 
During the development and fabrication of implantable materials for tissue engineering, 
several different aspects must be taken in account, namely biocompatibility, mechanical 
properties, scaffold morphology as well as healing and tissue replacement capacity. 
Chitosan has the ability to be shaped into different structures, such as microspheres [181], 
membranes [182], sponges [183], fibers [184], and porous scaffolds [185] for tissue 
engineering applications (Table 2). Due to its several remarkable properties, Ch appears 
as a pertinent candidate to substitute damage or missing tissues and to help in the repair 
of damaged organs [186].  
 
For wound dressing, engineered materials should be non-toxic and non-allergenic, 
minimize scarring, provide scaffold for cell growth, allow gas exchanges, keep moist wound 
environment, protect the wound against secondary infections, adsorb wound exudates and 
accelerate tissue repair [186, 187]. Chitosan-based hydrogel is considered as an ideal 
material for wound healing due to its biodegradable, biocompatible, antimicrobial effects, 
and these properties could be modified by the addition of different natural or synthetic 
polymers. Chitosan-based hydrogel could also be used for the delivery of therapeutic drugs 
or growth factors to allow the achievement of a more effective treatment [188].  
 
Nandi et al showed that Ch scaffolds alone or in combination with growth factors can be 
successfully used for bone defect healing. The similarities of the Ch scaffolds with natural 
bone tissue were useful to trigger the proliferation and differentiation of MSCs in 
osteoprogenitors cells [189]. 
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Table 3. Selected studies in vitro, in vivo, preclinical, clinical studies and commercially available of chitosan-based products for tissue engineering applications. 
Chitosan 
product Physical properties Chemical properties Applicability 
Results 
 
Chitosan 
Chitosan Microspheres 
(CMS) with an ECM-
mimicking nanofibrous 
structure 
DA: 5% - 20% 
MW: not provided 
 
Cartilage tissue engineering 
In vitro chondrocyte culture showed an enhanced cell 
attachment and proliferation and a macroscopic 3D 
geometrically shaped cartilage-like composite [190] 
Chitosan/aloe Membranes DA:23.4% MW:166kDa Wound healing 
A higher antimicrobial potential and good cell 
compatibility with primary human dermal 
fibroblasts when compared with chitosan 
membranes without aloe [191] 
Chitosan Porous 3D printed chitosan scaffolds 
DA:25% 
MW: 50-60kDa Wound healing 
In an in vivo test on rat models of diabetes, 
chitosan scaffolds promote the repair of skin, with 
an improved functionality, when compared with 
the commercial products [192] 
2-N,6-O-sulfated 
chitosan/recombin
ant human BMP-2 
 
Powder MW: 5-8x104 Bone healing 
Induce a favorable immune microenvironment 
enhancing crosstalk between immune cells and 
stem cells undergoing osteogenic differentiation 
[193] 
Porous Chitosan 
scaffolds Scaffolds 
MW: Low 
DA:25%-15% Bone healing 
Porous chitosan alone and in combination with 
insulin like growth factor-1 (IGF-1) or BMP2 
promote osteoblastic proliferation [189] 
Completed chitosan-related Clinical Studies 
Chitosan Gel Data not available Chronic Wound Significant reduction (>20%) of wound area in 90% of patients involved in the study [194] 
Chitosan Chitosan-based pads Data not available Haemostasis during percutaneous coronary procedures 
Significant reduced haemostasis time in treatment 
group, when compared with control group [195] 
 
Commercial Products 
Trademarks Properties 
 
[188] 
Chitoflex® 
Hemcon  Control severe bleeding, while also offering an antibacterial barrier against a wide range of gram-positive and gram-negative organisms. 
Tegasorb® 3M Chitosan particles will swell while absorbing exudate and forming a soft gel. 
Chitopack C® 
Eisai Cotton-like chitosan. Restoration of the normal subcutaneous tissue. 
Chitoseal®Abbott Haemostatic function. 
Chapter I – General Introduction 
 31 
7. Bone  
7.1. Bone tissue and mechanisms of bone remodeling 
 
Bone is a highly specialized mineralized connective tissue with crucial functions in the body, 
such as support and protection of soft tissues, locomotion, mineral storage and harboring 
of bone marrow [196]. Structurally, bone is composed of two components: cortical and 
trabecular bone [197]. At the molecular level, bone tissue is constituted by an ECM 
composed by an organic phase and a mineral phase. The organic phase of bone matrix is 
mainly constituted by type I of Coll, and a panoply of non-collagenous proteins (e.g. 
proteoglycans, osteocalcin, osteopontin), while the mineral phase is constituted by 
hydroxyapatite, crystals of calcium and phosphate [198]. The bone cellular fraction is 
composed by bone-lining cells, osteoblasts, osteocytes, osteoclasts and resident 
populations of immune cells, designated as osteomacs (a resident macrophage population) 
[197, 199].  
 
Osteoclasts are the only cells that are known to be able to resorb bone. These cells are 
derived from mononuclear precursor cells of the monocyte-lineage. Osteoclast formation is 
regulated by receptor activator of NF-kB ligand (RANKL) and macrophage colony-
stimulating factor (M-CSF). RANKL is critical for osteoclast formation and M-CSF is required 
for their proliferation [197, 200]. Osteoclasts activation and resorption are regulated by the 
ratio of RANKL and osteoprotegerin (OPG), IL-1 and IL-6, parathyroid hormone, 1,25-
dihydroxyvytamin D, and calcitonin [201, 202]. RANKL is produced by osteoblasts, 
osteoblasts precursors and T cells activated to stimulate osteoclast recruitment and 
activation.   
 
The osteoprogenitor cells give rise to and maintain the osteoblasts that synthesize new 
bone matrix, the osteocytes within bone matrix that support bone structure, and the 
protective lining cells that cover the surface of quiescent bone. Bone marrow contains a 
small population of mesenchymal stromal cells (MSCs) that are capable to differentiate to 
lineages of mesenchymal tissues, like bone, cartilage, fat or fibrous connective tissues 
[203]. Osteoblast precursors change from spindle-shaped osteoprogenitors to large 
cuboidal differentiated osteoblasts on bone matrix surfaces. Active mature osteoblasts have 
large nuclei, enlarged Golgi, extensive endoplasmic reticulum, secrete type I Coll and other 
matrix proteins [197].  
 
The bone lining cells (BLCs) are post-mitotic flat osteoblast lineage cells lining bone surface. 
There are no known markers to characterize BLCs or techniques to isolate them. BLCs are 
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pointed as a source of active osteoblasts [204-206] and one of their function is related with 
the removal of demineralized matrix prior to bone formation [207]. 
Osteocytes are the terminally differentiated osteoblasts that remained entrapped in bone 
matrix. Osteocytes major functions are to support bone structure, metabolism and are 
mechanosensitive. Osteocytes lie within lacunae within mineralized bone and present 
extensive filopodial processes [208]. Osteocytes could live decades in human bone. Empty 
lacunae in aging bone means that osteocytes may have suffered apoptosis [209]. 
 
Osteal macrophages (Osteomacs) are tissue resident macrophages in the endosteal and 
periosteal space that have a crucial role in bone homeostasis, supporting bone formation 
and mediating parathyroid hormone-dependent bone repair [210]. Osteomacs have been 
shown to support osteoblast differentiation and mineralization in vitro, and to be involved in 
intramembranous bone healing after fracture [211] and physiologic skeletal remodeling 
[212]. In addition, these cells also help the maintenance of hematopoietic stem cells niches 
[213].  
 
During development, bone is formed by either intramembranous or endochondral 
ossification. Flat bones are formed by intramembranous ossification and long bones are 
formed by endochondral ossification [214]. Bone is an active tissue that is continuously 
being remodeled to remove old and microdamaged bone and replaced with new bone, 
through the concerted actions of different cells, which include bone-resorbing cells, the 
osteoclasts and bone-forming cells, the osteoblasts, being the osteocytes the 
mechanosensors and orchestrators of the bone remodeling process [215, 216]. The 
remodeling of this complex tissue can be divided in four sequential phases: (i) Activation 
(activation and recruitment of mononuclear monocyte-macrophage osteoclast precursors 
from the circulation), (ii) Resorption (bone resorption is mediated by osteoclasts secreting 
tartrate-resistant acid phosphate, cathepsin K, MMP9 and gelatinase from cytoplasmic 
lysosomes to digest the organic matrix), (iii) Reversal (transition phase from bone resorption 
to bone formation) and (iv) Formation/termination (matrix synthesis by osteoblasts) (Fig.6) 
[197]. The bone remodeling process takes several weeks to occur and is performed by 
clusters of bone-resorbing osteoclasts and bone-forming osteoblasts arranged in a 
structure known as “basic multicellular units” (BMUs) [217]. The main recognized functions 
of bone remodeling include preservation of bone mechanical strength, bone health and 
mineral homeostasis. 
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Figure 6. Bone remodeling. The remodeling cycle is composed for 4 sequential phases, namely, 
activation/resting, resorption, reversal, formation/termination. Resting/activation phase is characterized by 
activation and recruitment of mononuclear monocyte-macrophage osteoclast precursors from the circulation. 
Resorption phase is mediated by osteoclasts starting the digestion of the organic matrix. In the reversal phase 
occurs the transition from bone resorption to bone formation. During formation/termination phase, osteoblasts 
are recruited to the resorbed area starting matrix synthesis. Osteoblasts that get trapped in the bone matrix 
during bone formation become osteocytes. 
 
 
7.2. The role of the immune system in bone fracture repair 
 
The repair of bone fractures recapitulates bone development and can be considered a form 
of tissue regeneration. Fracture healing involves numerous signaling pathways and cell 
types [218, 219]. It follows one of two processes: (i) primary or direct fracture repair and (ii) 
secondary fracture repair. Primary fracture requires proximity and rigidly stable conditions 
leading to little or no inflammation [220]. Secondary fracture repair is the most common 
form and consists of both endochondral and intramembranous bone [221] with highly 
regulated interactions between immune cells, MSCs, osteoblasts and osteoclasts [222, 
223]. Intramembranous ossification is characterized by direct differentiation of MSCs into 
the osteoblastic lineage, that will deposit bone matrix and promote its mineralization into 
mature woven bone. On the other hand, endochondral ossification requires the synthesis 
of a cartilage template by MSCs, the bone callus, being mineralized into woven bone and 
later replaced by mature bone [224, 225]. Due to the key role of the immune system in 
fracture repair Loi et al. suggested that the so-called “diamond concept” of fracture healing 
[226] should be modified to included immune cells and their mediators [220]. It involves 
three overlapping phases: (i) inflammatory; (ii) repair and (iii) remodeling phases (Fig. 7). 
During these processes innate and adaptive immune cells, cytokines and chemokines have 
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a significant role to play, since without an immune response, bone will not heal properly 
[222].  
 
(i) Inflammatory phase 
 
After bone injury, a local disruption of blood supply and soft tissue occurs. Vascular 
disruption results in clot formation to provide homeostasis and the establishment of a 
hematoma that will act as the future template for callus formation. Blood and immune cells, 
including platelets, neutrophils and monocyte/macrophages are recruited to the injury site 
[225]. T and B-lymphocytes are recruited 3 days after injury and are reduced with 
cartilaginous callus formation [227]. The acute inflammatory response peaks within the first 
24h and is normally complete after 14 days [219]. At this stage, mediators responsible for 
inflammation resolution, such as SPMs are reported to be secreted by neutrophils and 
macrophages, promoting the end of the inflammatory response [228]. The initial pro-
inflammatory response involves the secretion of TNF-a, IL-1, IL-18, IL-6, and IL-11 [225]. 
TNF-a, IL-1, and IL-6 are essential for the inflammatory response that triggers 
osteogenesis. In fact, TNF-a and IL-1 exhibit a biphasic response, with high levels 
expressed immediately following injury, decreasing within 72 hours. Both cytokines at 3 - 4 
weeks after injury exhibit again high levels that may correspond to the remodeling phase  
[229]. These factors will lead to the recruitment of inflammatory cells and MSCs and 
promote angiogenesis. Simultaneously, recruited osteoprogenitor cells produce BMPs 
which, in coordination with other factors, promote the local recruitment and osteogenic 
differentiation of MSCs [230]. The hematoma is reorganized and there is a deposition of a 
fibrin thrombus. As capillaries invade the thrombus, granulation tissue replaces the fibrin 
clot. Neutrophils and macrophages remove dead cells and debris [231] and promote the 
recruitment of MSCs (periosteum, bone marrow and systemic circulation) [225]. These cells 
have an immunosuppressive function which helps to resolve the inflammation and prepare 
the local for the next phase of healing.  
 
(ii) Repair phase: cartilaginous and bony callus formation 
-Cartilaginous callus formation 
During the inflammatory phase, MSCs are recruited to the site of injury and undergo 
chondrogenic differentiation. The decrease of mechanical stability at the fracture site 
promotes chondrogenesis. The granulation tissue is replaced by a semi-rigid 
fibrocartilaginous callus that provides mechanical support. In the initial phase, cartilaginous 
callus is avascular; but, as healing proceeds, the callus is invaded by endothelial cells 
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promoting angiogenesis. This induces terminal differentiation of chondrocytes, resulting in 
hypertrophy and the production of mineralized cartilaginous matrix [232-234]. 
 
-Bony callus formation 
Upon calcification of the fracture callus, osteoprogenitor cells are recruited from the 
periosteum, bone marrow, vasculature, and surrounding tissue to initiate osteogenesis and 
the deposition of bone onto the calcified cartilage. During this phase osteoclasts are 
activated to resorb the cartilaginous callus, resulting in the transformation of soft callus into 
a hard callus, with a mineralized matrix produce by osteoblasts. Woven bone formation is 
initiated, providing greater stability than the fibrocartilaginous callus. Immune cells, like 
macrophages T and B cells play a decisive role during mineralization [224, 232].  
 
(iii) Remodeling phase 
The remodeling phase correspond to the last stage of fracture repair. The woven bone (Coll 
fibrils are randomly oriented) within the callus is replaced with laminar bone (Coll fibrils are 
clustered in parallel arrays), consisting of highly organized matrix of Coll fibers, therefore 
restoring the original structure and function of the bone. This process is driven by 
osteoclast-mediated bone resorption followed by osteoblast-mediated bone formation [219, 
223, 235]. 
 
 
7.2.1. Immune dysfunction in bone repair 
 
A healthy immune system is fundamental for a precise fracture healing. Co-morbidities with 
chronic inflammation such as rheumatoid arthritis (RA) [236], diabetes mellitus [237], 
obesity and systemic lupus erythematosus (SLE) [238] are associated with a poor fracture 
healing [239, 240]. Pro-inflammatory cytokines such as IL-1 and TNF-a that are highly 
expressed in these diseases strongly induce osteoclastogenesis, impairing fracture healing 
[241]. In a diabetic model of fracture healing, TNF-a increased chondrocyte apoptosis and 
premature loss of cartilage diminishing bone formation [242]. Hence, a well orchestrate 
balance between anti and pro-inflammatory mediators is advantageous during bone 
fracture healing. 
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Figure 7. Role of immune cells during fracture repair. Bone fracture healing can be viewed as a three-stage 
process: (i) inflammatory, (ii) repair and (iii) remodeling phases. These three phases are characterized by 
different cell types, cytokines, chemokines and growth factors that are involved. (i) The inflammatory phase 
starts with the activation of blood coagulation cascade; formation of provisional fibrin matrix (hematoma); release 
of danger signal molecules and activation of local macrophages  followed by an acute inflammation that is 
characterized by the recruitment of neutrophils and macrophages; clearance of necrotic tissue and provisional 
matrix; production of pro-inflammatory cytokines, chemokines, growth factors and the recruitment and activation 
of MSCs, osteoprogenitors, fibroblasts. Inflammatory phase occurs at low pH and oxygen. (ii) Repair phase (soft 
and hard callus formation) proliferation of progenitor cells; deposition of immature fibrotic extracellular matrix; 
angiogenesis; differentiation of progenitor cells into chondrocytes and production of fibrocartilage; differentiation 
of progenitor cells into osteoblasts and production of woven bone; fracture stabilization; apoptosis of 
chondrocytes; woven bone deposition on cartilage scaffold. (iii) Remodeling phase, bone repair ends with 
resorption of cartilage and woven bone and restoration of harversian system.  Immune cells play important roles 
throughout this process; however, a majority of their activity occurs during early stages of fracture healing. IL-
interleukin; IFN-interferon; MCP - monocyte chemoattractant protein; RANKL - Receptor activator of nuclear 
factor kappa-Β ligand; PGE-prostaglandin; VEGF-vascular endothelial growth factor; CXCL-chemokine (C-X-C 
motif) ligand; SPMs-specialized proresolving mediators; TGF-transforming growth factor; MIP-macrophage 
inflammatory protein; BMP-bone morphogenetic protein; OPG-osteoprotegerin. 
 
 
7.2.2. Macrophages and bone repair 
 
Interplay between macrophages and bone cells is critical to bone formation and repair. 
Resident macrophages, the osteomacs, are present all over osteal tissue [210]. Osteomacs 
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differ from osteoclasts in expression of Siglec 1 (CD169) and its depletion compromised 
bone repair in two different models of bone injury, intramembranous (tibial injury) or 
endochondral (internally-plated femoral fracture model) [243]. Upon bone injury and similar 
to other tissues, resident macrophages release several factors, such as, cytokines, 
chemokines and growth factors to recruit other immune cells to engage the tissue repair. 
Through the release of MCP-1, TNF-a, IL-1, IL-6, CCL2, and RANTES (Regulated on 
Activation Normal T Cell Expressed and Secreted) macrophages stimulate the recruitment 
of MSCs in the early phase of fracture healing [229, 244]. It has been demonstrated the 
anabolic effect of macrophages on osteogenesis [245-247]. Monocytes and macrophages 
support osteoblast differentiation and proliferation. Schlundt et al. showed that for a fracture 
healing to successfully occur, a fine balance in M1/M2 macrophage function is required [41].  
 
 
7.3. Therapeutic approaches through a biomaterial inflammatory - centered 
methodology 
 
Fracture healing is a highly complex process that involves different cells and released 
factors, tissue matrix and the immune system. As described earlier, immune cells play a 
critical role in bone fracture healing being the first responders and the initiators of the repair 
processes. The gold standard therapeutic approaches include the use of autografts, 
allografts and xenografts. Some problems are associated to these strategies, such as the 
requirement of a second donor, in the case of autografts prolonged operative times and 
potential immune response in the case of allograft and xenografts. Thus, current therapies 
for the treatment of non-healing bone fractures and bone disease are inadequate [239]. 
Consequently, a more workable, long term treatment strategy is required. To that end, bone 
graft substitutes are being engineered to help in the surgical revision of non-healing 
fractures [248]. Depending on the severity of the fracture, different approaches for bone 
repair could be used: (i) synthetic scaffolds alone, (ii) scaffolds combined with active 
molecules and (iii) cell-based combination products with cells from different sources [248]. 
Indeed, scaffolds provide the structural support for tissue repair.  
 
The ideal scaffold for bone tissue engineering should be able to promote (i) osteoinduction, 
(ii) osteoconduction, (iii) osteogenesis and (iv) mechanical stability [249]. The 
functionalization of scaffolds should involve controlled release of active molecules and 
combine scaffold degradation with new bone formation [220, 250-252]. Biomaterial-immune 
system interactions are being increasingly recognized as a crucial factor influencing tissue 
repair. The development of novel materials that can diminish the FBR and improve 
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engraftment is a new trend in the tissue engineered products [76]. It is described that the 
host immune reaction following biomaterial implantation of a bone substitute material 
determines the success of bone repair [253]. More recently, increasing evidence has 
demonstrated that injuries with poor healing outcomes are associated with delayed M1-to-
M2 transition [254, 255].  
 
A novel therapeutic approach in the field is to replicate the sequential release of polarizing 
macrophage factors that promote the classical activation into M1-macrophage followed by 
the switch to M2 phenotype. Spiller et al. designed scaffolds for bone regeneration based 
on decellularized bone for a short release of IFN-g to promote M1 phenotype, followed by a 
prolonged release of IL-4 to promote M2 phenotype. Results showed that these scaffolds 
were able to promote in vitro a sequential M1 and M2 polarization in primary human 
macrophages and in vivo exhibited increased vascularization in scaffolds releasing IFN, 
when comparing with controls [92]. It is described that M1 phenotype initiate angiogenesis 
while M2 macrophages promote vessel maturation [256]. Alhamdi et al. tested a biomimetic 
calcium phosphate coating (bCap) as a platform for local delivery to guide macrophage 
phenotype using old mice [257]. They observed that aging delayed bone healing due to 
alterations in bone cells and in the immune system. The bCap was used to separate 
physically and temporally the pro-inflammatory stimulus IFN-g from the pro-reparative 
mediator simvastatin (described to have a modulatory effect on the inflammatory mediators 
[258]). The results obtained showed a sequential M1-to-M2 transition in THP-1 cells and in 
macrophages from old mice [257]. Li et al. showed in a 3D printed scaffold designed for the 
repair of massive bone defects that the release of IFN-g and silicon ions promoted 
sequential M1 to M2 polarization improving angiogenesis [259]. Zheng et al. using a 
decellularized bone matrix (DBM) to delivery IL-4 demonstrated that a proper delivery of IL-
4 can generate an accurate immunomodulation via the synchronized involvement of M1 
and M2 macrophages resulting in a pro-healing microenvironment with a significantly 
osteogenesis and angiogenesis [260]. 
 
The low success rates achieved in rebuilding human bone tissues may be due in part to the 
propensity for therapeutic strategies to target later processes in fracture healing and repair, 
such as MSCs differentiation [261]. Since the immune system is a highly plastic network 
that acts as a guardian of tissue integrity and is able to adapt to the nature of the local 
microenvironment [262], the modulation of the inflammatory signaling pathways using 
engineered biomaterials emerges as a promising new strategy to promote bone repair. 
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7.4. The socio – economic impact of bone fractures 
Bone fractures are one of the most common organ injuries in humans. Bone fracture healing 
is a complex process that under healthy circumstances occurs without scar tissue formation. 
However, due to several causes such as fractures above critical size and co-morbidities, 
i.e. systemic inflammations, tumors, genetic factors and poor lifestyle (i.e. smoking or 
alcohol abuse), 5 - 10% of bone fractures do not heal properly leading to non-union fractures 
[239, 248]. Fracture treatments and bone repair solutions generate important revenues. The 
global orthopedic market was valued at approximately $52.8 billion USD in 2017, driven by 
the growth of the aging population. The orthopedic market includes, surgical power tools, 
all products used to repair fractures internally or externally, spinal fusion and orthobiologics 
that include different strategies to heal bone defects more quickly, such as active molecules, 
stem cells or demineralized bone grafts. The market is expected to present an annual 
growth rate of 3.8% until 2023 [248, 263]. The current “gold standard” treatment for slow or 
incomplete bone healing is to perform bone grafting. Nonetheless, there are limitations to 
bone grafting regarding the limited volume of bone that can be harvested and also donor 
site morbidity [264, 265]. Therefore, a more workable long-term treatment strategy is 
required. To that end, biomaterials are being engineered to help impaired fracture healing 
[248]. 
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Thesis Outline 
 
This thesis is divided in seven chapters that provide a detailed review of literature, presents 
the developed work, and discuss the findings and their implications for the field. 
 
Chapter I provides a general overview regarding the progress in biomaterials field and their 
applications through the years. The inflammatory response to biomaterials is described 
along with the new trend in biomaterials development (immunomodulatory materials); the 
relevance of a well-orchestrated inflammatory response for tissue repair and the key role of 
macrophages during tissue healing. A general information about Ch-based products and 
their biomedical applications is also provided with emphasis on the immunomodulatory 
properties of Ch. Finally, the role of immune system on bone repair is illustrated together 
with the major limitations on bone fractures treatments, the socio-economic impact of bone 
fractures worldwide and new approaches for the improvement of bone healing are also 
highlighted.  
 
Chapter II offers a comprehensive explanation of the main aims and motivations of the work 
developed in this thesis. 
 
Chapter III is the first chapter of original data and describes the role of NLRP3 
inflammasome in macrophage response to 3D Ch scaffolds with different DA (4% and 15%). 
The NLRP3 inflammasome activation pathway was recently linked to macrophage response 
to Ch-based products. Due to the lack of studies related with the role of NLRP3 
inflammasome and macroscopic Ch-based products, in this chapter we explored the effect 
of 3D Ch scaffolds on NLRP3 inflammasome activation in primary mouse and human 
macrophages. Chitosan scaffolds were able to modulate NLRP3 inflammasome activation 
in mouse and human macrophages, an effect not dependent on the DA. This study allows 
us to start to dissect the role of NLRP3 inflammasome in macrophage response to 
macroscopic biomaterials. 
 
Chapter IV presents the development of a novel immunomodulatory biomaterial. Resolvin 
D1 (RvD1), a pro-resolving mediator with relevant functions in the resolution of inflammatory 
responses, was incorporated in 3D Ch scaffolds with higher DA (15%) and lyophilized 
immediately. The developed material (Ch + RvD1 lyophilized); Ch scaffolds with fresh RvD1 
solution (Ch + RvD1) were implanted in vivo, in a model of inflammation, the mouse air-
pouch model. Each animal received an implant and Ch scaffolds alone were used as 
controls. Four days after materials implantation, the inflammatory exudates and Ch 
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scaffolds were recovered for analysis of macrophage cell markers; cytokines produced, and 
cell infiltrate in Ch scaffolds. The developed material was able to shift the macrophage 
phenotype transition from M1 to M2 polarization. The sequential transition of macrophage 
phenotype induced by the developed material offers a new strategy to improve tissue repair, 
since a M2 anti-inflammatory pro-reparative phenotype is associated to an amelioration of 
tissue healing outcome.  
 
Chapter V describes the application of the immunomodulatory material previously 
developed in an in vivo model of tissue repair. As the results presented in chapter IV were 
very promising, herein we present the proof of concept of the developed material. The main 
aim of this work was verified if the Ch + RvD1 lyophilized could improve tissue healing. For 
that, a rat femoral defect model was used. Each animal was implanted with a Ch scaffold 
in the defect created in the right condyle of femurs and two months after injury, femurs were 
collected and analyzed for new bone and Coll formation. Non-operated animals were used 
as controls. The results showed that RvD1 has a positive effect on the new bone formation, 
since the new bone formed presented features that are linked with high quality and strength.  
 
Chapter VI focuses on the development of a new strategy to improve the release time and 
the half-life of RvD1. A sustained release of RvD1 would improve the outcomes concerning 
tissue repair. Solid lipid nanoparticles (SLNs) were used as delivery system for RvD1. 
RvD1-loaded SLNs were developed and tested to assess its capacity to modulate the 
macrophage response to lipopolysaccharide (LPS). The developed nanoparticles allowed 
the decrease of pro-inflammatory cytokines in human macrophages primed with LPS. The 
results of RvD1-loaded SLNs were similar to the results obtained with fresh RvD1 free 
solution even when prepared a day before use, which suggest that the stability of this 
mediator was improved. 
 
Chapter VII presents a general discussion of the results described in the previous chapters 
and suggestions of future work in this research area. We have decided to present a general 
discussion instead of detailed discussion because the latter is presented in each of the 
preceding chapters. 
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AIMS & MOTIVATIONS 
 
 
 
Designing materials to modulate the immune response requires an understanding of the 
role of the immune system in physiologic processes including tissue repair, development 
and tissue homeostasis.  
Chitosan-based products have several interesting properties that could be useful on the 
tissue engineering field. A remarkable one is the capacity to induce a pro- or an anti-
inflammatory response depending on their physical and chemical properties. 
The immune response is fundamental for tissue repair, and Ch scaffolds can be used as a 
template for new tissue formation. The implantation of a biomaterial causes injury to the 
tissue and leads to the onset of an immune response. It begins with an innate response, 
which includes macrophages and the release of several immune factors, that will trigger a 
cascade of immune responders. So, it is important to deeply understand macrophage 
behavior towards a specific biomaterial. The development of materials able to modulate 
macrophage responses appears as a new trend in regenerative medicine. 
The NLRP3 inflammasome, one of the biggest intracellular complexes activated during an 
immune response to several danger signals, was described to have an important role in the 
inflammatory response to Ch-based nanoproducts. However, due to the lack of studies 
showing the role of macroscopic Ch products on NLRP3 inflammasome activation, we 
decided in this research work to understand: (i) the role of a recently described intracellular 
pathway in the macrophage response to macroscopic Ch-based products, the NLRP3 
inflammasome pathway; (ii) develop an immunomodulatory material, through the sequential 
transition of macrophage polarization from a M1 to a M2 macrophage phenotype and finally 
(iii) verify in an in vivo model of bone tissue repair the capacity of the developed material to 
improve bone healing.  
 
 
Hypothesis and goal 
 
Throughout the development of this research work I have explored the idea that Ch-based 
products have favorable immunomodulatory properties that can shift the default response 
to a foreign body implant towards one of tissue integration and functional remodeling. 
 
In order to test this hypothesis, experiments were conducted using a 3D Ch scaffold with 
different DA.  
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In vitro studies were performed using primary mouse and human macrophages and the in 
vivo studies using two different animal models: a mouse model of inflammation and a rat 
femoral defect model (tissue injury model).  
 
 
Specific Aims 
 
i. Investigate the NLRP3 inflammasome role in the inflammatory response to 3D Ch 
scaffolds with different DA. To accomplish this goal, we analyzed the inflammasome 
activation in primary and human macrophages cultured in 3D Ch scaffolds with different 
DA. Cytokine production, cell death and NLRP3 oligomerization were evaluated. Chitosan 
scaffolds were not able to activate per se NLRP3 inflammasome. Interestingly Ch scaffolds 
revealed to have an immunomodulatory effect in the NLRP3 inflammasome activation. 
These results are presented in Chapter III.  
 
ii. Development of a strategy to deliver a pro-resolving lipid mediator to modulate 
macrophage response to 3D Ch scaffolds. In order to achieve this objective, a pro-resolving 
mediator, Resolvin D1 was incorporated in 3D Ch scaffolds with a higher DA (described to 
induce a M1 macrophage phenotype). The developed material was implanted in an in vivo 
model of inflammation, the air pouch model. The inflammatory exudates, the cells that were 
recruited to the implant site and Ch scaffolds were analyzed. The results showed that the 
developed material was able to modulate the macrophage response to 3D Ch scaffolds, 
leading to an increase of M2/M1 macrophage ratio. These results are described in Chapter 
IV. 
 
iii. Evaluate the effect of the material developed in (ii) in an in vivo model of bone injury. To 
test the developed material rat femoral defect model was used. Animals were evaluated 
two months post-injury for the new bone formation and Coll deposition. The femurs were 
collected and analyzed by µCT and histological analysis. We observed an improvement in 
trabecular thickness and in Coll type I in the animals that received the material developed 
in (ii). These results are described in Chapter V. 
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ABSTRACT 
 
Chitosan (Ch) is used in different biomedical applications to promote tissue repair. However, 
tissue injury caused by biomaterial implantation lead to the release of danger signals that 
engage different inflammatory pathways on the host. Different implanted materials activate 
the inflammasome leading to the modulation of the immune response. Here we have 
studied how macroscopic biomaterials, Ch scaffolds with different chemical composition: 
4% or 15% degree of acetylation (DA) modulate the activation of the NLRP3 inflammasome 
in vitro. For that, we assessed the NLRP3 inflammasome in bone marrow derived mouse 
macrophages (BMDM) and human macrophages cultured within 3D Ch scaffolds. We found 
that both Ch scaffolds did not trigger the NLRP3 inflammasome activation in macrophages. 
Furthermore, BMDMs and human macrophages cultured in both Ch scaffolds presented a 
reduction in the number of apoptosis-associated speck-like protein containing a caspase 
activating recruitment domain (ASC) specks and in IL-1b release upon classical NLRP3 
inflammasome stimulation. We also found a decrease in proIL-1b in BMDMs after priming 
with LPS when cultured in Ch scaffolds with DA 4% DA after priming with LPS when 
compared to Ch scaffolds with 15% DA or to macrophages cultured in cell-culture plates. 
Our results shows that 3D Ch scaffolds with different DA impair NLRP3 inflammasome 
priming and activation. 
 
KEYWORDS 
Biomaterials; macrophages; inflammasomes; interleukin-1; immunomodulation; 3D 
scaffolds 
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1. INTRODUCTION 
 
Chitosan (Ch) is a glucosamine and N-acetyl glucosamine polysaccharide widely 
used in biomedical applications to achieve tissue repair through mechanisms involving 
biological responses that are still poorly understood [1-6]. The immune response is 
intimately involved in the success of tissue repair or its potential dysregulations [7, 8]. Tissue 
repair is divided in three stages that could partly occur at the same time: inflammation, new 
tissue formation, and remodeling [8, 9]. Due to their plasticity, macrophages have an 
important role in all of the three stages [10].  In recent years, the immune-mediated tissue 
repair triggered by a biomaterial has become an emergent strategy to repair tissue damage 
[11, 12]. Different approaches can be used to obtain a desired immune response, most of 
them through the modulation of macrophage functions [11, 13-19]. Although several studies 
have demonstrated the immunomodulatory properties of Ch, the exact intracellular 
pathways that are involved in these events have started to be elucidated [13, 20-22]. 
Recently, the nucleotide-binding oligomerization domain-like receptor containing pyrin 
domain 3 (NLRP3) inflammasome and cGAS – STING (cyclic GMP-AMP synthase-
stimulator of interferon genes) were identified as signal pathways involved in the cellular 
immune response to Ch products [23-25]. 
 
Tissue injury after biomaterial implantation leads to the release of danger signals 
that are responsible in part for an inflammatory response that, if it is exacerbated and 
continued during the time it may impair the function of the implant [26]. Danger signals, such 
as alarmins, released from injured tissues are associated with the activation of the 
inflammasome. Moreover, inflammasome components were recently found to modulate 
foreign body response to implanted materials [27]. The inflammasomes are immune 
platforms that tightly regulate the production of the pro-inflammatory cytokines interleukin 
(IL)-1b and IL-18 [28, 29]. Several studies have indicated that Ch is a powerful activator of 
the NLRP3 inflammasome, being the phagocytosis of Ch particles pivotal for this activation 
[24, 25, 30].  The NLRP3 inflammasome is a major component of the innate immune system 
and it is expressed mainly by myeloid cells. NLRP3 is upregulated in response to different 
pathogen-associated molecule patterns (PAMPs), or danger-associated molecule patterns 
(DAMPs) that are linked to tissue injury or tissue stress [31-33]. The NLRP3 inflammasome 
is formed by a cytosolic sensor NOD-Like receptor (NLR) that is the NLRP3 protein, an 
adaptor protein called apoptosis-associated speck-like protein containing a caspase 
activating recruitment domain (ASC), and the cysteine protease pro-caspase-1 as the 
effector molecule. The activation of the NLRP3 inflammasome is closely regulated by two-
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step signals in macrophages [34]. The first “priming” signal enhances the expression of the 
inflammasome components and target proteins via activation of the nuclear factor (NF)-kB 
transcription factor [35]. This first signal also result in a post-transcriptional priming of the 
NLRP3 protein mainly involving deubiquitination [36, 37]. The second “activation” signal 
promotes the assembly of the inflammasome components, and pro-caspase-1 undergoes 
autocatalytic processing resulting in caspase-1 activation which in turn cleaves the pro-IL-
1β and pro-IL-18 into the mature and active forms. Caspase-1 also cleaves gasdermin D to 
promote plasma membrane pore formation, the release of the mature cytokines and 
pyroptotic cell death [38, 39]. The second NLRP3 activating signal involves three major 
mechanisms, including generation of reactive oxygen species (ROS), lysosomal damage, 
and intracellular potassium efflux [40-42]. Inflammasome activation by biomaterials has 
been explored mostly with engineered nanomaterials [43, 44]. 
 
Studies that show inflammasome activation by Ch are related to nanoscale Ch products 
and Ch activates NLRP3 by a mechanism that is dependent on phagocytosis [24] and 
lysosomal destabilization [25]. In contrast, the activation of inflammasome by large scale 
Ch structures has not been investigated yet. Tissue engineering approaches, such as for 
example those for bone repair comprises the implantation of macroscopic scaffolds or 
devices [45]. Thus, advanced information on how these large Ch materials modulate the 
NLRP3 inflammasome will be of key importance to improve biomaterial integration. In this 
study, we have investigated the activation of the NLRP3 inflammasome in macrophages 
cultured in vitro into 3D Ch scaffolds with different degree of acetylation (DA). For that, we 
have used both primary mouse BMDMs and human macrophages derived from primary 
blood monocytes of healthy donors. We found that 3D Ch scaffolds inhibit the activation of 
the NLRP3 inflammasome, by affecting both the priming and the activation step. To our 
knowledge this is the first work that demonstrates the modulatory capacity of 3D porous Ch 
scaffolds in the activation of the NLRP3 inflammasome.  
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2. MATERIALS & METHODS 
 
2.1. Chitosan 3D scaffolds preparation 
Squid pen Ch (ref. 114, Batch No. S4; DA w2%; Mahtani Chitosan Pvt. Ltd) was purified 
through filtration of Ch acidic solution and subsequent alkali precipitation. The DA of the 
purified Ch was assessed by Fourier transform infrared spectroscopy (FTIR) and a DA of 
4% was obtained. This Ch was subsequently N-acetylated in order to prepare Ch with a DA 
of 15% according to the method described by Vachoud et al. [46], in a water/acetic acid/1,2-
propanediol solution, using acetic anhydride as reactive. The 3D porous scaffolds were 
prepared from both Ch solutions (4 and 15%) through thermally induced phase separation 
(-20°C) and consequent sublimation of the ice crystals. Following lyophilization (-85°C; 0.2 
mbar; 24h), the obtained scaffolds were prepared as discs having a diameter of 4 mm (for 
BMDM experiments) and 11mm (for human macrophages experiments) and a thickness of 
2mm. In accordance to previous results of ours, these scaffolds revealed for both of the DA 
that were used, a highly porous and homogeneous microstructure with interconnected 
pores with diameters in the range of 100 µm [47].  
 
2.2. Mouse bone marrow-derived macrophages (BMDM) 
C57BL/6 (wild type, WT) mice were purchased from Harlan. ASC-deficient (Pycard -/-) [48] 
and Caspase-1/11 deficient (Casp1/11-/-) [49] mice were in C57BL/6 background. For all 
experiments, mice between 8-10 weeks of age bred under SPF conditions were used and 
in accordance with the Spanish national (RD 1201/2005 and Law 32/2007) and EU 
(86/609/EEC and 2010/63/EU) legislation, no specific approval is needed to extract tissues 
from euthanized mice. BMDM were obtained from femurs and tibias of mice euthanized by 
CO2 inhalation as previously described [50]. Briefly, the bone marrow was flushed out and 
resuspended in DMEM (LONZA, Verviers, Belgium) supplemented with 25% of L929 
medium containing macrophage colony-stimulating factor, 15% FCS (Invitrogen Life 
Technologies, Madrid, Spain), 100U/ml penicillin-streptomycin (Lonza), and 1% L-
glutamine (Lonza) and plated onto 150-mm dishes, and cultures at 37°C with 5% CO2. After 
6 days, the resulting BMDM were detached with cold PBS, and seeded into the Ch scaffolds 
at a confluence of 0.328 x 106 cells/cm2, left to adhere for 3h at 37°C with 5% CO2 and 
primed at day 7 as described below. As controls, the same number of cells were plated in 
wells without Ch scaffold. The macrophage purity of these preparations was > 90% F4/80 
positive cells. Cells were primed for 4h at 37°C with 1 μg/ml of Escherichia coli LPS serotype 
055:B5 (Sigma – Aldrich), rinsed three times with Et-buffer (147 mM NaCl, 10 mM HEPES, 
13 mM D-glucose, 2 mM KCl, 2 mM CaCl2, and 1 mM MgCl2; pH 7.4) and incubated in the 
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same buffer at 37°C with 10 μM of nigericin (Sigma – Aldrich) during 20 min for NLRP3 
activation. 
 
2.3. Human monocytes and monocyte-derived macrophages 
Human monocytes were isolated by negative selection from healthy donors buffy coats by 
using RosetteSep human monocyte enrichment cocktail (StemCell Technologies), as 
previously described [51, 52]. The buffy coats were provided by the Immunohemotherapy 
Department of Centro Hospitalar São João (CHSJ) from Porto (Portugal) with the approval 
of the clinical ethical committee (Protocol reference 260/11). Cells were resuspended in 
complete medium (RPMI 1640 medium (Corning) supplemented with 10% FBS (Biowest), 
100 U/mL penicillin, 100 μg/mL streptomycin (both from Immunotools). For macrophage 
differentiation, cells were plated in Ch scaffolds at a confluence of 0.5 × 106 
monocytes/scaffold and left to adhere for 3 h. As controls, the same number of cells were 
plated in tissue culture plates (TCPS). Monocytes were cultured for 6 days in complete 
medium and 50 ng/ml of macrophage colony-stimulating factor (M-CSF) (Immunotools). 
After 6 days of differentiation the medium was changed, cells were washed and fresh 
medium without M-CSF was added. At day 7, cells were LPS-primed and stimulated with 
nigericin using the same conditions used for the BMDM. Controls were left unstimulated. 
 
2.4. Lactate dehydrogenase (LDH)  
The presence of LDH in cell-free supernatants was measured using the cytotoxicity 
detection kit (Roche, Barcelona, Spain) following the manufacturer’s instructions, and read 
in a synergy Mx plate reader (BioTek). Lactate dehydrogenase was used as marker for cell 
death. Cell death was defined as the percentage of released LDH compared with maximal 
LDH activity from cell lysates obtained using 1% Triton X-100 on cells plated on TCPS.   
 
2.5. ELISA assays 
Different cytokines were quantified in cell culture supernatants using commercially available 
ELISA kits. Mouse and human IL-1β (Mouse -Ready-SET-Go, eBiosciene; Human – 
Quantikine, R&D), were performed according to the supplier indications. 
 
2.6. Immunocytochemistry and confocal microscopy 
Macrophages stimulated on coverslips and Ch scaffolds were fixed for 15 min with 4% 
formaldehyde, and then washed three times with PBS. For ASC speck quantification and 
CD68 analysis, nonspecific binding was blocked with 2% bovine serum albumin (BSA, 
Sigma) and cells were permeabilized for 30 min with 0.1% Triton (Sigma) in PBS and 
afterwards incubated for 2h at with the primary antibody mouse anti-ASC (1:500, Biolegend) 
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or anti-human CD68 (clone 514H12; 1:100, Biorad), respectively. Subsequently, cells were 
washed and incubated for 1h with the appropriate fluorescence-conjugated secondary 
antibody: for ASC, Alexa Fluor® 647 anti-mouse IgG1 (clone RMG1-1; 1:200, Biolegend) 
was used and for CD68 Alexa Fluor® 488 anti-mouse IgD (1:100, Biolegend) then rinsed in 
PBS and incubated for 20 min with phalloidin-rhodamine (300 nM), rinsed again in PBS, 
and incubated for 10 min with DAPI (1µg/ml). All described procedures were performed at 
RT. Coverslips were mounted on slides with Fluoroshield without DAPI (Sigma). Images 
were acquired with a confocal microscopy (Leica TCS SP5 or TCS SP8) and analysed using 
Image J 2.0 software. 
 
2.7. Western blot 
After cell priming, 25 µl of ice-cold cell lysis buffer supplemented with proteases inhibitor 
cocktail (Sigma) was added to cells in TCPS and 50 µl to cells in Ch scaffolds. Samples 
were incubated for 30 min on ice with frequent shacking, and then centrifuge for 15 min at 
16000g at 4ºC. Supernatants were transferred to a fresh tube and were stored at -80ºC, 
until analysis. Proteins from the lysate were separated in 8-12% denaturing SDS-
polyacrylamide gels and electrotransferred onto nitrocellulose membrane (Bio-Rad). 
Membranes were probed with different antibodies: anti-NLRP3 mouse monoclonal (Cryo-2 
clone; 1:1000; Adipogen), anti-IL-1β rabbit polyclonal antibody (H-153; 1:5000, Santa Cruz 
Biotechnology); anti-IL-1β (clone 2805; 1:5000, R&D); anti-β-actin mouse monoclonal 
antibody (C4; 1:10000, Santa Cruz Biotechnology) and mouse anti-human GAPDH (sc-
47724; 1:5000, Santa Cruz Biotechnology). For BMDM experiments, western blot 
quantification was performed with Image Lab software (version 4.1 Copyright© BioRad 
laboratories) normalizing the values of each sample with the values of β-actin. 
 
2.8. Degradation assay 
Chitosan scaffolds without cells were incubated at 37ºC / 120 rpm during 72h with complete 
medium to evaluate if the Ch extracts (or the Ch degradation products) were able to induce 
inflammasome activation. After 72h, chitosan extracts were collected and frozen at -80ºC 
until use. Chitosan scaffolds extracts were prepared at 0.1mg of scaffold to 1 ml of fluid, 
according to ISO 10993-5:2009 standard.  
The effect of Ch extracts was assessed using human macrophages at day 7 of 
differentiation. For macrophage differentiation, cells were plated in TCPS at a confluence 
of 0.5 × 106 cells/well. Monocytes were cultured for 6 days in complete medium and 50ng/ml 
of M-CSF. After 6 days of differentiation the medium was changed, cells were washed and 
fresh medium without M-CSF was added. Cells were primed at day 7 for 4h at 37°C with 1 
μg/ml of LPS or Ch extracts (Ch4% extracts or Ch15% extracts) working as the first step 
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signal of inflammasome activation, rinsed three times with Et-buffer and incubated in the 
same buffer at 37°C with 10 μM of nigericin (Sigma – Aldrich) or Ch extracts (Ch4% extracts 
or Ch15% extracts)  during 20 min for NLRP3 activation, as the second step signal. 
 
2.9. Statistical analysis 
Comparisons of multiple groups were analyzed by one-way analysis of variance ANOVA 
with Kruskal-Wallis test with Dunn’s multiple comparisons test using Prism 6 software 
(GraphPad). P-values <0.05 were considered statistically significant. 
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3. RESULTS 
 
3.1. Effect of 3D Ch scaffolds with different degrees of acetylation reduce IL-1b 
release upon NLRP3 activation 
To assess the role of the inflammasome in the macrophage response to 3D Ch scaffolds, 
BMDMs from C57BL/6J mice were analyzed in response to 3D Ch scaffolds with different 
DAs (4% and 15%). BMDMs were plated in the Ch scaffolds at day 6 and primed at day 7 
with LPS (1 μg/ml, 4h) being the subsequent NLRP3 activation achieved after incubation 
with nigericin (10 μM, 20 min). Interestingly, our results showed that 3D Ch scaffolds per se 
were not able to activate the inflammasome, and no IL-1b release was detected with Ch 
scaffolds without stimulus and even after LPS priming (Fig. 1A). In addition, the release of 
IL-1b after NLRP3 inflammasome activation with nigericin was significantly decreased in 
BMDMs plated in 3D Ch scaffolds with lower DA when compared with cells in TCPS (Fig. 
1A). Cells cultured in 3D Ch scaffolds with 15% DA also showed a decrease in IL-1b 
release, although the difference was not statistically significant (Fig. 1A). To reject the idea 
that LPS or nigericin could be adsorbed by Ch scaffolds thus being less bioavailable to 
activate inflammasomes, cells were primed with LPS for 4h (previously incubated with Ch 
scaffolds) and the subsequent NLRP3 activation was achieved after incubation with 
nigericin (also previously incubated with Ch scaffolds) during 20 min. The results showed 
that prior incubation of LPS and nigericin with Ch scaffolds (Ch4% or Ch15%) did not affect 
their bioavailability to activate inflammasomes (data not shown). 
As a control, we confirmed that the absence of ASC (Pycard-/-) and Caspase-1 
(Caspase1/11-/-), impaired the release of IL-1b after NLRP3 activation in macrophages 
cultured in 3D Ch scaffolds (Fig. 1B). 
 
We observed that when BMDMs were seeded in Ch scaffold, a considerable number of 
macrophages migrated and attached to the bottom of the well (Fig. 1C, right column). 
Therefore, to assess if the macrophages within the Ch scaffolds and the ones migrating to 
the well, will have a differential effect in NLRP3 activation, 24 hours after cell seeding the 
Ch scaffolds were changed to a new well and inflammasome priming and activation was 
performed on both sets of macrophages (the cells within the scaffolds and the cells that 
attached to the bottom of the wells). Similar results were obtained on both fractions (Fig. 
1D), showing that Ch scaffolds were able to modulate macrophage response to NLRP3 
inflammasome activation in both cells, the ones within and the ones outside the scaffold. 
The effect observed in the macrophages that migrate to the bottom of the well could be 
related with their short interaction with the scaffolds, but also due to the released mediators 
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by macrophages adherent to the scaffolds, or even due to degradation products released 
by the scaffolds. 
 
Inflammasome activation leads to a type of lytic cell death known as pyroptosis [33]. Lactate 
dehydrogenase (LDH) is a cytosolic enzyme that is released into the culture medium 
following pyroptosis [53], therefore the presence of LDH in cell supernatants was 
determined. LDH leakage induced by inflammasome activation was lower in BMDMs 
seeded on 3D Ch scaffolds comparing with cells in TCPS, presenting the macrophages 
39% less pyroptosis when cultured in Ch4% scaffolds than in TCPS (Fig. 1E). Finally, to 
reject the hypothesis that the decrease of IL-1b could be related with a low number of 
macrophages present in the Ch scaffolds, we decided to measure total intracellular LDH 
activity in LPS-primed macrophages cultured in TCPS and the Ch scaffolds. We found that 
the number of macrophages was higher in Ch scaffolds with lower DA compared with TCPS 
(Fig. 1F). We have measured the cell number after LPS priming in order to confirm that 
equal number of cells were in the scaffolds and TCPS before nigericin stimulation so that 
when inflammasome is trigger we have a similar number of cells in all the experimental 
conditions. It is important to clarify that LPS + nigericin is not a co-stimulation, but a serial 
stimulation. Thus, the LPS is the base for the priming time and then nigericin is added for a 
short time, which induces pyroptotic cell death. Variations in NLRP3 activation will lead to 
different degree of pyroptosis and different number of cells in the final cultures. This could 
be explained in base on previous studies demonstrating that Ch scaffolds lead to an 
increase in the metabolic activity of macrophages, comparing with cells in TCPS, proving 
that Ch scaffolds supports adhesion and development of macrophages [54]. This result 
confirms that the decrease of IL-1b is due to the modulatory effect of 3D Ch scaffolds with 
lower DA on macrophage function. Chitosan scaffolds with higher DA also induced a 
decrease of IL-1b, although with a lower effect when compared to Ch scaffolds with lower 
DA.  
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Figure 1 | IL-1β release after NLRP3 activation is decreased in macrophages plated on 3D Ch scaffolds. 
(A, B) ELISA for IL-1β release after NLRP3 activation in BMDMs from wild type mice (A, B), Pycard-/- or 
Caspase1/11-/- (B) cultured in tissue culture plates (TCPS) or 3D Ch scaffolds with different DAs (n>5 for A, n=1 
for B). (C) Representative images of wild type BMDMs in culture. Scale bar=100µm; dotted line represents the 
edge of the Ch scaffold. (i,ii) Schematic representation of the experiment. i) Ch scaffolds were transferred to a 
new well 24h after cell seeding; ii) the inflammasome activation was performed as in A on both cell fractions. 
(D) ELISA for IL-1β release after transfer the scaffold to a new well (n=3). Chitosan scaffolds were transferred 
to a new well 24hrs after cell seeding and treated as in A. (White bars represents cells that have migrated from 
the respective Ch scaffolds to the bottom of the well and treated as in A); (Light Grey bars represents cells in 
the Ch scaffolds that were transferred to a new well and treated as in A). (E) Percentage of extracellular LDH 
activity measured in supernatants from wild type BMDMs treated as in A. (F) Percentage of LDH activity from 
cell lysates of from BMDMs cultured in different Ch scaffolds normalized to BMDMs cultured in TCPS (100%, 
indicated by a dashed line). Statistically significant differences: *p<0.05; **p<0.01 using Kruskal-Wallis test with 
Dunn’s multiple comparisons test. 
3.2. Chitosan scaffolds with lower degree of acetylation impair NLRP3 inflammasome 
oligomerization 
The effect of 3D Ch scaffolds on NLRP3 inflammasome oligomerization was analyzed 
through the staining of the ASC protein. Upon activation of NLRP3, ASC proteins 
oligomerize into fiber-like structures and the ASC filaments recruit caspase-1 leading to the 
formation of the inflammasome; staining of the large protein aggregates formed by ASC 
assembly makes possible the visualization of the inflammasome complex [55]. As shown in 
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the Fig. 2A, ASC oligomers (red dots) are mostly visualized near the nucleus. The number 
of ASC oligomers per cell was quantified with the Image J software. The images confirmed 
that macrophages cultured into 3D Ch scaffolds (4% and also 15%) were not able to induce 
inflammasome oligomerization, since no ASC oligomerization was detected after LPS 
priming (Fig. 2A, first column).  
 
Since IL-1b release was strongly down-modulated in presence of 3D Ch scaffolds, we then 
confirmed that the formation of ASC oligomers followed the same trend. As depicted in Fig. 
2B, BMDMs seeded in Ch scaffolds with 4% DA presented a significantly lower number of 
macrophages containing ASC oligomers, 20.35 ± 9.75 % when compared with cells in 
TCPS, 60.73 ± 17.44 % (Fig 2B). Macrophages seeded on 15% DA Ch scaffolds also 
presented a reduced number of cells with ASC oligomers, though the differences were not 
statistically significant compared to cells plated on TCPS (Fig 2B). After inflammasome 
activation, together with IL-1b release, oligomeric particles of inflammasomes are also 
released as particulate danger signals that could amplify the inflammatory response [56, 
57]. We quantified extracellular ASC oligomers and the results showed a reduced number 
of ASC specks released after NLRP3 activation from macrophages plated in Ch scaffolds 
with lower DA comparing with TCPS and with Ch scaffolds with higher DA (Fig. 2C). 
 
Figure 2 | Chitosan scaffolds decrease the formation of ASC specks after NLRP3 activation. (A) 
Representative images of LPS-primed macrophages cultured in TCPS or Ch scaffolds with different DAs and 
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stimulated or not with nigericin as indicated, followed by staining of ASC (red), actin (yellow; phalloidin) and 
nuclei (blue; DNA-binding dye DAPI). Arrows indicate ASC oligomers. Scale bar=10µm. (B) Percentage of 
BMDMs with ASC specks quantified from images as in A, average data from n=4 independent experiments. (C) 
Percentage of extracellular ASC oligomers (n=4) from macrophages cultured and stimulated with LPS + 
Nigericin. Statistically significant differences: *p<0.05 using Kruskal-Wallis test with Dunn’s multiple 
comparisons test. 
 
3.3. Chitosan scaffolds affect NLRP3 inflammasome priming 
To assess the effect of 3D Ch scaffolds on inflammasome priming, we next studied pro-IL-
1b and NLRP3 protein expression in BMDMs cultured on 3D Ch scaffolds and TCPS after 
LPS priming and NLRP3 activation by nigericin. For that, macrophages cultured in Ch 
scaffolds were lysed for Western blot analysis. As shown in Fig. 3A, scaffolds did not 
stimulate the expression of inflammasome components after LPS priming. In fact, we 
observed that the expression of pro-IL-1b after LPS priming was highly reduced in BMDMs 
seeded on both Ch scaffolds, being the differences statistically significant once again for 
Ch scaffolds with lower DA when compared with cells in TCPS (Fig. 3A, B). The results also 
showed that after nigericin stimulation most of pro-IL-1b from cells in TCPS and on Ch 
scaffolds with higher DA is lost in the cellular fraction, suggesting its release (Fig. 3A). On 
the other hand, in Ch scaffolds with lower DA we observed a slightly increase in the 
intracellular detection of pro-IL-1b after NLRP3 activation (Fig. 3A, B). In contrast, no 
differences were found in the transcriptional priming of NLRP3 when compared 
macrophages cultured in TCPS or Ch scaffolds (Fig. 3A, C). These results, together with 
the decrease of IL-1b release and the reduced number of ASC specking macrophages, 
suggest that 3D Ch scaffold with lower DA decrease the NLRP3 inflammasome activation.  
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Figure 3 | Pro-IL-1b, but not NLRP3, transcriptional priming is affected by Ch scaffolds. (A) 
Representative Western blot analysis of NLRP3 and pro-IL-1b in cell lysates of BMDMs primed for with LPS 
followed by no stimulation or stimulation of NLRP3 with nigericin; β-actin serves as a loading control throughout. 
(B, C) Quantification of pro-IL-1β (B) or NLRP3 (C) from n=3 independent blots as the one shown in panel A. 
Kruskal-Wallis with Dunn’s multiple comparisons test. Statistically significant differences: **p<0.01. 
 
3.4. NLRP3 inflammasome activation is impaired in human macrophages cultured on 
Ch scaffolds 
Human macrophages from “buffy coats” of healthy donors were cultured in 3D Ch scaffolds 
with different DA (4% and 15%). After 7 days of culture we confirmed that human 
macrophages cultured in Ch scaffolds were viable and expressed the 
monocyte/macrophage marker CD68 (Fig. 4A). As CD68 is a member of the scavenger 
receptor family with a role in phagocytosis, macrophages cultured in Ch scaffolds showed 
a CD68 distribution mostly in the adhesion region to the scaffolds, in contrast with cells in 
TCPS where the staining is distributed uniformly through the cell (Fig. 4A). We observed 
that human macrophages released a small amount of IL-1b during LPS priming when 
cultured in either TCPS or in Ch scaffolds (Fig. 4B). Since human monocytes exhibit an 
alternative one-step pathway of NLRP3 activation in response to LPS alone [58], and our 
macrophage cultures derive from monocytes, it could be feasible that some alternative 
NLRP3 activation could account for this release. However, after NLRP3 activation with 
nigericin human macrophages seeded in Ch scaffolds presented a decrease of IL-1b 
release, being statistically significant different for cells cultured in Ch scaffolds with higher 
DA (Fig. 4B).  
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Figure 4 | IL-1β release after NLRP3 activation in human macrophages cultured in Ch scaffolds. (A) 
Representative image of CD68 expression on human macrophages after 7 days in culture, CD68 (green) and 
nuclei (blue; DNA-binding dye DAPI); scale bar = 20µm. (B) ELISA for IL-1β release after NLRP3 activation in 
human macrophages cultured in TCPS or Ch scaffolds with different degree of acetylation (n=5). (C) 
Representative blots of NLRP3 and pro-IL-1b in cell lysates of human macrophages primed with LPS followed 
by no stimulation or stimulation of NLRP3 with nigericin; GAPDH serves as a loading control throughout. (D) 
Percentage of LDH activity in the supernatant of human macrophages treated as in A and normalized to total 
intracellular LDH levels. (E)  Percentage of LDH activity in lysates from Ch scaffolds, dotted line represents the 
LDH activity of macrophages cultured in TCPS. Statistically significant differences: *p<0.05 using Kruskal-Wallis 
test with Dunn’s multiple comparisons test. 
 
To assess if Ch scaffolds were able to influence the transcriptional priming step of NLRP3 
inflammasome in human macrophages, NLRP3 and pro-IL-1b protein expression was 
analyzed in cell extracts. We observed a decrease of NLRP3 expression after LPS priming 
in both Ch scaffolds when compared to cells in TCPS (Fig. 4C). Surprisingly, human 
macrophages cultured in Ch scaffolds with lower DA showed an increase of pro-IL-1b after 
LPS priming, when compared with macrophages cultured in TCPS and Ch scaffolds with 
higher DA (Fig. 4C). The amount of pro-IL-1b protein did not change after nigericin 
stimulation (Fig. 4C), probably due to the low expression of NLRP3 that compromise the 
activation of NLRP3. These results confirmed the low amount of IL-1b released from 
macrophages cultured in Ch scaffolds. This is in line with the reduced pyroptosis found in 
human macrophages cultured in Ch scaffolds after NLRP3 activation (Fig. 4D). This result 
was not due to a lower number of macrophages present in the Ch scaffolds, as similar levels 
of LDH was found in macrophages lysates when cultured in TCPS and Ch scaffolds (Fig. 
4E).  
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In order to assess if the Ch scaffold degradation products could influence macrophage 
behavior, the effect of Ch degradation products (extracts) on human macrophages was 
investigated and the results demonstrated that the extracts from both scaffolds (4% and 
15%) were not able to induce a significant release of IL-1b when compared with the controls 
(Fig. 5 A, B). 
 
Figure 5 | IL-1b release in human macrophages cultured in TCPS after NLRP3 inflammasome activation 
with chitosan degradation products. (A) ELISA for IL-1β release after human macrophages priming with LPS 
or Ch4% extracts (first step signal) and subsequent NLPR3 activation with nigericin or Ch 4% extracts (second 
step signal) (n=3). (B) ELISA for IL-1β release after human macrophages priming with LPS or Ch15% extracts 
(first step signal) and subsequent NLPR3 activation with nigericin or Ch 15% extracts (second step signal) 
(n=3)). Statistically significant differences: *p<0.05 using Kruskal-Wallis test with Dunn’s multiple comparisons 
test. 
 
In addition, human macrophages cultured in Ch scaffolds with lower DA presented a 
decreased number of ASC specks (7.22 ± 2.74%) being this also observed for the 
macrophages cultured in Ch scaffolds with higher DA (6.64 ± 2.47%) when compared with 
cells plated in TCPS (29.27%±6.59), although this decrease was not statistically significant 
(Fig. 6 A, B). Taken together, our data show that 3D Ch scaffolds are able to down-regulate 
the activation of the NLRP3 inflammasome in human macrophages. 
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Figure 6 | Chitosan scaffolds decrease the formation of ASC specks after NLRP3 activation in human 
macrophages. (A) Representative images of LPS-primed human macrophages cultured in TCPS or Ch 
scaffolds with different DAs and stimulated or not with nigericin as indicated, followed by staining of ASC (red), 
actin (yellow; phalloidin) and nuclei (blue; DNA-binding dye DAPI). Arrows indicate ASC specks. Scale 
bar=20µm. Orthogonal views of cells within the Ch scaffold (right column). (B) Percentage of human 
macrophages with ASC specks quantified from images as in A, average data from n=3 independent 
experiments. Statistically significant differences: *p<0.05 using Kruskal-Wallis test with Dunn’s multiple 
comparisons test. 
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4. DISCUSSION 
 
In this study, 3D Ch scaffolds with different DA were used to determine their modulation on 
NLRP3 inflammasome activation in the release of pro-inflammatory IL-1b from macrophage 
responding to macroscopic biomaterials. Our main finding is that Ch scaffolds decrease 
NLRP3 inflammasome priming and activation in in vitro cultured macrophages. This 
inhibition was found at the level of ASC oligomerization, IL-1b release and pyroptosis 
execution for both DAs studied. 
 
Interestingly, although several studies have reported that Ch leads to inflammasome 
activation, by inducing K+ efflux, reactive oxygen species production or lysosomal 
destabilization [24, 30] our data show that Ch 3D scaffolds were not able to activate the 
inflammasome in both mouse BMDMs and human macrophages. In addition, results also 
showed that the degradation products of Ch are not able to induce changes in the release 
of IL-1b in human macrophages. This could be due to the size of the material used in the 
different studies. It is known that implanted biomaterials with different sizes, induce 
distinctive immune responses [59]. Bueter et al. described an inverse association of the Ch 
particles size and inflammasome activity, suggesting that phagocytosis is required for 
inflammasome activation [24], and in our 3D scaffold-culture system, macrophages would 
not phagocyte Ch particles. Fong et al. found in U937 human macrophage-like cell line that 
biodegradable Ch microparticles selectively induced the release of IL-1b [60]. In this same 
cell line different Ch particles with controlled DA lead to either a type I IFN or inflammasome 
response, being this activation dependent on the extent of lysosomal rupture and cytosolic 
foreign body internalization [25]. Due to size disparity, macrophages are not able to 
phagocyte the 3D Ch scaffolds used in this study since they have a diameter of 11 mm and 
a thickness of 0.2 mm. Therefore, this work shows that the NLRP3 inflammasome is 
impaired when macrophages are cultured in Ch 3D macroscopic scaffolds. The impact of 
3D macroscopic scaffolds on immune cells has not been well explored. A previous work 
showed differences in the cytokine secretion profile of from human macrophages interacting 
with different 3D structures. Chitosan scaffolds stimulated production of TNF-a and small 
amounts of IL-10 [61]. Different outcomes on macrophages behavior could be achieved 
changing the properties of the substrates. Our data show that material morphology and 
chemistry is an important aspect in biomaterial design that influence immune cell 
responses. 
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Interleukin-1b is a major pro-inflammatory cytokine with an important role in host-defense 
responses to infection and injury [62]. However, an exacerbated release of IL-1b can be 
related to severe inflammatory diseases [63]. Here, we found that the physical and chemical 
properties of Ch scaffolds were able to negatively modulate NLRP3 inflammasome 
activation in macrophages, decreasing the release of IL-1b and the degree of pyroptosis 
and suggesting a potential beneficial anti-inflammatory effect of implanted Ch scaffolds. 
Chitosan has been widely used to modulate the immune response, through the regulation 
of macrophage response [13, 20]. However, identifying the mechanisms behind these 
responses have been elusive. Our data show that 3D Ch scaffolds have a modulatory effect 
not only in cells inside in the scaffolds, but also in the cells that shared the same well, as a 
decrease of IL-1b was observed from macrophages that migrate or goes outside the 
scaffold when seeded. The decrease of IL-1b production was partially explained by a defect 
on the transcriptional priming, as murine, but not human, macrophages cultured in Ch 
scaffolds expressed less pro-IL-1b after LPS priming. This effect could be explained by the 
immunomodulatory capacity of Ch, previous described by us and others [13, 20, 52, 60, 64-
66] demonstrating the production of several immune factors. Opposite results have been 
reported on the immune response obtained when Ch was present in different forms. 
Physical and chemical properties of Ch and the time of culture could dictate the type of the 
inflammatory response. We showed in a in vivo model of inflammation that 3D Ch scaffolds 
with higher DA increase the number of inflammatory cells recruited to the implant site the 
production of pro-inflammatory cytokines, such as IL-6 and TNF-a and also attracted mainly 
M1 macrophages, whereas 3D scaffolds with lower DA increase M2 macrophages in the 
implant site and IL-4 three days after of implantation [13, 47]. On the other hand, human 
macrophages cultured in Ch films with higher DAs presented a down-regulation of pro-
inflammatory markers and cytokines, particularly TNF-a, and an increase of anti-
inflammatory products such as IL-10 and TGF-b1 [20]. Oliveira M. et al. also showed that 
Ch films were not able to activate MAPK pathways ERK1/2 and JNK [66]. Tu J. et al. showed 
in LPS-primed Caco-2 cells that Ch nanoparticles were able to reduce inflammatory reaction 
decreasing cytoplasmic IkB-a degradation and nuclear NF-kB p65 levels [65]. However, it 
is noticeable that we found Ch scaffolds with lower degree of acetylation, to cause an 
increase pro-IL-1b in LPS-treated human macrophages. In any case, the release of IL-1b 
was still decreased in human macrophages after NLRP3 activation. This data confirms the 
importance of inflammasome activation for IL-1b release, even if enough pro-IL-1b is 
produced [67]. 
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The NLRP3 inflammasome is also required for tissue repair and regeneration as reported 
in recent studies demonstrating its role in wound repair and liver regeneration [68-70]. 
However, when NLRP3 activation is exacerbated the correct resolution of inflammation 
does not occur and lead to fibrosis [71, 72], being high concentration of IL-1b negatively 
influence the healing process [73]. Our results are particularly important in this regard, as 
Ch scaffolds were able to decrease IL-1b release and pyroptotic cell death of macrophages. 
Consistently Ch scaffolds also decrease the number of ASC oligomers released, as these 
oligomers could be released as particulate danger signals [56, 57]. Therefore, the 
modulation of NLRP3 activity by Ch scaffolds can be in our opinion an interesting approach 
to improve biomaterial integration and enhance the outcomes of clinical conditions that 
involve tissue repair when excessive inflammation is present. Nevertheless, further studies 
in an in vivo model of tissue repair must be conducted to clearly assess the ability of the 3D 
Ch scaffolds to modulate the NLRP3 inflammasome activity leading to an improvement in 
biomaterial integration and subsequent tissue healing. 
 
The overall inflammatory / anti-inflammatory effect of the scaffolds has been extensively 
investigated by us using a rodent air pouch model of inflammation where we have observed 
clear differences between both scaffolds: different DA (4% and 15%) hints distinctive 
macrophage polarization phenotype following material implantation. Chitosan scaffolds with 
higher DA induce a typical pro-inflammatory response mediated by M1 macrophages. On 
the other hand, Ch scaffolds with lower DA caused an inflammatory reaction characteristic 
of a macrophage M2 reparative response [13]. Following these results, we anticipated to 
observe clear differences in NLRP3 inflammasome activation in this study. These 
differences were not found, moreover the results on both DA were rather similar. We 
assume that these differences are related to the fact that in vivo, different cell types are 
present at the implant site and will secrete different mediators that will have an influence in 
the fate of macrophage polarization in response to the implanted material. In fact, there are 
clear differences between in vitro and in vivo models. The in vivo microenvironment is rather 
more complex, with a multiplicity of players that cannot be mimic in the in vitro studies. 
Together our data have demonstrated that 3D Ch scaffolds impair NLRP3 inflammasome 
activity in macrophages resulting in a significant decrease of ASC oligomers formation, IL-
1b release and pyroptotic cell death in both mouse and human macrophages. This effect 
was dependent on both, the transcriptional priming and activation of the NLRP3 
inflammasome by macrophages cultured in Ch scaffolds and independently of the DA. 
Another important conclusion that can be taken from our results is that the inflammasome 
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activation is dependent of phagocytosis which does not occur with our 3D macroscopic 
scaffolds. 
5. CONCLUSIONS 
We report for the first time that 3D Ch scaffolds modulate NLRP3 inflammasome activity. 
Interestingly, our results are in contrast with studies reported in the literature that indicate 
that Ch is a powerful activator of the NLRP3 inflammasome in nanoscale Ch products. Our 
studies that were performed in large scale Ch scaffolds, stressing out that the process of 
small Ch particles phagocytosis is pivotal in inflammasome assembly and activation. Our 
results revealed that macrophage culture in Ch scaffolds results in a significant decrease of 
IL-1b release, a decrease of ASC oligomer formation in both BMDMs and human 
macrophages after NLRP3 activation, and a decrease of LPS induced pro-IL-1b production 
in BMDMs and of NLRP3 in human macrophages. This effect was observed when 
macrophages were cultured in Ch scaffolds with different DAs. Interestingly the same 
behavior was observed for both DAs, which is in contrast with previous in vivo results of 
ours that demonstrated clear differences in the macrophage polarization profile, highlighting 
the importance of performing further studies using in vivo models. These findings provide 
an important understanding of the immunological properties of 3D Ch scaffolds, which will 
dictate a favorable fate for biomaterial integration.  
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ABSTRACT 
 
In our search for immunomodulatory biomaterials capable of modulating the inflammatory 
response through M2 macrophage polarization, we report here on a new strategy that 
resulted from the incorporation of resolvin D1 (RvD1), a pro-resolution lipid mediator in 
porous 3D chitosan (Ch) scaffolds, followed by its lyophilization. We have investigated the 
inflammatory response caused by this biomaterial in vivo using a mouse air-pouch model 
of inflammation. We found that this developed material caused a decrease in inflammatory 
cells recruited to the implant site, together with higher numbers of F4/80+/CD206+ cells (M2 
macrophages) and lower numbers of F4/80+/CCR7+ cells (M1 macrophages). It also 
induced a general decrease in pro-inflammatory cytokines and caused a decrease in the 
inflammatory cells observed around and within the implanted scaffolds, when compared 
with Ch alone or Ch not submitted to lyophilization after RvD1 incorporation. Our results 
demonstrate that we were able to develop an immunomodulating biomaterial that triggers 
a shift in the macrophage response towards a M2 reparative response that will be 
advantageous for the host. 
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1. INTRODUCTION 
 
Biomaterial scaffolds are central to many tissue engineering and regenerative medicine 
strategies as they create a space for tissue growth and provide support for cell adhesion 
and migration. However, biomaterial implantation results in unavoidable injury and an 
inflammatory response, which can impair integration with the host and tissue 
repair/regeneration [1]. The persistence of an inflammatory stimulus results in chronic 
inflammation that is a hallmark of the non-healing wound. Therefore, successful tissue 
repair and regeneration requires the coordinate expression of both inflammation and 
resolution of inflammation [2]. The magnitude and duration of acute inflammation are 
controlled by active resolution programs involving specialized pro-resolving lipid mediators 
that have potent anti-inflammatory and pro-resolving actions and thus actively drive 
termination of inflammation [3,4]. 
 
Lipid mediators of resolution of inflammation, including resolvins, protectins, lipoxins and 
maresins, are biosynthesized during the resolution phase of acute inflammation. These 
mediators exert their anti-inflammatory actions by inhibiting formation of free oxygen 
radicals by leukocytes, decreasing transendothelial migration of these cells, stimulating 
nonphlogistic recruitment of monocytes and by enhancing macrophage clearance of 
apoptotic leukocytes [4,5]. Based on previous studies of ours using different pro-resolution 
mediators we have decided to use Resolvin D1 (RvD1) [6]. Resolvin D1 is derived from u-
3-PUFAs docosahexaenoic acid (DHA). In the presence of aspirin, w-3-PUFAs are 
converted to the aspirin triggered form of resolvin through a cyclooxygenase-2 dependent 
pathway [7]. Resolvins induce the hallmark functions of resolution of inflammation, including 
prevention of neutrophil penetration, phagocytosis of apoptotic neutrophils and enhanced 
clearance of inflammation within the lesion and thus promoting tissue regeneration [4]. 
 
Macrophages have a key role in the outcome of the healing process following biomaterial 
implantation [8]. Macrophage lineage displays high plasticity and pivotal roles in 
inflammation [3]. In response to external cues, these cells change their activation state. 
Inflammatory cytokines and chemokines at the inflamed biomaterial implantation site 
typically drive the differentiation of M1 macrophages in the early biomaterial healing 
response. Dampening of these inflammatory signals is often disturbed due to the presence 
of the biomaterial resulting in a persistent inflammatory environment and leading to the well-
known foreign body response. Persistent macrophage polarization into M1 is often 
associated with fibrotic and scar tissue formation in the biomaterial integration process. 
Thus, to enable a favorable healing response associated with functional tissue formation, 
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putative activation of inflammatory M1 macrophages and favor differentiation towards M2 
wound healing/regulatory macrophages differentiation [8-12]. 
 
Previous results of ours revealed that successive local administrations of RvD1 enables the 
modulation of the inflammatory response to Ch scaffolds through M2 macrophage 
polarization [6]. The purpose of this study was to develop an immunomodulatory biomaterial 
through the incorporation of RvD1 into Ch 3D porous scaffolds in order to obtain a 
continuous release of this mediator locally. The data of the current investigation indicate 
that this strategy provides in vivo control of macrophage phenotypes which may be of great 
value in regenerative medicine applications. Our main goal is to develop an 
immunomodulatory biomaterial capable of promoting tissue regeneration, exploring the link 
between inflammation resolution and tissue regeneration. Important clinical endpoints are 
enhanced functional tissue regeneration and improved device integration and 
biocompatibility within the host. 
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2. MATERIALS & METHODS 
 
2.1. Chitosan purification and characterization 
Squid pen Ch (ref. 114, Batch No. S4; DA ~2%) was supplied by Mahtani Chitosan Pvt. Ltd. 
and subsequently purified by filtration of Ch acidic solution and subsequent alkali 
precipitation. Chitosan with a degree of acetylation (DA) of 15% was prepared by N-
acetylation of the former, according to Vachoud et al. [13], in a water/acetic acid/1,2-
propanediol solution, using acetic anhydride as reactive. Following acetylation, a DA of 
15.71 ± 0.52, weight-average molecular weight (Mw) of 8.3 ± 0.9 x 105 and polydispersity 
index (PDI) of 1.3 ± 0.1, was found, as previously described [14]. Ch with DA 15% revealed 
endotoxin levels below 0.1EU/mL, respecting the FDA guidance documents for implantable 
devices, as determined using the Limulus Amebocyte Lysate test (QCL-1000® test, 
Cambrex) in Ch water extracts [15]. 
 
2.2. Preparation of Ch 3D scaffolds and incorporation of resolvin D1 (RvD1) 
The 3D porous scaffolds were prepared from degassed 2% w/v Ch solutions in 0.2 M acetic 
acid via thermally induced phase separation (-20ºC; 24 h) and subsequent sublimation of 
the ice crystals. Following lyophilization (Labconco 7420031; -80ºC; 0.2 mbar; 72 h) the 
resultant scaffolds were cut in discs with 8.5 mm in diameter and 2 mm in thickness. The 
scaffolds were then submitted to sterilization in an ethanol series: immersed in absolute 
ethanol (B Braun) for 1 h and then sequentially in 70% (v/v) for 30 min, 50% (v/v) and 25% 
(v/v) ethanol for 10 min each. Afterwards, Ch scaffolds were washed twice with ultrapure 
water (Milli Q) for 10 min. Scaffolds were then frozen (-20ºC; 24 h) and lyophilized for the 
second time (-80ºC; 0.2 mbar; 48 h), under sterile conditions (scaffolds were placed in 24 
well plates at the freeze dryer with a filter membrane of 0.22 µm). 
 
The incorporation of RvD1 in the Ch scaffolds was performed after their preparation and 
sterilization by an embedding technique under sterile conditions in a flow hood chamber. 
An ethanolic solution of RvD1 from Cayman Chemical (molecular weight 376,4865; pKa 1/4 
4.58; water solubility: approximately 0.05 mg/mL at 25ºC or PBS pH 7,4) with a 
concentration of 1.66 ng/ml was prepared according to the provider instructions. A volume 
of 60 ml of the RvD1 solution was added drop-wise with a micropipette into the scaffold 
which was then lyophilized again (-80ºC; 0.2 mbar; 24 h). A control group was also prepared 
by adding 60 ml of the RvD1 solution using the same technique, but the scaffolds were not 
submitted to lyophilization after incorporation of RvD1. In this control group the scaffolds 
were lyophilized again prior to RvD1 incorporation (-80ºC; 0.2 mbar; 24 h), so that scaffolds 
of the two experimental groups are subjected to the same number of lyophilizations. 
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2.3. Characterization of 3D scaffolds by scanning electron microscopy (SEM) 
The morphology of the scaffolds was investigated by SEM in transversal and longitudinal 
cross-sections. The materials were analyzed after preparation and also after 
incorporation of RvD1 and subsequent lyophilization. The samples were coated with 
Au/Pd thin film, by sputtering, using the SPI Module Sputter Coater equipment and 
observed using a High resolution (Schottky) Environmental Scanning Electron 
Microscope with X-Ray Microanalysis and Electron Backscattered Diffraction analysis: 
Quanta 400 FEG ESEM/EDAX Genesis X4M. 
 
 
Figure 1 | SEM micrographs of 3D porous scaffolds. SEM micrographs of 3D porous scaffolds. (a) Ch 
15%; (b) Ch 15% + RvD1; (c) Ch 15% + RvD1 Lyophilized. Scale bar: 200 µm. 
 
2.4. Release studies of resolvin D1 
The release kinetics of RvD1 was investigated both for the lyophilized and non- lyophilized 
scaffolds after incorporation of RvD1, by immersing them in 3 mL of Dulbecco's phosphate-
buffered saline (DPBS) at 37ºC under mild agitation (40 rpm). Samples were collected at 
the following time points: 0.5; 1; 2; 4; 6; 10; 24; 48 and 72 h. At each time point 1.5 mL of 
the solution was collected and replaced by the same volume of fresh DPBS. Quantitative 
analyses of RvD1 released was performed using a commercially available kit for the 
detection of RvD1 (Resolvin D1 Enzyme Immunoassay, Cayman Chemical). The results 
are presented as cumulative percentage of RvD1 mass released. 
 
2.5. Animal model of inflammation 
The air-pouch model of inflammation was used according to the method of Sedwick et al. 
[16] as adapted by Castro et al. [17]. Briefly, mice were anaesthetized by intramuscular 
injection of ketamine (Ketalar, Parke-Davis Co., Spain; 4.0-8.0 mg/ kg of weight) and 
xylazine (Rompum, Bayer Co., Portugal; 0.8-1.6 mg/kg) and subsequently injected 
subcutaneously in the dorsal area with 5 mL of sterile air to induce the formation of an air 
pouch. A second subcutaneous injection of 3 mL of sterile air was performed 5 days later 
collected per sample. Analysis of the results obtained was performed using FlowJo
software.
2.9. Cytokine production
A commercially available cytokine array of 40 cytokine proteins (Mouse Cyto-
kine Array Panel A; R&D Systems; Catalogue #ARY006) was used to evaluate the
relative levels of cytokine production in the inflammatory exudates. A pool of 6
inflammatory exudates of each experimental group was prepared for this deter-
mination, and 1 mL of the prepared pooled was used. Data shown are from 5 min
exposure in Chemidoc XRSþ (BioRad). Quantification of the results was generated by
quantifying the mean spot pixel density from the array using image software ana-
lyses (ImageLab 4.1; BioRad). Briefly, the pixel intensities gathered from the array
spots are obtained using the volume tools option of the software. We have defined
an area of interest of the reference spots by surrounding it with a circle, and then
equal circles were used for all spots of the array. Afterwards, the circles were ana-
lysed and the densities of signals were normalized with the background.
2.10. Histological analysis
The explanted scaffolds were processed and embedded in paraffin wax, and cut
in thin sections of 3 mm. Three sections of each scaffold were prepared and stained
using standard Masson trichrome. The stained sections were visualized using light
microscopy (Zeiss, Axiovert 200M) under 10" magnification.
2.11. Statistical analysis
Statistical analysis was performed using the non-parametric test Man-
neWhitney with Graph Pad v6.02. for Windows. A value of p < 0.05 was considered
statistically significant: *p < 0.05; **p < 0.01; ***p < 0.001. Data are presented
showing individual groups and respective mean ± SEM.
3. Results
3.1. Characterization of Ch 3D scaffolds
In accordance to previous results Ch scaffolds revealed a highly
porous and homogeneous microstructure with interconnected
pores with diameters in the range of 100 mm [14]. This was
observed both for the Ch scaffolds immediately after its preparation
and for those subjected to lyophilisation after RvD1 incorporation.
The results obtained by SEM analyses revealed that lyophilisation
after RvD1 incorporation did not affect the microstructure (Fig. 1).
3.2. Release of resolvin D1 from Ch scaffolds
RvD1 was embedded on the 3D porous Ch scaffolds by adding it
drop-wis with a micropipette, followed by lyophilisation. We have
also characterized Ch scaffolds that were not submitted to lyophi-
lisation after the incorporation of RvD1. The elease profile of RvD1
was then assessed in both groups of samples, and the results are
presented in Fig. 2. Release results showed for both cases an initial
burst period that lasted for 10 h, after which a plateau was reached,
with RvD1 being released in reduced amounts until the end of the
study (72 h). Nevertheless, we observed some differences in the
two groups of samples. The group with lyophilized RvD1 presented
a delay in the release of RvD1 but afterwards released higher
concentrations of RvD1 when compared with the non-lyophilized
samples.
3.3. Flow cytometry
The inflammatory exudate were collected from the mouse air-
pouches 4 days after the implantation of the scaffolds and analysed
by flow cytometry. Macrophages were detected using F4/80, a
commonly used murine macrophage marker; the M1 and M2
subpopulations of macrophages were identified by CCR7 and
CD206 markers respectively. Dot plots from a representative
experime t are depicted in Fig. 3. The results presented in
Fig. 4a show a decrease in the total number of inflammatory cells
recruited to the implant sitewhen RvD1was incorporated in the Ch
scaffolds, being this decrease more noticeable for scaffolds sub-
jected to lyophilisatio fter RvD1 incorporation. The use of
phenotypic markers of theM1 andM2macrophage subpopulations
showed that the inflammatory exudates collected from a r pouches
with scaffolds embedded with RvD1 and followed by lyophilisation
presented higher percentage of CD206þ cells (M2 macrophages),
together with a lower percentage of CCR7þ cells (M1 macrophages)
Fig. 1. SEM micrographs of 3D porous scaffolds. SEM micrographs of 3D porous scaffolds. (a) Ch 15%; (b) Ch 15% þ RvD1; (c) Ch 15% þ RvD1 Lyophilized. Scale bar: 200 mm.
Fig. 2. Release studies of Resolvin D1 (RvD1) from the Ch scaffolds. The release of RvD1
was investigated both for scaffolds lyophilized and non-lyophilized after its incorpo-
ration. The results are presented as cumulative percentage of RvD1 mass released.
D.P. Vasconcelos et al. / Biomaterials 53 (2015) 566e573568
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to reinforce the air pouch, and 24 h after the scaffolds were implanted. Mice were 
anaesthetized as described above and the skin covering the air pouch area was shaved 
and cleaned. A surgical incision was made, the Ch DA 15% scaffolds were placed inside 
the air pouch and the incision was sutured. A single scaffold was implanted in each animal. 
For each experimental group, 6 male BALB/c mice (Charles River, Spain) with 7 weeks of 
age were used. Three experimental groups were used: One group with Ch DA 15% only 
(Ch 15%); one group with Ch DA 15% and RvD1 100 ng/mL lyophilized (Ch 15% + RvD1 
Lyophilized); and one group with Ch DA 15% and RvD1 100 ng/mL not submitted to 
lyophilization (Ch 15% + RvD1). 
The procedures involved in the animal model were approved by the in-house ethics 
committee and also by the Portuguese official authority responsible for animal welfare and 
experimentation (Direção Geral de Veterinária, DGV). 
 
2.6. Inflammatory exudates 
The exudates were recovered from the mouse air-pouches 4 days after implantation. The 
mice were euthanized with a lethal injection of ketamine (Ketalar, Parke-Davis Co., Spain) 
and xylazine (Rompum, Bayer Co). Harvesting of inflammatory exudates was done by 
washing the air pouch cavity with 4 mL of PBS. The suture area was clumped, and 4 mL of 
PBS were injected using a 26-gauge needle (B Braun) in the air pouch at the caudal region. 
The pouches were then gently agitated at the sides to facilitate mixing. The recovery of the 
lavage fluid was done using a 20-gauge needle (B Braun) with the needle opening turned 
to the inner of the pouch. On average 2 mL of the lavage fluid were collected back in each 
aspiration. When the exudates were collected the pouches still contained the scaffolds. 
 
2.7. Explants 
Explantion occurred immediately after the recovery of the inflammatory exudates (4 days 
after implantation). The sutures were cut, and the wound edges separated; the scaffolds 
were then carefully removed from the pouches and fixed in 4% formaldehyde (Panreac) for 
histological analysis. 
 
2.8. Flow cytometry 
The following antibodies, all from R&D Systems, were used in this study: phycoerythrin 
(PE)-labelled anti-mouse F4/80 (clone 521204, 4:50 µl), allophycocyanin-labelled anti-
mouse CCR7 (clone 4B12 7:50 µl), Alexa Fluor®488 labelled anti-mouse MMR/CD206 
(3:50 µl). The isotype controls PE-labelled IgG2A (clone 54447), APC-labelled IgG2A 
(54447) and Alexa Fluor®488-labelled IgG, were used as negative controls to define 
background staining at corresponding concentrations. 
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The exudates were filtered through 40 mm nylon mesh (BD Biosciences) to remove cell 
clumps and spun at 1200 rpm for 5 min at 4ºC. Supernatants were removed, and cell pellets 
re-suspended in 1xPBS/0.5%BSA/0.1%Azide. Single-cell suspensions were preincubated 
with Fc-receptor-blocking antibodies (Miltenyi Biotec) for 10 min at 4ºC. Labelling was 
performed in a final volume of 50 ml with the indicated fluorescently conjugated antibodies 
for 30 min at 4ºC in the dark. Cells were then washed three times with staining buffer and 
transferred to FACS tubes for analysis by flow cytometry. Fluorescence was measured 
using FACS Calibur flow cytometer (BD biosciense) with Cell Quest software, and 10,000 
events were 
 
2.9. Cytokine production  
A commercially available cytokine array of 40 cytokine proteins (Mouse Cytokine Array 
Panel A; R&D Systems; Catalogue #ARY006) was used to evaluate the relative levels of 
cytokine production in the inflammatory exudates. A pool of 6 inflammatory exudates of 
each experimental group was prepared for this determination, and 1 mL of the prepared 
pooled was used. Data shown are from 5 min exposure in Chemidoc XRS+ (BioRad). 
Quantification of the results was generated by quantifying the mean spot pixel density from 
the array using image software analyses (ImageLab 4.1; BioRad). Briefly, the pixel 
intensities gathered from the array spots are obtained using the volume tools option of the 
software. We have defined an area of interest of the reference spots by surrounding it with 
a circle, and then equal circles were used for all spots of the array. Afterwards, the circles 
were analysed, and the densities of signals were normalized with the background. 
 
2.10. Histological analysis 
The explanted scaffolds were processed and embedded in paraffin wax, and cut in thin 
sections of 3 mm. Three sections of each scaffold were prepared and stained using 
standard Masson trichrome. The stained sections were visualized using light microscopy 
(Zeiss, Axiovert 200M) under 10x magnification. 
 
2.11. Statistical analysis 
Statistical analysis was performed using the non-parametric test Mann-Whitney with Graph 
Pad v6.02. for Windows. A value of p<0.05 was considered statistically significant: *p<0.05; 
**p<0.01; ***p<0.001. Data are presented showing individual groups and respective mean 
± SEM. 
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3. RESULTS 
 
3.1. Characterization of Ch 3D scaffolds  
In accordance to previous results Ch scaffolds revealed a highly porous and homogeneous 
microstructure with interconnected pores with diameters in the range of 100 µm [14]. This 
was observed both for the Ch scaffolds immediately after its preparation and for those 
subjected to lyophilization after RvD1 incorporation. The results obtained by SEM analyses 
revealed that lyophilization after RvD1 incorporation did not affect the microstructure (Fig. 
1). 
 
 
Figure 2 | Release studies of Resolvin D1 (RvD1) from the Ch scaffolds. The release of RvD1 was 
investigated both for scaffolds lyophilized and non-lyophilized after its incorporation. The results are 
presented as cumulative percentage of RvD1 mass released. 
 
3.2. Release of resolvin D1 from Ch scaffolds 
RvD1 was embedded on the 3D porous Ch scaffolds by adding it drop-wise with a 
micropipette, followed by lyophilization. We have also characterized Ch scaffolds that 
were not submitted to lyophilization after the incorporation of RvD1. The release profile 
of RvD1 was then assessed in both groups of samples, and the results are presented in 
Fig. 2. Release results showed for both cases an initial burst period that lasted for 10 h, 
after which a plateau was reached, with RvD1 being released in reduced amounts until 
the end of the study (72 h). Nevertheless, we observed some differences in the two 
groups of samples. The group with lyophilized RvD1 presented a delay in the release of 
RvD1 but afterwards released higher concentrations of RvD1 when compared with the 
non-lyophilized samples. 
 
collected per sample. Analysis of the results obtained was performed using FlowJo
software.
2.9. Cytokine production
A commercially available cytokine array of 40 cytokine proteins (Mouse Cyto-
kine Array Panel A; R&D Systems; Catalogue #ARY006) was used to evaluate the
relative levels of cytokine production in the inflammatory exudates. A pool of 6
inflammatory exudates of each experimental group was prepared for this deter-
mination, and 1 mL of the prepared pooled was used. Data shown are from 5 min
exposure in Chemidoc XRSþ (BioRad). Quantification of the results was generated by
quantifying the mean spot pixel density from the array using image software ana-
lyses (ImageLab 4.1; BioRad). Briefly, the pixel intensities gathered from the array
spots are obtained using the volume tools option of the software. We have defined
an area of interest of the reference spots by surrounding it with a circle, and then
equal circles were used for all spots of the array. Afterwards, the circles were ana-
lysed and the densities of signals were normalized with the background.
2.10. Histological analysis
The explanted scaffolds were processed and embedded in paraffin wax, and cut
in thin sections of 3 mm. Three sections of each scaffold were prepared and stained
using standard Masson trichrome. The stained sections were visualized using light
microscopy (Zeiss, Axiovert 200M) under 10" magnification.
2.11. Statistical analysis
Statistical analysis was performed using the non-parametric test Man-
neWhitney with Graph Pad v6.02. for Windows. A value of p < 0.05 was considered
statistically significant: *p < 0.05; **p < 0.01; ***p < 0.001. Data are presented
showing individual groups and respective mean ± SEM.
3. Results
3.1. Characterization of Ch 3D scaffolds
In accordance to previous results Ch scaffolds revealed a highly
porous and homogeneous microstructure with interconnected
pores with diameters in the range of 100 mm [14]. This as
observed both for the Ch scaffolds immediately after its preparation
and for those subjected to lyophilisation after RvD1 incorporation.
The results obtained by SEM analyses revealed that lyophilisation
after RvD1 incorporation did not affect the microstructure (Fig. 1).
3.2. Release of resolvin D1 from Ch scaffolds
RvD1 was embedded on the 3D porous Ch scaffolds by adding it
drop-wise with a micropipette, followed by lyophilisation. We have
also characterized Ch scaffolds that were not submitted to lyophi-
lisation after the incorporation of RvD1. The release profile of RvD1
was then assessed in both groups of samples, and the results are
presented in Fig. 2. Release results showed for both cases an initial
burst period that lasted for 10 h, after which a plateau was reached,
with RvD1 being released in reduced amounts until the end of the
study (72 h). Nevertheless, we observed some differences in the
two groups of samples. The group with lyophilized RvD1 presented
a d lay in the rel ase of RvD1 but afterwar released hi her
concentrations of RvD1 when compared with the non-lyophilized
samples.
3.3. Flow cytometry
The inflammatory exudates were collected from the mouse air-
pouches 4 day after the implantation of the scaffolds an a alysed
by flow cytometry. Macrophages were detected using F4/80, a
commonly used murine macrophage marker; the M1 and M2
subpopulations of macrophages were identifi d by CCR7 and
CD206 markers respectively. Dot plots from a representative
experiment are depicted in Fig. 3. The results presented in
Fig. 4a show a decrease in the total number of inflammatory cells
recruited to the implant sitewhen RvD1was incorporated in the Ch
scaffolds, being this decrease more noticeable for scaffolds sub-
jected to lyophilisation after RvD1 incorporation. The use of
phenotypic markers of theM1 andM2macrophage subpopulations
showed that the inflammatory exudates collected from air pouches
with scaffolds embedded with RvD1 and followed by lyophilisation
presented higher percentage of CD206þ cells (M2 macrophages),
together with a lower percentage of CCR7þ cells (M1 macrophages)
Fig. 1. SEM micrographs of 3D porous scaffolds. SEM micrographs of 3D porous scaffolds. (a) Ch 15%; (b) Ch 15% þ RvD1; (c) Ch 15% þ RvD1 Lyophilized. Scale bar: 200 mm.
Fig. 2. Release studies of Resolvin D1 (RvD1) from the Ch scaffolds. The release of RvD1
was investigated both for scaffolds lyophilized and non-lyophilized after its incorpo-
ration. The results are presented as cumulative percentag of RvD1 mass released.
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3.3. Flow cytometry 
The inflammatory exudates were collected from the mouse air-pouches 4 days after the 
implantation of the scaffolds and analyzed by flow cytometry. Macrophages were 
detected using F4/80, a commonly used murine macrophage marker; the M1 and M2 
subpopulations of macrophages were identified by CCR7 and CD206 markers 
respectively. Dot plots from a representative experiment are depicted in Fig. 3. The 
results presented in Fig. 4a show a decrease in the total number of inflammatory cells 
recruited to the implant site when RvD1 was incorporated in the Ch scaffolds, being this 
decrease more noticeable for scaffolds subjected to lyophilization after RvD1 
incorporation. The use of phenotypic markers of the M1 and M2 macrophage 
subpopulations showed that the inflammatory exudates collected from air pouches with 
scaffolds embedded with RvD1 and followed by lyophilization presented higher 
percentage of CD206+ cells (M2 macrophages), together with a lower percentage of 
CCR7+ cells (M1 macrophages) in comparison with the other experimental groups, being 
these differences always statistically significant (Fig. 4c and d). These results can be 
confirmed in Fig. 4e that displays the ratio of M2/M1 positive cells and shows a marked 
increase in the ratio of M2/M1 cells for scaffolds embedded with RvD1 and followed by 
lyophilization when compared with the other experimental groups. These data are 
indicative of an M2 macrophage phenotypic response, which is in contrast with the 
response caused by Ch alone or Ch with RvD1 without lyophilization which triggered an 
M1 macrophage response. 
 
 
Figure 3 | Representative dot plots of the expression of cell surface markers on macrophages of 
inflammatory exudates retrieved from mouse air-pouches 4 days after biomaterial implantation. (a) in comparison with the other experimental groups, being these
differences always statistically significant (Fig. 4c and d). These
results can be confirmed in Fig. 4e that displays the ratio of M2/M1
positive cells and shows a marked increase in the ratio of M2/M1
cells for scaffolds embedded with RvD1 and followed by lyophili-
sation when compared with the other experimental groups. These
data are indicative of an M2 macrophage phenotypic response,
which is in contrast with the response caused by Ch alone or Ch
with RvD1 without lyophilisation which triggered an M1 macro-
phage response.
3.4. Cytokine production
The detected cytokines are listed in Fig. 5a together with an
image of the membranes obtained, and in Fig. 5b the quantification
of the results is presented. We concluded that the implantation of
scaffolds with RvD1 subjected to lyophilisation caused a general
decrease in pro-inflammatory cytokines, in comparison with the
effect of Ch alone or Ch with RvD1 not submitted to lyophilisation.
In fact, this material induced a clear decrease (i) in pro-
inflammatory cytokines IL-1a and IL-1b; (ii) in CD54 concentra-
tions, an intercellular adhesion molecule that is continuously pre-
sent in low concentration on the membranes of leukocytes, a
molecule that can be induced by IL-1; (iii) in macrophage inflam-
matory proteinsMIP-1a, MIP-1b andMIP-2; (iv) in the cytokines IL-
6 and IL-16 that were not detectable. These results are indicative of
anM2macrophage responsewhich is in agreement with the results
obtained by the flow cytometry analysis presented above.
3.5. Histological analysis
The implanted Ch scaffolds were analysed by histology, 4 days
after implantation, to assess their infiltration by inflammatory cells.
The tissue sections were stained using Masson trichrome and the
results are presented in Fig. 6. In the lower magnification images
(aec) a general view of the inflammatory cells surrounding and
colonizing the implanted scaffolds can be observed, whereas in the
higher magnification images (def) a more detailed view of the in-
flammatory cells that are infiltrating the Ch scaffolds is presented.
In the presence of either Ch alone (Fig. 6a and d) or Ch with RvD1
non-lyophilised (Fig. 6b and e), high numbers of inflammatory cells
were seen surrounding and infiltrating the implanted scaffolds. In
samples of Ch with RvD1 subjected to lyophilisation (Fig. 6c and f)
there are lower numbers of inflammatory cells both surrounding
and colonizing the implanted material, indicating that a less severe
inflammatory cell infiltration was triggered by the developed
biomaterial.
4. Discussion
A key factor for the long-term survival and function of bio-
materials is not to elicit a detrimental immune response in the host.
As biomaterials can have profound impacts on the host immune
response, efforts have been made to design biomaterials that are
able to lead to desired immunological outcomes and thus favour
the healing process [9]. Host macrophage response is an essential
component of the tissue remodelling process that follows the
Fig. 3. Representative dot plots of the expression of cell surface markers on macrophages of inflammatory exudates retrieved from mouse air-pouches 4 days after biomaterial
implantation. (a) aspect ratio; (b) expression of F4/80, CD206 and CCR7 antigens. Gates were drawn from isotype control staining. (FSC: forward scatter; SSC: side scatter).
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aspect ratio; (b) expression of F4/80, CD206 and CCR7 antigens. Gates were drawn from isotype control 
staining. (FSC: forward scatter; SSC: side scatter). 
 
 
Figure 4 | Characterization by flow cytometry of the inflammatory exudates recovered from mouse 
air-pouches 4 days after implantation. Results are presented as average ± s.e.m. (a) Total number of 
cells recruited to the air-pouches. (b) Percentage of F4/80+ cells. (c) Cells expressing both F4/80+ and 
CD206+. (d) Cells expressing both F4/80+ and CCR7+. (e) Ratio of M2/M1 cells. (Statistically significant 
differences: *p < 0.05; **p < 0.01). 
 
3.4. Cytokine production  
The detected cytokines are listed in Fig. 5a together with an image of the membranes 
obtained, and in Fig. 5b the quantification of the results is presented. We concluded that 
the implantation of scaffolds with RvD1 subjected to lyophilization caused a general 
decrease in pro-inflammatory cytokines, in comparison with the effect of Ch alone or Ch 
with RvD1 not submitted to lyophilization. In fact, this material induced a clear decrease 
(i) in pro-inflammatory cytokines IL-1a and IL-1b; (ii) in CD54 concentrations, an 
implantation of biomaterials [18]. Macrophages have heteroge-
neous phenotypes ranging from M1 (classically activated, pro-
inflammatory) to M2 (anti-inflammatory, homoeostatic, wound-
healing) and the remarkable plasticity makes them an interesting
target for immunomodulation, since transition to anM2 phenotype
is associated with improved tissue repair and regeneration [9,18].
The localized delivery of immunomodulatory factors has
emerged as a strat gy for controlling the local immune response to
implanted biomaterials as an attempt to enhance and accelerate
implant-tissue integration [1,19e23]. In our research, we aimed at
developing a material capable of eliciting an appropriate immune
response through the polarization of macrophages to an M2 anti-
inflammatory, pro-tissue healing phenotype which is considered
as a promising strategy to mitigate potential adverse effects of
biomaterial-induced inflammation [24].
In previous investigations we have concluded that the injection
of resolvin D1 (RvD1) every 12 h during 3 days in air pouches where
Ch scaffolds are implanted caused a shift in the inflammatory
response to the implanted materials through the polarization of
macrophages towards an M2 phenotype [6]. In the present study
we have incorporated RvD1 in 3D porous Ch scaffolds, previous to
implantation, allowing the continuous release of RvD1 from the
implanted Ch scaffolds. Using this strategy wewere able to develop
a new functional biomaterial capable of triggering an appropriate
immune response in the host. The presence of RvD1 induces a more
pro-wound healing state at the implant location.
We have used the inflammatory air-pouch model of inflamma-
tion. This model involves the formation of a sterile subcutaneous
cavity that can be used to insert a biomaterial and to study the
inflammatory reaction caused by the biomaterial, providing a
localized environme t in which to study cell t fficking and the
inflammatory response through the infiltration of inflammatory
cells and the production of cytokines/chemokines [25,26]. The air
pouch model has also been extensively used by other research
groups for the study of various types of inflammation and inflam-
matory processes. This model has distinct advantages over other
models of inflammation because of the technical ease of the pro-
cedure and the ability to perform biochemical analy is of both the
exudate and inflammatory cells together with the histological
analysis of the air-pouch lining [27].
Resolvins are molecules that were first identified in self-
resolving murine exudates, using the murine air pouch model of
inflammation, and have been suggested to ensure restoration of
tissue homoeostasis and prevention of fibrosis after the acute in-
flammatory response [28]. Resolvins are currently under investi-
gation for different applications. For instance, it has been reported
Fig. 4. Characterization by flow cytometry of the inflammatory exudates recovered from mouse air-pouches 4 days after implantation. Results are presented as average ± s.e.m. (a)
Total number of cell recruited to the air-pouches. (b) Percentage of F4/80þ cells. (c) Cells expressing both F4/80þ and CD206þ. (d) Cells expressing both F4/80þ and CCR7þ. (e) Ratio
of M2/M1 cells. (Statistically significant differences: *p < 0.05; **p < 0.01).
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intercellular adhesion molecule that is continuously pre- sent in low concentration on the 
membranes of leukocytes, a molecule that can be induced by IL-1; (iii) in macrophage 
inflammatory proteins MIP-1a, MIP-1b and MIP-2; (iv) in the cytokines IL-6 and IL-16 that 
were not detectable. These results are indicative of an M2 macrophage response which 
is in agreement with the results obtained by the flow cytometry analysis presented above. 
 
 
Figure 5 | Evaluation of cytokine production by inflammatory cells on the recovered exudates 4 days 
after implantation using a cytokine array. Quantification of the results was generated by quantifying the mean 
spot pixel density from the array using image software analyses (ImageLab; BioRad). The densities of signals 
were normalized with the background. (a) Images of the array membranes obtained for each experimental group 
and a table with the detected cytokines. (b) Quantification of the detected cytokines, values are expressed as 
average of two dots. (CD: cluster designation; IL: interleukin; IP: Interferon gamma-induced protein; MIP: 
macrophage inflammatory protein; TNF: tumour necrosis factor; TREM: triggering receptor expression on 
myeloid cells). 
 
3.5. Histological analysis 
The implanted Ch scaffolds were analyzed by histology, 4 days after implantation, to 
assess their infiltration by inflammatory cells. The tissue sections were stained using 
Masson trichrome and the results are presented in Fig. 6. In the lower magnification 
that RvD1 is a potent inhibitor of cigarette smoke-induced pro-
inflammatory signalling in human lung cells in vitro and that it has
potent anti-inflammatory properties in a mouse model of acute
cigarette smoke-induced lung inflammation [29]. It was also
demonstrated that RvD1 causes a functional switch in adipose
tissue macrophage polarization towards an M2-like phenotype in
obese mice [30]. Resolvins also reduce inflammation-induced me-
chanical hypersensitivity in the carrageenan model of peripheral
inflammation in the rat through its spinal administration [7].
We have used Ch scaffolds with a DA of 15% because they are
particularly adequate to study dampening of inflammation. In our
previous investigations we concluded that these scaffolds caused
an intense inflammatory response mediated by M1 pro-
inflammatory macrophages, with large numbers of M1 macro-
phages present in the inflammatory exudates together with high
levels of pro-inflammatory cytokines [15]. We have thus selected
this material so that we can test how it is possible to shift the
macrophage phenotypic response using this new strategy. Also in
agreement with previous studies, we have chosen 4 days of Ch
implantation to recover the inflammatory exudates, to analyse
them by flow cytometry, to assess the levels of cytokines using a
cytokine array, and to remove the implants for histological analysis.
The implantation of Ch sc ffolds subject d to ly philisation after
RvD1 incorporation (the new strategy herein presented) caused a
macrophage M2 reparative response, in contrast with a M1 pro-
inflammatory response observed with the two other experi-
mental groups used as controls. Through the analyses of the in-
flammatory exudates by flow cytometry we detected that the
developed material induced a significant decrease in the number of
recruited inflammatory cells to the implant site, together with a
higher percentage of CD206þ cells (M2 macrophages) and a lower
percentage of CCR7þ cells (M1 macrophages). Using a cytokine
array we have investigated the levels of some cytokines in the
retrieved inflammatory exudates and found a general decrease in
several pro-inflammatory cytokines (such as IL-1a, IL-1b and IL-6).
Histology of explanted scaffolds revealed a decrease of inflamma-
tory cells around and within the implanted scaffolds. These results
confirmed that we were able to design an immunomodulatory
biomaterial that once implanted caused a shift in the host response
fostering faster tissue repair and regeneration, since higher ratios of
Fig. 5. Evaluation of cytokine production by inflammatory cells on the recovered exudates 4 days after implantation using a cytokine array. Quantification of the results was
generated by quantifying the mean spot pixel density from the array using image software analyses (ImageLab; BioRad). The densities of signals were normalized with the
background. (a) Images of the array membranes obtained for each experimental group and a table with the detected cytokines. (b) Quantification of the detected cytokines, values
are expressed as average of two dots. (CD: cluster designation; IL: interleukin; IP: Interferon gamma-induced protein; MIP: macrophage inflammatory protein; TNF: tumour necrosis
factor; TREM: triggering receptor expression on myeloid cells).
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images (a-c) a general view of the inflammatory cells surrounding and colonizing the 
implanted scaffolds can be observed, whereas in the higher magnification images (d-f) a 
more detailed view of the inflammatory cells that are infiltrating the Ch scaffolds is 
presented. In the presence of either Ch alone (Fig. 6a and d) or Ch with RvD1 non-
lyophilised (Fig. 6b and e), high numbers of inflammatory cells were seen surrounding 
and infiltrating the implanted scaffolds. In samples of Ch with RvD1 subjected to 
lyophilisation (Fig. 6c and f) there are lower numbers of inflammatory cells both 
surrounding and colonizing the implanted material, indicating that a less severe 
inflammatory cell infiltration was triggered by the developed biomaterial. 
 
 
 
Figure 6 | Histological images of the Ch scaffolds 4 days after implantation in the mouse air-pouches. (a-f) 
Masson trichrome stained sections showing inflammatory cells around and within the implanted scaffolds. (a, d) 
Ch 15%; (b, e) Ch 15% + RvD1; (c, f) Ch 15% + RvD1 Lyophilized. (a, b, c: magnification10x; Scale bar =200µ 
mm); (d, e, f: magnification 40x; Scale bar = 10 µm). 
 
 
 
 
 
 
 
 
 
  
M2:M1 macrophages are associated with better remodelling out-
comes [12]. We were not able to detect in the recovered inflam-
matory exudates the anti-inflammatory cytokines IL-4 and IL-10 in
any of the experimental groups. In previous investigations wewere
not able to detect the presence of anti-inflammatory cytokines in
the collected exudates even using ELISA kits with higher sensitivity
[15].
We have incorporated RvD1 in the Ch scaffolds through an
embedding technique immediately followed by lyophilisation; to
assess the effect of lyophilisation after RvD1 incorporation a control
group not submitted to lyophilisation after RvD1 incorporationwas
included in the study. We concluded that lyophilisation after RvD1
incorporation delayed its release, and that, after the release was
initiated, higher concentrations of RvD1 were detected, when
compared with control groups. Our results suggest that this delay
in RvD1 release together with the subsequent continuous release of
this lipid mediator is of great importance to induce the shift to an
M2macrophage phenotype. It has been reported that lyophilisation
is a common procedure to increase the long-term stability of
pharmaceutical formulations [31] and is also reported to be a lipid
stabilizer [32]. As pro-resolution lipid mediators are rapidly
degraded [33,34], the effect of lyophilisation after the incorporation
of RvD1 in the scaffolds seems to be critical for its successful
application. Also, the protective effect of the lyophilisation in RvD1
may explain why this pro-resolution mediator is released in lower
concentrations by the scaffolds not submitted to lyophilisation af-
ter RvD1 incorporation. It is possible that the in this case RvD1
undergoes a fast degradation and consequently is not detected in
the release assay.
The engineering of materials that can modulate the immune
system is an emerging field that is progressing alongside immu-
nology, furthermore it is recognized the potential of biomaterials
that are able of modulate immune cell function and thus eliciting
appropriate immune responses [35]. Taken together, our results
demonstrate that we were able to develop a process of immuno-
modulation by incorporation of bioactive molecules. Using this
strategy, we were able to create a simple and inexpensive method
to deliver an anti-inflammatory mediator that allowed the in vivo
modulation of the inflammatory response, with expected beneficial
effects upon tissue remodelling.
To the best of our knowledge this is the first in vivo study using
Ch scaffolds incorporated with RvD1 as an immunomodulatory
biomaterial that allowed the modulation of macrophage polariza-
tion towards an M2 anti-inflammatory, pro-tissue healing pheno-
type. This strategy provides control of macrophage phenotype and
may meet with great success in regenerative medicine.
5. Conclusions
We have developed a new strategy to produce an immuno-
modulatory biomaterial that is able of guiding the inflammatory
response through a M2 macrophage reparative response. We have
incorporated a pro-resolution lipid mediator, resolvin D1 (RvD1), in
chitosan (Ch) scaffolds and afterwards phenotypic and functional
polarization of macrophages in response to the implanted scaffolds
was assessed according to their cell surface markers and their
cytokine expression profiles. Our data demonstrated that with the
developed material we induced (i) a significant decrease in the
number of recruited inflammatory cells to the implant site, together
with a higher percentage of CD206þ cells (M2 macrophages) and a
lower percentage of CCR7þ cells (M1 macrophages); (ii) a general
decrease in several pro-inflammatory cytokines; (iii) a decrease in
inflammatory cells observed around and within the implanted
scaffolds. These results document that we were able to experi-
mentally shift the inflammatory response to the implanted mate-
rials, being thus a promising strategy to be used in regenerative
medicine applications since the manipulation of macrophage
effector mechanisms will promote constructive tissue remodelling.
Fig. 6. Histological images of the chitosan scaffolds 4 days after implantation in the mouse air-pouches. (aef) Masson trichrome stained sections showing inflammatory cells around
and within the implanted scaffolds. (a, d) Ch 15%; (b, e) Ch 15% þ RvD1; (c, f) Ch 15% þ RvD1 Lyophilized. (a, b, c: magnification10"; Scale bar ¼ 200 mm); (d, e, f: magnification 40";
Scale bar ¼ 10 mm).
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4. DISCUSSION 
 
A key factor for the long-term survival and function of biomaterials is not to elicit a 
detrimental immune response in the host. As biomaterials can have profound impacts on 
the host immune response, efforts have been made to design biomaterials that are able to 
lead to desired immunological outcomes and thus favor the healing process [9]. Host 
macrophage response is an essential component of the tissue remodeling process that 
follows the implantation of biomaterials [18]. Macrophages have heterogeneous 
phenotypes ranging from M1 (classically activated, pro-inflammatory) to M2 (anti-
inflammatory, homoeostatic, wound- healing) and the remarkable plasticity makes them an 
interesting target for immunomodulation, since transition to an M2 phenotype is associated 
with improved tissue repair and regeneration [9,18]. 
 
The localized delivery of immunomodulatory factors has emerged as a strategy for 
controlling the local immune response to implanted biomaterials as an attempt to enhance 
and accelerate implant-tissue integration [1,19-23]. In our research, we aimed at developing 
a material capable of eliciting an appropriate immune response through the polarization of 
macrophages to an M2 anti-inflammatory, pro-tissue healing phenotype which is considered 
as a promising strategy to mitigate potential adverse effects of biomaterial-induced 
inflammation [24]. 
 
In previous investigations we have concluded that the injection of resolvin D1 (RvD1) every 
12 h during 3 days in air pouches where Ch scaffolds are implanted caused a shift in the 
inflammatory response to the implanted materials through the polarization of macrophages 
towards an M2 phenotype [6]. In the present study we have incorporated RvD1 in 3D porous 
Ch scaffolds, previous to implantation, allowing the continuous release of RvD1 from the 
implanted Ch scaffolds. Using this strategy, we were able to develop a new functional 
biomaterial capable of triggering an appropriate immune response in the host. The presence 
of RvD1 induces a more pro-wound healing state at the implant location. 
 
We have used the inflammatory air-pouch model of inflammation. This model involves the 
formation of a sterile subcutaneous cavity that can be used to insert a biomaterial and to 
study the inflammatory reaction caused by the biomaterial, providing a localized 
environment in which to study cell trafficking and the inflammatory response through the 
infiltration of inflammatory cells and the production of cytokines/chemokines [25,26]. The 
air pouch model has also been extensively used by other research groups for the study of 
various types of inflammation and inflammatory processes. This model has distinct 
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advantages over other models of inflammation because of the technical ease of the 
procedure and the ability to perform biochemical analysis of both the exudate and 
inflammatory cells together with the histological analysis of the air-pouch lining [27]. 
 
Resolvins are molecules that were first identified in self-resolving murine exudates, using 
the murine air pouch model of inflammation, and have been suggested to ensure restoration 
of tissue homoeostasis and prevention of fibrosis after the acute inflammatory response 
[28]. Resolvins are currently under investigation for different applications. For instance, it 
has been reported that RvD1 is a potent inhibitor of cigarette smoke-induced pro-
inflammatory signalling in human lung cells in vitro and that it has potent anti-inflammatory 
properties in a mouse model of acute cigarette smoke-induced lung inflammation [29]. It 
was also demonstrated that RvD1 causes a functional switch in adipose tissue macrophage 
polarization towards an M2-like phenotype in obese mice [30]. Resolvins also reduce 
inflammation-induced mechanical hypersensitivity in the carrageenan model of peripheral 
inflammation in the rat through its spinal administration [7]. 
 
We have used Ch scaffolds with a DA of 15% because they are particularly adequate to 
study dampening of inflammation. In our previous investigations we concluded that these 
scaffolds caused an intense inflammatory response mediated by M1 pro-inflammatory 
macrophages, with large numbers of M1 macrophages present in the inflammatory 
exudates together with high levels of pro-inflammatory cytokines [15]. We have thus 
selected this material so that we can test how it is possible to shift the macrophage 
phenotypic response using this new strategy. Also, in agreement with previous studies, we 
have chosen 4 days of Ch implantation to recover the inflammatory exudates, to analyse 
them by flow cytometry, to assess the levels of cytokines using a cytokine array, and to 
remove the implants for histological analysis. The implantation of Ch scaffolds subjected to 
lyophilisation after RvD1 incorporation (the new strategy herein presented) caused a 
macrophage M2 reparative response, in contrast with a M1 pro-inflammatory response 
observed with the two other experimental groups used as controls. Through the analyses 
of the inflammatory exudates by flow cytometry we detected that the developed material 
induced a significant decrease in the number of recruited inflammatory cells to the implant 
site, together with a higher percentage of CD206+ cells (M2 macrophages) and a lower 
percentage of CCR7+ cells (M1 macrophages). Using a cytokine array, we have 
investigated the levels of some cytokines in the retrieved inflammatory exudates and found 
a general decrease in several pro-inflammatory cytokines (such as IL-1a, IL-1b and IL-6). 
Histology of explanted scaffolds revealed a decrease of inflammatory cells around and 
within the implanted scaffolds. These results confirmed that we were able to design an 
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immunomodulatory biomaterial that once implanted caused a shift in the host response 
fostering faster tissue repair and regeneration, since higher ratios of M2:M1 macrophages 
are associated with better remodelling outcomes [12]. We were not able to detect in the 
recovered inflammatory exudates the anti-inflammatory cytokines IL-4 and IL-10 in any of 
the experimental groups. In previous investigations we were not able to detect the presence 
of anti-inflammatory cytokines in the collected exudates even using ELISA kits with higher 
sensitivity [15]. 
 
We have incorporated RvD1 in the Ch scaffolds through an embedding technique 
immediately followed by lyophilisation; to assess the effect of lyophilisation after RvD1 
incorporation a control group not submitted to lyophilisation after RvD1 incorporation was 
included in the study. We concluded that lyophilisation after RvD1 incorporation delayed its 
release, and that, after the release was initiated, higher concentrations of RvD1 were 
detected, when compared with control groups. Our results suggest that this delay in RvD1 
release together with the subsequent continuous release of this lipid mediator is of great 
importance to induce the shift to an M2 macrophage phenotype. It has been reported that 
lyophilisation is a common procedure to increase the long-term stability of pharmaceutical 
formulations [31] and is also reported to be a lipid stabilizer [32]. As pro-resolution lipid 
mediators are rapidly degraded [33,34], the effect of lyophilisation after the incorporation of 
RvD1 in the scaffolds seems to be critical for its successful application. Also, the protective 
effect of the lyophilisation in RvD1 may explain why this pro-resolution mediator is released 
in lower concentrations by the scaffolds not submitted to lyophilisation after RvD1 
incorporation. It is possible that the in this case RvD1 undergoes a fast degradation and 
consequently is not detected in the release assay. 
 
The engineering of materials that can modulate the immune system is an emerging field 
that is progressing alongside immunology, furthermore it is recognized the potential of 
biomaterials that are able of modulate immune cell function and thus eliciting appropriate 
immune responses [35]. Taken together, our results demonstrate that we were able to 
develop a process of immunomodulation by incorporation of bioactive molecules. Using this 
strategy, we were able to create a simple and inexpensive method to deliver an anti-
inflammatory mediator that allowed the in vivo modulation of the inflammatory response, 
with expected beneficial effects upon tissue remodelling. 
 
To the best of our knowledge this is the first in vivo study using Ch scaffolds incorporated 
with RvD1 as an immunomodulatory biomaterial that allowed the modulation of macrophage 
polarization towards an M2 anti-inflammatory, pro-tissue healing phenotype. This strategy 
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provides control of macrophage phenotype and may meet with great success in 
regenerative medicine. 
  
5. CONCLUSIONS 
 
We have developed a new strategy to produce an immuno- modulatory biomaterial that is 
able of guiding the inflammatory response through a M2 macrophage reparative response. 
We have incorporated a pro-resolution lipid mediator, RvD1, in Ch scaffolds and afterwards 
phenotypic and functional polarization of macrophages in response to the implanted 
scaffolds was assessed according to their cell surface markers and their cytokine 
expression profiles. Our data demonstrated that with the developed material we induced (i) 
a significant decrease in the number of recruited inflammatory cells to the implant site, 
together with a higher percentage of CD206+ cells (M2 macrophages) and a lower 
percentage of CCR7+ cells (M1 macrophages); (ii) a general decrease in several pro-
inflammatory cytokines; (iii) a decrease in inflammatory cells observed around and within 
the implanted scaffolds. These results document that we were able to experimentally shift 
the inflammatory response to the implanted materials, being thus a promising strategy to 
be used in regenerative medicine applications since the manipulation of macrophage 
effector mechanisms will promote constructive tissue remodeling. 
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ABSTRACT 
 
The aim of this study was to investigate the effect chitosan (Ch) porous 3D scaffolds 
embedded with resolvin D1 (RvD1), an endogenous pro-resolving lipid mediator, on bone 
tissue healing. These scaffolds previous developed by us have demonstrated to have 
immunomodulatory properties namely in the modulation of the macrophage inflammatory 
phenotypic profile in an in vivo model of inflammation. Herein, results obtained in an in vivo 
rat femoral defect model demonstrated that two months after Ch+RvD1 scaffolds 
implantation, an increase in new bone formation, in bone trabecular thickness, and in Coll 
type I and Coll I/ Coll III ratio were observed. These results suggest that Ch scaffolds 
embedded with RvD1 were able to lead to the formation of new bone with improvement of 
trabecular thickness. This study shows that the presence of RvD1 in the acute phase of the 
inflammatory response to the implanted biomaterial had a positive role in the subsequent 
bone tissue repair, thus demonstrating the importance of innovative approaches for the 
control of immune responses to biomedical implants in the design of advanced strategies 
for regenerative medicine. 
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1. INTRODUCTION 
Regenerative medicine is an emerging field with great potential and vast applications. There 
are two main strategies for tissue repair: cell-based therapies and the promotion of 
endogenous repair. Recent findings have highlighted new and often unexpected roles for 
immune cells in promoting a permissive local environment for effective cell replacement and 
restoration of tissue integrity [1]. Biomaterial scaffolds are central to many tissue repair 
strategies as they create a space for tissue growth and provide a support for cell adhesion 
and migration. However, biomaterial implantation causes injury resulting in inflammatory 
response which can impair its integration and the subsequent tissue repair [2]. As 
biomaterials can have profound impacts on the host immune response the concept of 
designing immunomodulatory biomaterials, able to trigger desired immunological 
outcomes, has emerged [3]. Bone tissue repair is currently under extensive investigation in 
tissue engineering and regenerative medicine research. Bone fracture is a common and 
increasing medical affliction that results from both traumatic injury and disease-related bone 
fragility [4,5].
 
Even when adequate bone repair is achieved within the expected time frames, 
treating fractures is costly. The most common cause of bone fragility is osteoporosis, and 
the socioeconomic burden of osteoporotic fractures alone is an increasing global problem 
for healthcare systems. Clearly, benefit can be gained from improved understanding of bone 
tissue repair [6]. The inflammatory response is an inevitable consequence of tissue injury, 
and its resolution is essential to return to tissue homeostasis [7]. A rapid resolution of the 
inflammatory response and transition to the repair phase is crucial to a favorable outcome 
of the tissue under regeneration [8].
 
The resolution of the inflammatory response is an active 
process controlled by endogenous mediators such as resolvins, lipoxins, protectins, and 
maresins that have selective actions on inflammatory cells and actively drive the termination 
of inflammation [9,10]. Resolvins are generated from docosahexaenoic acid [11]. It has 
been demonstrated that RvD1 controls neutrophils recruitment [12] and modulates 
macrophages toward a phenotype more prone to a healing response [13]. Resolvins also 
improve wound healing and reduce the time of wound closure [14].
 
Biomaterial-based 
scaffolds such as polymeric porous blocks have gained some success in the field of bone 
regeneration, with data providing that these materials are biocompatible and enable the 
incorporation of bioactive molecules and also the regulation of their kinetics release [15]. 
Chitosan is a natural polymer chemically constituted by b (1–4) linked D-glucosamine 
residues with N-acetyl-glucosamine side chains. Chitosan has been used for several 
biomedical applications, namely for bone tissue engineering studies [16-18].
 
We have 
previously reported the development of an immunomodulatory strategy that results from the 
incorporation of RvD1, in a porous 3D Ch scaffold (Ch + RvD1). Using this strategy, we 
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were able to trigger in vivo a shift in the macrophage response toward a M2 reparative 
response using a rodent air-pouch model of inflammation [19].
 
In the present study, we have 
investigated the ability of this novel immunomodulatory strategy to improve bone tissue 
healing, using a rat femoral bone defect model.  
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2. MATERIALS & METHODS 
 
2.1. Preparation of 3D Ch Scaffolds  
Squid pen Ch (reference 114, Batch No. S4; DA ~2%) was supplied by Mahtani Chitosan 
Pvt. Ltd., purified and prepared with a degree of acetylation (DA) of 15%, as previously 
described [13,20]. Briefly, 3D porous scaffolds were prepared from degassed 2% w/v Ch 
solutions in 0.2M acetic acid via thermally induced phase separation (-20º) and subsequent 
sublimation of the ice crystals. Following lyophilization (-80ºC; 0.2mbar; 24 h), the resultant 
scaffolds were cut in a cylinder shape with 4 mm in diameter and a height of 5 mm. The 
scaffolds were then submitted to sterilization in an ethanol series: immersed under vacuum 
in absolute ethanol (B Braun) for 1 h and then sequentially in 70% (v/v) for 30 min, 50% 
(v/v) and 25% (v/v) ethanol for 10 min each. Afterwards, Ch scaffolds were washed twice 
with ultrapure water (Milli Q) for 10 min. Scaffolds were then frozen (-20ºC; 24 h) and 
lyophilized again (-80ºC; 0,2mbar; 48 h) under sterile conditions (scaffolds were placed in 
96 well plates at the freeze dryer with a filter membrane of 0,22 µm). 
 
2.2. Incorporation of RvD1 in the Ch scaffolds  
The incorporation of RvD1 (Cayman Chemical, Ann Arbor, Michigan) in the Ch scaffolds is 
described in detail elsewhere [19]. Briefly, RvD1 was incorporated in Ch scaffolds by an 
embedding technique under sterile conditions. An ethanolic solution of RvD1 (Cayman 
Chemical) with a concentration of 3.33 ng/µL was prepared according to the provider 
instructions. A volume of 30 µL of RvD1 solution was added drop-wise with a micropipette 
into the scaffold which was then lyophilized again (-80ºC; 0,2mbar; 24 h). Chitosan scaffolds 
without RvD1 were used as a control group, being these scaffolds submitted to the same 
number of lyophilizations.  
 
2.3. Animal Model 
We have used a rat femoral defect model based on the study of Le Guehennec et al [21] 
previously adapted by our research group [16]. Three-month-old male Wistar rats 
purchased from Charles River Laboratories Spain, (Barcelona, Spain) (n=5 per group) were 
used. Animals were anesthetized for surgery through isoflurane inhalation. The knees were 
shaved and disinfected, an incision was made in the skin and muscles were retracted. After 
lateral knee arthrotomy, a cylindrical defect with a diameter of 3 mm and a depth of 
approximately 4 mm was created using a surgical drill in the anterolateral wall of the lateral 
condyle of right femur. Animal care and analgesics (subcutaneous injection of Buprex-
Buprenorfina, 0.05 mg/Kg-1) were provided post- surgery. Each animal was implanted with 
Ch + RvD1 or Ch alone in the right femur defect. All animals were sacrificed 2 months after 
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implantation. Non-operated animals were used as additional controls. Experimental 
protocols were performed in accordance with guidelines approved by the Ethics Committee 
and the Portuguese Official Authority on Animal Welfare and Experimentation.  
 
2.4. Bone histological analysis 
Cleaned femurs were fixed, decalcified in 0.25M EDTA (Sigma) (pH 7.3) for 7 weeks at 
room temperature with agitation and dehydrated in an ethanol series. Samples were 
embedded in paraffin blocks and eight serial sections of each femur, with 30 µm between 
sections (seven slices per section with 3 µm-thickness for each slice) were prepared. The 
histological sections were then stained with both Masson’s trichrome and picrosirius red, 
according to standard protocols, being afterwards observed and digitalized using a 
stereomicroscope (SZX10, Olympus) or an inverted microscope (Axiovert 200M, Zeiss).  
 
 
 
Figure 1 | Histological sections stained with Masson’s trichrome of the femur of non-operated and with critical 
size bone defects created in the anterolateral wall of the lateral condyle and subsequently implanted with Ch or 
Ch+RvD1 scaffolds. Histological evaluation was performed 2 months after implantation. (A) Global view of the 
defects with implanted scaffolds (Scale bar = 1 mm) and (B) detailed view of the implanted area (scale bar = 1 
mm). 
 
 
 
 
sections for each femur) with 3 lm thickness, were stained
with picrosirius red and visualized through a polarized lens
coupled to a binocular inverted microscope (Zeiss, Axiovert
200M) under 203 magnification, being the images acquired
using MosaiX software. All images were captured with the
same parameters (light intensity and angle of the polarizing
lens). Image J software (version 2.2) was used to delimit
the region of interest (ROI, defect and scaffold area) and for
the quantification of the birefringence brightness. For that,
images were binarized for definition of green, blue and red
color spectra, and the quantity of each color pixels corre-
sponding to the total area were measured. The Col I/Col III
ratios were calculated as fold change relative to the non-
operated animals. Values of 3 sections from each animal
were calculated.
Micro-computed tomography
Bone defects (n55) were fixed in 10% formalin. Micro-
computed tomography (lCT) was used to evaluate new
bone formation within the defect region. The structure of
the samples was acquired by X-ray and then reconstructed
and analyzed. The hard tissues (corresponding to bone)
were achieved through the volume of interest (VOI), consist-
ing of a stack of ROIs drawn over 150 cross sections. For
morphometric analysis, the following structural parameters
were calculated over each VOI: bone volume fraction (BV/
TV) and trabecular thickness (Tb.Th). Data acquisition was
performed in a SkyScan 1272 scanner with a pixel size of
7.4 lm. Approximately 600 projections were acquired over
a rotation range of 1808, with a rotation step of 0.458. Data-
sets were reconstructed using standardized cone-beam
reconstruction software (NRecon v. 1.6.10.2, SkyScan). The
output format for each sample was bit-map images. The set
of images was orientated with DataViewer (v. 1.5.2.4, Sky-
Scan) to obtain all samples in the same axis. A representa-
tive dataset of the slices was segmented into binary images
with a dynamic threshold of 70–255 for hard tissue analy-
sis. Afterwards, the binary images were used for morpho-
metric analysis (CT Analyser, v. 1.16.4.1, SkyScan).
Statistical analysis
Statistical analysis was performed using the non-parametric
test Mann–Whitney to compare data from two different
groups, with Prism v6 for Mac OS X. A value of p< 0.05 was
considered statistically significant: *p<0.05. Data are pre-
sented showing individual groups and respective mean6 SD.
RESULTS
Histological analysis and quantification of birefringent
collagen fibers
Bone histological analysis was performed on the right
femurs of the animals of all experimental groups. Figure 1
presents Masson!s trichrome stained sections of a general
view of the femurs (A) and the detailed view of the
implanted area (B). For both experimental groups (Ch or
Ch1RvD1) a layer of newly formed bone was observed
delimiting the defect area, being thicker in the case of the
animals implanted with Ch1RvD1 scaffolds. We have also
investigated whether the formation of collagen (Coll) fibers
was affected by the presence of RvD1. For that, we used the
picrosirius-polarization method with analysis of birefringent
fibers that allows the quantification of the Coll fibers. Figure
2 documents images of picrosirius red-stained sections
acquired using MosaiX software and the quantification of
FIGURE 1. Histological sections stained with Masson’s trichrome of the femur of non-operated and with critical size bone defects created in the
anterolateral wall of the lateral condyle and subsequently implanted with Ch or Ch1RvD1 scaffolds. Histological evaluation was performed 2
months after implantation. (A) Global view of the defects with implanted scaffolds (Scale bar51 mm) and (B) detailed view of the implanted
area (scale bar51 mm).
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2.5. Collagen quantification 
The picrosirius red staining was used as a method for the quantification of Coll birefringent 
fibers to assess the structural changes in the newly formed bone, as described elsewhere 
[22,23]. Serial sections (three slices of different serial sections for each femur) with 3 µm 
thickness, were stained with picrosirius red and visualized through a polarized lens coupled 
to a binocular inverted microscope (Zeiss, Axiovert 200M) under 20X magnification, being 
the images acquired using MosaiX software. All images were captured with the same 
parameters (light intensity and angle of the polarizing lens). Image J software (version 2.2) 
was used to delimit the region of interest (ROI, defect and scaffold area) and for the 
quantification of the birefringence brightness. For that, images were binarized for definition 
of green, blue and red color spectra, and the quantity of each color pixels corresponding to 
the total area were measured. The Coll I/Coll III ratios were calculated as fold change 
relative to the non-operated animals. Values of 3 sections from each animal were 
calculated. 
 
 
 
Figure 2 | Histological sections of picrosirius red staining of the non-operated animals and of critical size bone 
defects of animals with implanted Ch or Ch + RvD1 scaffolds, visualized upon polarized and conventional light 
to identify Coll fibers types. Histological evaluation was performed 2 months after implantation. (A) Transmitted 
light. (B) Polarized light. Green birefringence colour indicates thin fiber and red colours in the birefringence 
analysis indicate thick Coll fibers. Original magnification 20x. Bar= 500 µm. 
 
birefringent fibers. Figure 2(A) shows sections viewed by
transmitted light, whereas Figure 2(B) illustrates sections
obtained usi g polarized lens. All images were captured
with the same parameters (light intensity and angle of the
polarizing lens). Collagen type I (classically called collagen
fibers), that is more birefringent and thick correspond to
the red or yellow fibers whereas collagen type III (classi-
cally called reticulum fibers), that is less birefringent and
thin correspond to the green fibers. Figure 3 presents the
results of the collagen quantification together with an exam-
ple of a defect area used for this evaluation. Animals with
Ch1RvD1 scaffolds exhibited a statistically significant
increase in coll type I fibers (red fibers) when compared
with animals with Ch scaffolds being the ratio of Coll I/Coll
III also increased for this experimental group.
mCT analysis
We have used mCT images of the different experimental
groups to assess the effect of RvD1 in new bone formation.
The mCT reconstruction of the defect area is showed in
Figure 4(A), whereas Figure 4(B) presents transversal
sections of the defects and Figure 4(C) presents detailed
sections of the ROI used for the analysis. Transversal
sections showed that two months after implantation the
defects are still open in both experimental groups, being the
defect smaller in the femurs of rats submitted to Ch1RvD1
scaffolds implantation [Fig. 4(B)]. Interestingly, some areas
with new bone formation can be observed inside the defects
of this experimental group [Fig. 4(C)]. Concerning the m-CT
data analysis, Figure 5(A) shows the quantification of bone
volume fraction (bone volume/tissue volume; BV/TV); and
Figure 5(B) presents the differences in the bone trabecular
thickness (Tb.Th). The animals of the experimental group
implanted with Ch1RvD1 scaffolds presented a statistically
significant increase of the bone trabecular thickness [Fig.
5(B)], indicating the formation of a more robust bone when
compared to the animals implanted with Ch scaffolds. In
addition, animals implanted with Ch1RvD1 scaffolds
showed higher bone volume than animals implanted with
Ch scaffolds [Fig. 5(A)].
DISCUSSION
Bone tissue engineering, consists in the use of a scaffolding
material that will both induce formation of bone from sur-
rounding tissues and act as a carrier of bioactive agents.24,25
Several strategies have been proposed to improve the effi-
ciency of bone regeneration by making it faster, more con-
trolled and predictable. Among them, the association
between biomaterials and molecules capable of stimulating
osteoblast function or that modulate inflammation or angio-
genesis.26 We report here a strategy to improve bone tissue
healing through the implantation of porous 3D Ch scaffolds
embedded with RvD1, an endogenous pro-resolution lipid
mediator. Previous studies of ours have demonstrated that
FIGURE 2. Histological sections of picrosirius red staining of the non-operated animals and of critical size bone defects of animals with
implanted Ch or Ch1RvD1 scaffolds, visualized upon polarized and conventional light to identify collagen fibers types. Histological evaluation
was performed 2 months after implantation. (A) Transmitted light. (B) Polarized light. Green birefringence colour indicates thin fiber and red col-
ours in the birefringence analysis indicate thick collagen fibers. Original magnification 203. Bar5 500 lm.
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2.6. Micro – computed tomography 
Bone defects (n=5) were fixed in 10% formalin. Microcomputed tomography (µCT) was 
used to evaluate new bone formation within the defect region. The structure of the samples 
was acquired by X-ray and then reconstructed and analyzed. The hard tissues 
(corresponding to bone) were achieved through the volume of interest (VOI), consisting of 
a stack of ROIs drawn over 150 cross sections. For morphometric analysis, the following 
structural parameters were calculated over each VOI: bone volume fraction (BV/TV) and 
trabecular thickness (Tb.Th). Data acquisition was performed in a SkyScan 1272 scanner 
with a pixel size of 7.4 µm. Approximately 600 projections were acquired over a rotation 
range of 180º, with a rotation step of 0.45º. Datasets were reconstructed using standardized 
cone-beam reconstruction software (NRecon v. 1.6.10.2, SkyScan). The output format for 
each sample was bit-map images. The set of images was orientated with DataViewer (v. 
1.5.2.4, SkyScan) to obtain all samples in the same axis. A representative dataset of the 
slices was segmented into binary images with a dynamic threshold of 70–255 for hard tissue 
analysis. Afterwards, the binary images were used for morphometric analysis (CT Analyser, 
v. 1.16.4.1, SkyScan). 
 
2.7. Statistical analysis 
Statistical analysis was performed using the non-parametric test Mann–Whitney to compare 
data from two different groups, with Prism v6 for Mac OS X. A value of p<0.05 was 
considered statistically significant: *p<0.05. Data are presented showing individual groups 
and respective mean ± SD.  
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Figure 3 | Quantification of birefringent Coll fibers. Intensity of birefringence was measured with the image-
analysis software (Image J, v. 2.0.). (A) Region of interest (defect and scaffold area). (B) Total area of Coll fibers 
from each birefringence colour (%). (C) Coll I/Coll III ratio. Results are presented as the mean (±SEM) of area 
of Coll fibers (%) for each colour in the birefringence analysis. (Statistically significant differences: *p < 0.05). 
  
with the use of this mediator of the resolution of inflamma-
tion incorporated in Ch scaffolds we were able to develop
an immunomodulatory strategy, that induces in vivo a shift
in the macrophage phenotypic profile toward an M2 repara-
tive phenotype during an inflammatory response to an
implanted biomaterial, and thus creating an environment
for prone to tissue repair.19 In this research work we envis-
age the use of these Ch scaffolds embedded with RvD1 to
create a local environment favorable to bone tissue repair
since higher ratios of M2:M1 macrophages are associated
with better remodeling outcomes.27 Biomaterials have an
important role in the implantable medical device industry
improving therapeutic efficacy. The engineering of biomate-
rials that can modulate the immune system is today an
emerging field that is progressing alongside with advances
in immunology. There is solid hope on the potential of bio-
materials to modulate immune cell function and thus elicit
appropriate immune responses, the so called immunomodu-
latory biomaterials.28 Manipulating the immune system
using biomaterials engineering may support the develop-
ment of therapies that promote both systemic and local pro-
regenerative immune responses, ultimately stimulating tis-
sue repair.29 We have used the rat femoral defect model
that involves the formation of a cylindrical defect in the
anterolateral wall of the lateral condyle of right femur.
Based in our previous experience with this model,16,30 and
taking in consideration the time required for bone remodel-
ing we have decided to recover the femurs two months
after biomaterial implantation, being then processed for the
evaluation of the bone defect area both by lCT and histolog-
ical techniques. The implantation of Ch1RvD1 scaffolds
induced an enhancement in bone formation, detected both
by lCT and histological analysis of the defect area two
months after implantation, when compared with animals
implanted with Ch scaffolds alone. Histological evaluation of
the different experimental groups revealed that a layer of
newly formed bone was observed delimiting the defect area,
being thicker in the case of the animals implanted with
Ch1RvD1 scaffolds. Using lCT, a widely applied technique
for the 3D study of bone microstructure, we observed a
statistically significant increase in trabecular thickness
(Tb.Th), that is, considered a reliable indicator of bone
strength,31 and a key factor for the success of implant-
supported rehabilitation.26 This result is particularly rele-
vant when considering that this healing occurred at the
bone/implant interface since conventional materials fail the
FIGURE 3. Quantification of birefringent collagen fibers. Intensity of birefringence was measured with the image-analysis software (Image J,
v. 2.0.). (A) Region of interest (defect and scaffold area). (B) Total area of collagen fibers from each birefringence colour (%). (C) Coll I/Coll III
ratio. Results are p sented as the mean (6SEM) of area of c llagen fibers (%) for each colour in the birefringence analysis. (Statistically signifi-
cant differences: *p< 0.05).
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3. RESULTS 
 
3.1. Histological analysis and quantification of birefringent collagen fibers 
Bone histological analysis was performed on the right femurs of the animals of all 
experimental groups. Figure 1 presents Masson’s trichrome stained sections of a general 
view of the femurs (A) and the detailed view of the implanted area (B). For both experimental 
groups (Ch or Ch+RvD1) a layer of newly formed bone was observed delimiting the defect 
area, being thicker in the case of the animals implanted with Ch+RvD1 scaffolds. We have 
also investigated whether the formation of Coll fibers was affected by the presence of RvD1. 
For that, we used the picrosirius-polarization method with analysis of birefringent fibers that 
allows the quantification of the Coll fibers. Figure 2 documents images of picrosirius red-
stained sections acquired using MosaiX software and the quantification of birefringent 
fibers. Figure 2(A) shows sections viewed by transmitted light, whereas Figure 2(B) 
illustrates sections obtained using polarized lens. All images were captured with the same 
parameters (light intensity and angle of the polarizing lens). Collagen type I (classically 
called Coll fibers), that is more birefringent and thicker correspond to the red or yellow fibers 
whereas Coll type III (classically called reticulum fibers), that is less birefringent and thin 
correspond to the green fibers. Figure 3 presents the results of the Coll quantification 
together with an example of a defect area used for this evaluation. Animals with Ch+RvD1 
scaffolds exhibited a statistically significant increase in Coll type I fibers (red fibers) when 
compared with animals with Ch scaffolds being the ratio of Coll I/Coll III also increased for 
this experimental group. 
 
 
Figure 4 | Micro-computed tomography (µCT) images of bone defects. Samples were scanned with µCT 
System (Skyscan, 1272). Images were reconstructed using NRecon software. (A) Reconstructed images of the 
defect area. (B) Transversal section of bone defects. (C) Representative images inside the defect. 
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these fibers are important for the mechanical properties of
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3.2. µCT analysis 
We have used µCT images of the different experimental groups to assess the effect of RvD1 
in new bone formation. The µCT reconstruction of the defect area is showed in Figure 4(A), 
whereas Figure 4(B) presents transversal sections of the defects and Figure 4(C) presents 
detailed sections of the ROI used for the analysis. Transversal sections showed that two 
months after implantation the defects are still open in both experimental groups, being the 
defect smaller in the femurs of rats submitted to Ch+RvD1 scaffolds implantation (Fig. 4B). 
Interestingly, some areas with new bone formation can be observed inside the defects of 
this experimental group (Fig. 4C). Concerning the µCT data analysis, Figure 5A shows the 
quantification of bone volume fraction (bone volume/tissue volume; BV/TV); and Figure 5(B) 
presents the differences in the bone trabecular thickness (Tb.Th). The animals of the 
experimental group implanted with Ch+RvD1 scaffolds presented a statistically significant 
increase of the bone trabecular thickness (Fig. 5B), indicating the formation of a more robust 
bone when compared to the animals implanted with Ch scaffolds. In addition, animals 
implanted with Ch+RvD1 scaffolds showed higher bone volume than animals implanted 
with Ch scaffolds (Fig. 5A).  
 
 
Figure 5 | Micro-computed tomography (µCT) analysis of bone healing process. (A) Bone volume, (B) 
Trabecular thickness (Tb.Th). Results are presented as average ±SEM. (Statistically significant differences: *p 
< 0.05). 
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4. DISCUSSION 
Bone tissue engineering consists in the use of a scaffolding material that will both induce 
formation of bone from surrounding tissues and act as a carrier of bioactive agents [24,25].
 
Several strategies have been proposed to improve the efficiency of bone regeneration by 
making it faster, more controlled and predictable. Among them, the association between 
biomaterials and molecules capable of stimulating osteoblast function or that modulate 
inflammation or angiogenesis [26]. We report here a strategy to improve bone tissue healing 
through the implantation of porous 3D Ch scaffolds embedded with RvD1, an endogenous 
pro-resolution lipid mediator. Previous studies of ours have demonstrated that with the use 
of this mediator of the resolution of inflammation incorporated in Ch scaffolds we were able 
to develop an immunomodulatory strategy, that induces in vivo a shift in the macrophage 
phenotypic profile toward an M2 reparative phenotype during an inflammatory response to 
an implanted biomaterial, and thus creating an environment for prone to tissue repair [19]. 
In this research work we envisage the use of these Ch scaffolds embedded with RvD1 to 
create a local environment favourable to bone tissue repair since higher ratios of M2:M1 
macrophages are associated with better remodelling outcomes [27]. Biomaterials have an 
important role in the implantable medical device industry improving therapeutic efficacy. 
The engineering of biomaterials that can modulate the immune system is today an emerging 
field that is progressing alongside with advances in immunology. There is solid hope on the 
potential of biomaterials to modulate immune cell function and thus elicit appropriate 
immune responses, the so-called immunomodulatory biomaterials [28]. Manipulating the 
immune system using biomaterials engineering may support the development of therapies 
that promote both systemic and local pro-regenerative immune responses, ultimately 
stimulating tissue repair [29]. We have used the rat femoral defect model that involves the 
formation of a cylindrical defect in the anterolateral wall of the lateral condyle of right femur. 
Based in our previous experience with this model, [16,30] and taking in consideration the 
time required for bone remodeling we have decided to recover the femurs two months after 
biomaterial implantation, being then processed for the evaluation of the bone defect area 
both by µCT and histological techniques. The implantation of Ch+RvD1 scaffolds induced 
an enhancement in bone formation, detected both by µCT and histological analysis of the 
defect area two months after implantation, when compared with animals implanted with Ch 
scaffolds alone. Histological evaluation of the different experimental groups revealed that a 
layer of newly formed bone was observed delimiting the defect area, being thicker in the 
case of the animals implanted with Ch+RvD1 scaffolds. Using µCT, a widely applied 
technique for the 3D study of bone microstructure, we observed a statistically significant 
increase in trabecular thickness (Tb.Th), that is, considered a reliable indicator of bone 
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strength, [31] and a key factor for the success of implant- supported rehabilitation [26]. This 
result is particularly relevant when considering that this healing occurred at the bone/implant 
interface since conventional materials fail the integration with surrounding tissues. Aseptic 
loosening is a typical case study of the limited integration of joint prostheses, highly 
motivated by adverse immune responses [32]. Furthermore, these approaches are quite 
relevant in diseases such as osteoporosis in which high remodeling with negative balance 
induces bone loss and deep alterations in the rearrangement of the microarchitecture, such 
as the decrease of trabecular thickness and connectivity [31]. Bone strength depends not 
only on the quantity of bone tissue but also on its quality. Quantity is in part evaluated by 
bone mineral density, whereas the quality is assessed in part by Coll [31,33]. To further 
analyze the new bone, we have determined the Coll that was formed through the picrosirius-
polarization method and the quantification of birefringent fibers, described by Junqueira et 
al. [34,35] and previously used in the characterization Coll networks [36,37]. The evaluation 
of the Coll type I and type III fibers that were present in defect area implanted with scaffolds 
showed a significant increase in Coll type I (Coll fibers) in animals implanted with Ch+RvD1 
scaffolds when compared with animals implanted with Ch scaffolds. Also, Coll I/Col III ratio 
showed an increase in Ch+RvD1 experimental group, although not statistically significant. 
These results strengthen the evidence on the new bone formation that was detected by 
µCT analysis, once crystals of hydroxyapatite tend to be oriented in the same direction as 
the Coll type I fibers, showing that these fibers are important for the mechanical properties 
of bone [31]. Interestingly, the loss of mechanical integrity of fibromuscular tissues is also 
related with a lower Coll I/Coll III ratio [37]. Although we have not found statistically 
significant differences in the increase bone volume fraction (BV/TV), results from trabecular 
thickness (Tb.Th), together with Coll quantification, show us that RvD1 induced the 
formation of bone with parameters associated with increased strength and quality. The role 
of resolvins has been studied in many pathologies [38]. For instance, in adipose tissue, 
RvD1 is responsible for switching macrophage polarization toward an M2-like phenotype in 
obese mice [39]. It was also reported in an in vitro study that RvD1 was able to suppress 
factors that are involved in osteoarthritis pathogenesis [40]. Local delivery of RvD1 leads to 
the resolution of inflammatory response after myocardial infarction improving ventricular 
function, [41] and to the enhancement of wound closure in diabetic mice by promoting 
macrophage polarization toward the anti-inflammatory M2 phenotype [14]. Additionally, the 
treatment of mice with RvD1 exposed to cigarette smoke, significantly reduced lung 
inflammation [42]. The use of biomaterials to locally deliver suitable levels of RvD1 
constitute a promising approach to mitigate exacerbated immune responses in bone injury 
contexts. We hypothesize that to achieve a clear improvement of bone repair it would be 
necessary to accomplish a more sustained delivery of RvD1, since the injury performed in 
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the in vivo model used in this research work requires several weeks to heal. Our previous 
in vitro findings showed that RvD1 is released from Ch scaffolds mainly in 72 h [19]. 
Nevertheless, the presence of RvD1 will induce a more pro- wound healing state at the 
implant area during the early inflammatory stage of the bone healing response [4,43] being 
this important for the subsequent steps of bone tissue repair. We have also studied immune 
cell populations in blood and draining lymph nodes (data not shown) 2 months after 
implantation but no significant differences were observed in the immune cell populations, 
most likely because the changes in these cell populations can only be detected at the early 
time points of the biological response to implanted scaffolds. Based on the results obtained 
in this research work, we came to the conclusion that RvD1 has a positive effect in bone 
healing, thus a more in-depth understanding of the early effects of RvD1 in bone tissue 
healing must be now detailed dissected. To our knowledge, this is the first study to suggest 
that RvD1 can improve bone healing, as indicated by an increase in bone formation, 
trabecular thickness and Coll type I. These results may be related with the capacity of RvD1 
to modulate the inflammatory response to implanted materials, showing that its presence in 
the acute phase of the inflammatory response to the implanted biomaterial can have a 
positive role in the subsequent bone repair, most likely due to the presence of macrophages 
exhibiting phenotypes associated with anti-inflammatory, pro-healing functions. 
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ABSTRACT 
 
The aim of the present work was to develop a strategy for the sustained release throughout 
time and also to improve the stability of Resolvin D1 (RvD1), using solid lipid nanoparticles 
(SLNs). RvD1-loaded SLNs were successfully developed by hot ultrasonication method. All 
the developed formulations were systematically characterized regarding their diameter, 
polydispersity index (PDI) and zeta potential (ZP). The results showed a significant 
decrease of SLNs size after RvD1 incorporation comparing with unloaded-SLNs, revealing 
that an interaction between RvD1 and the lipid nanoparticles occurs. Cytotoxic analysis 
revealed that RvD1-loaded SLNs and unloaded-SLNs are non-toxic for human 
macrophages. The biological activity of RvD1-loaded SLNs one week after preparation 
indicates that the phospholipid layer has a protective effect in RvD1, suggesting that the 
biological half-life of this pro-resolving mediator can be increased by the association with 
these lipidic nanostructures. 
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1. INTRODUCTION 
 
The process of implantation of a biomaterial causes injury to tissue and organs of the host 
leading to the immediate onset of an acute inflammatory response. Acute inflammatory 
response is mediated by a plethora of well-known chemical messengers, including 
cytokines, chemokines and lipid-derived mediators released by immune cells [1-3]. The 
perpetuation of the inflammatory cascade culminates either in resolution of inflammation, 
return to homeostasis and tissue healing or in chronic inflammation and biomaterial 
impairment.  
The resolution of inflammation is an active process controlled by endogenous mediators, 
with selective actions on inflammatory cells. The resolution phase of the inflammatory 
response is characterized by the local production of anti-inflammatory and specialized 
proresolving mediators (SPMs) such as lipoxins, protectins, maresins and resolvins [4]. 
These mediators exert their anti-inflammatory roles, acting as stop signals of inflammation, 
by blocking the further recruitment of polymorphonuclear cells (PMNs), stimulating 
nonphlogistic recruitment of monocytes and also the uptake of apoptotic PMNs by 
macrophages [5]. SPMs are derived from different polyunsatured fatty acids (omega-3 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) [3].  
Several studies report the biological actions of SPMs, namely, their role in metabolic 
diseases in the resolution of acute inflammation and tissue repair. It has been described 
that SPMs are beneficial for tissue repair in different models of injury, including bone [6]. 
Kruger MC et al. showed that SPMs inhibit inflammation that induces bone resorption and 
therefore provide a mechanism by which the SPMs have a protective role against bone loss 
[7]. In the adipose tissue, RvD1 enhances wound healing by promoting macrophage 
polarization towards the anti-inflammatory M2 phenotype [8, 9]. Resolvin D1 accelerates 
the resolution of lung inflammation after smoke exposure [10] and has been shown to have 
a therapeutic effect controlling acute respiratory syndrome [11]. Benabdoune H. and 
colleagues showed that RvD1 suppressed several factors that are involved in osteoarthritis, 
inhibiting IL-1b induced activation of NF-kB/p65, p38MAPK and JNK (1/2) [12]. So, pro-
resolving mediators are promising endogenous natural mediators that could be used for 
several applications. 
Nowadays, the usage of biomaterials for the improvement of tissue healing has being 
pointed as the future for tissue repair, being the materials with immunomodulatory 
properties the most promising in the tissue engineering field [13]. One of the strategies that 
can be used to improve tissue repair, through the modulation of immune response is the 
delivery of anti-inflammatory mediators, namely, the delivery of specific SPMs. The main 
purpose of delivering SMPs is the modulation of macrophage phenotype, from a pro-
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inflammatory M1 phenotype to a pro-resolving, anti-inflammatory M2 phenotype [14]. In a 
previous work, we showed, in an in vivo model of inflammation (air pouch model), that 
successive local administrations of RvD1, modulate the inflammatory response to 
biomaterials driving macrophage polarization to an anti-inflammatory pro-reparative 
phenotype (M2 phenotype) and significantly decreased the thickness of the fibrous capsule 
around the implant [15]. Taking these results in account we decided to use 3D Ch scaffolds 
as a delivery system for RvD1. Using the same in vivo model and after 4 days of 
implantation we observed the same tendency, the developed material was able to modulate 
the macrophage response to implanted materials [16]. Considering the previous results, we 
verified in an in vivo model of tissue repair, if the developed material was able to improve 
bone tissue healing. The results showed that the material developed was able to increase 
the trabecular thickness and Coll type I in the critical size bone defect model. However, we 
observed only a slightly increase in the new bone formation without statistical significance 
[17]. These results could be related with the fact that RvD1, is rapidly inactivated by 15-
prostaglandin dehydrogenase/eicosanoid oxidoreductase (EOR). RvD1 is converted by 
EOR, 25 min after incubation with the enzyme [18]. So, the time and the amount of RvD1 
released might not be enough to induce a higher improvement in tissue repair.  
Solid lipid nanoparticles, have shown to be one of the most promising delivery systems of 
hydrophobic drugs [19]. Solid lipid nanoparticles comprise a physiological compatible solid 
lipid core and an amphiphilic surfactant shell. These particles can improve the solubility of 
poorly soluble drugs through their incorporation in the lipid matrix and are able to improve 
physical stability, protection from in vivo degradation and controlled release [20]. Other 
advantages include low production cost and easy scale up. 
 
Thus, the main purpose of this work was to develop a new approach able to obtain a 
sustained release of RvD1 through time and improve its half-life activity. In order to achieve 
this objective, SLNs were used as delivery systems. Production and characterization 
methodologies were set up and primary human macrophages were used to accessed SLNs 
cytotoxicity and RvD1 biological activity. 
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2. MATERIALS & METHODS 
2.1. SLNs preparation  
SLNs were produced by hot ultrasonication [21] using 250 mg of Precirol ATO5® 
(Gattefosé, France) and 30 mg of Tween 80® (Merck, Germany). Briefly, the lipid (Precirol 
ATO5®) and Tween80® were weighted and heated together at 65°C to promote their 
mixture. Ultrapure water (5 mL) preheated at 65°C was added. Afterward, a sonicator was 
used (Vibra-Cell model VCX 130 equipped with a VC 18 probe, Sonics and Materials Inc., 
Newtown, USA), with a tip diameter of 1/4" (6 mm), at 70% amplitude for 5 min to obtain 
the SLNs. For the production of RvD1-loaded SLNs, RvD1 (Cayman Chemical Company, 
USA) was added (1 µM) before the addition of hot ultrapure water. 
2.2. SLNs characterization 
The size and surface charge (x-potential) of the produced SLNs were characterized by 
dynamic light scattering (DLS) and electrophoretic light scattering (ELS) respectively, using 
a Malvern Zetasizer Nano ZS (Malvern Instruments, UK). Diluted NLC (1:50 in ultrapure 
water) were placed on a disposable capillary cell and triplicate measurements were 
conducted at a backscattering angle of 173º at 25°C.  
The SLNs morphology was evaluated by NanoSight®, using a NanoSight NS300 (Malvern 
Instruments, UK). For NanoSight® analysis, NLC were diluted (1:40000) with ultrapure 
water and morphology was evaluated. 
2.3. Human macrophages 
Human monocytes were isolated by negative selection from buffy coats of healthy donors 
by using RosetteSep human monocyte enrichment cocktail (StemCell Technologies), as 
previously described [22, 23]. The buffy coats were provided by the Immunohemotherapy 
Department of Centro Hospitalar São João (CHSJ) from Porto, Portugal with the approval 
of the clinical ethical committee (Protocol reference 260/11). Cells were resuspended in 
complete medium (RPMI 1640 medium (Corning) supplemented with 10% FBS (Biowest), 
100 U/mL penicillin, 100 μg/mL streptomycin (both from Immunotools). For macrophage 
differentiation, cells were plated in TCPS at a confluence of 0.5 × 106 monocytes/well. 
Monocytes were cultured for 7 days in complete medium in the absence of M-CSF or others 
exogenous factors.  
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2.4. Cell metabolic activity  
In order to assess the biocompatibility of SLNs, cytotoxicity studies were performed using 
human macrophages. RvD1 – Loaded SLNs (60 nM – 30 µL), Unloaded-SLNs (30 µL) or 
RvD1 free solution (60 nM) were added to macrophages for 1h or 3h, and cells without 
treatment were used as controls. The metabolic activity of these cells was determined by 
resazurin reduction assay. Briefly, 1h or 3h after SLNs addition, cells were incubated with 
resazurin redox dye (0.01 mg/mL) (Sigma-Aldrich) for 4h at 37 °C and 5% CO2. 
Fluorescence intensity was measured at 590 nm in a synergy Mx plate reader (BioTek), 
and values normalized to unstimulated cells. 
2.5. Cytokine Profile 
The cytokine profile after macrophage incubation with SLNs was assessed by ELISA 
assays. Macrophages were pre-treated with SLNs for 1 h, washed and stimulated with LPS 
for 2 h (10 ng/mL). The supernatants were recovery and the levels of IL-6, TNF-a, IL-1b, 
CCL2 and IL-10 were measured by LegendMax Elisa (Biolegend), according to the supplier 
indications. 
 
2.6. Statistical analysis 
Comparisons of multiple groups were analysed by one-way analysis of variance ANOVA 
with Kruskal-Wallis test with Dunn’s multiple comparisons test using Prism 6 software 
(GraphPad). P-values <0.05 were considered statistically significant.  
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3. RESULTS 
 
3.1. Resolvin D1 nanoencapsulation 
SLNs size and x-potential were determined by DLS and ELS. Unloaded-SLNs (without 
RvD1) presented diameters of 467 ± 60 nm. After RVD1 incorporation, SLNs diameter 
significantly decrease, exhibiting diameters of 351 ± 93 nm (Fig. 1A). Moreover, SLNs 
presented a rather homogeneous size distribution with low polydispersion index (<0.2), for 
RvD1-loaded SLNs ~0.17 and for Unloaded SLNs ~0,09 (Fig. 1B). Surface x-potential of 
SLNs in water was around -39 mV ± 11 mV for the Unloaded-SLNs and -37 mV ± 3 for 
RvD1-loaded SLNs (Fig. 1C).  
The morphology of these SLNs (unloaded and RvD1-loaded) was observed by Nano Sight. 
Images from Fig. 2 demonstrate that SLNs displayed an almost spherical morphology and 
were not aggregated. 
 
 
Figure 8: SLNs characterization. SLNs were characterized in terms of: diameter (A); podydispersion index (B) 
and charge surface (x-potential) (C) performed using dynamic light scattering at 25ºC. *p<0.05; statistically 
significant differences between unloaded-SLNs and RvD1-loaded SLNs (Kruskal-Wallis test). Summary of all 
data (D) (n>3). 
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Figure 9: SLNs morphology characterization. Unloaded-SLNs (A) and RvD1-Loaded SLNs (B) morphology was 
evaluated by Nanosight®.   
 
3.2. Metabolic activity of macrophages after incubation with SLNs 
RvD1-loaded SLNs development aims to modulate macrophage response. Thus, human 
primary macrophages were used for the cell viability analysis. Studies were conducted with 
unloaded, RvD1-loaded SLNs and RvD1 free solution. We decided to use a concentration 
of nanoparticles corresponding to 60 nM of RvD1. The concentration of RvD1 was decided 
taking in account what is described in the literature as having an anti-inflammatory effect 
[24]. Unloaded, RvD1-loaded SLNs and RvD1 free solution were incubated with human 
macrophages during 1h and 3h. The results (Fig. 3) showed that there was not a significant 
decrease in cell viability caused by the presence of SLNs (Unloaded and RvD1-loaded) 
compared to the controls. These results showed that the nanoparticles were safe as the 
viability of the cells was superior to 80%. 
 
 
Figure 10: Cell viability of human macrophages upon exposure to SNLs. (A) Cell viability 1 hr after incubation 
with SLNs (n=6); (B) cell viability 3hr after SLNs incubation (n=3). 
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3.3. Anti-inflammatory properties of SLNs 
 
To assess if RvD1-loaded SLNs were able to modulate the macrophage response to LPS 
stimulus, cytokine profile of macrophages was analysed. Interestingly, our results showed 
that macrophages treated with RvD1-Loaded SLNs (even several days after its preparation) 
were able to reduce the production of IL-6 and TNF-a to values similar to the macrophages 
that were pre-treated with RvD1 free solution (fresh solution) (Fig. 4A, B). So, these results 
showed that SLNs were able to increase the half-life of RvD1. No differences were found in 
CCL2 and IL-10 production, indicating that RvD1 only affects the NF-kB pathway (Fig. 4C, 
D). 
 
 
Figure 11: Cytokine profile after SLNs pre-treatment. After 7 days of culture, macrophages were pre-treated 
with SLNs (Unloaded or RvD1-loaded) and RvD1 free solution for 1 hr, after that, cells were washed and 
stimulated with LPS (10ng/ml) for 2hr. The supernatants were analysed for IL-6 (A); TNF-a (B); CCL2 (C) and 
IL-10 (D) by ELISA (n=3). 
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4. DISCUSSION 
 
The intensity of the inflammatory response to tissue injury dictates the fate of tissue repair. 
An immune response well balanced will lead to an efficient tissue healing. However, when 
the inflammatory response to tissue injury is not well controlled can become chronic leading 
to fibrosis and the impairment of tissue function [25]. The usage of biomaterials to improve 
tissue repair has been pointed as a good strategy, since these materials can work as 
template for new tissue formation and can also be modified in order to give rise to a desired 
immune response, improving new tissue formation.  
 
So, the development of immunomodulatory materials is the new trend in the tissue 
engineering field [13]. Different strategies can be used to obtain a desire immune response. 
Physical and chemical properties of materials can be changed in order to obtain different 
immune behaviours. The material itself can be used as a delivery platform for immune 
modulators (pro- or anti-inflammatory mediators). Recently, was suggested a more complex 
strategy, the “sequential immunomodulation” that comprise the stimulation of an initial pro-
inflammatory response after material implantation followed by the initiation of the resolution 
phase of the immune response [14].  
 
The demonstration of the key role of macrophages in tissue repair, prompts the search for 
new strategies to modulate the response of these cells to biomaterials, and consequently 
influencing the functional outcome of the implanted material. In an initial phase M1 
macrophages are important in fighting pathogens through the secretion of pro-inflammatory 
mediators and later M2 macrophages have an important role in the wound healing, through 
secretion of anti-inflammatory mediators and promotion of extracellular matrix (ECM) 
remodelling [26]. 
 
Specialized pro resolving mediators are endogenous mediators that are actively involved in 
the resolution of the inflammatory response, providing a huge potential for novel therapeutic 
approaches [27]. We have recently reported that two of these mediators, lipoxin A4 (LxA4) 
and RvD1 were able to modulate the macrophage response to implanted 3D Ch scaffolds 
with 15% degree of acetylation (DA) [15]. We have demonstrated that Ch scaffolds with 
15% DA induce the increase of M1 macrophages in the implant site and also the amount of 
pro-inflammatory cytokines [28]. Successive administrations of LxA4 and RvD1 change the 
polarization phenotype of macrophages from a pro-inflammatory M1 phenotype to an anti-
inflammatory, pro-resolution M2 phenotype [15]. Thus, we were able to induce a sequential 
immunomodulation. To translate this knowledge into a more effective therapy in vivo, we 
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developed a strategy to incorporate the RvD1 into 3D Ch scaffolds. Chitosan scaffolds work 
as delivery system for RvD1 [16]. Since the developed material was capable to modify the 
macrophage response in an in vivo model of inflammation, we decided to test it in vivo in a 
model of tissue repair. For that a critical size bone defect was used. Two months after 
implantation we observed a slightly increase in the new bone formation, a significant 
increase in trabecular thickness and Coll type I [17]. The results were not as expected, since 
we were predicting larger amount of new bone formation. In fact, this could be related with 
the tissue injury size that needs several days to be resolved. In vitro studies showed that 
RvD1 incorporated in the scaffolds is totally released in 72h [16] and therefore, we 
hypothesize that the amount of RvD1 is not enough to induce the expected modulatory 
effect.   
 
Taking this in account we develop a new strategy to increase the release time of RvD1 
together with the improvement of RvD1 half-life. RvD1 has a half-life of minutes [18], and it 
is crucial that the delivery system is able to improve its stability. It has been described that 
phospholipids increase SPMs stability. Studies were performed using liposomes, which are 
extremely expensive [29, 30]. Meanwhile, Solid lipid nanoparticles (SLNs) are pointed as a 
noble delivery system of hydrophobic drugs (e.g. lipids) [19]. The costs of SLNs production 
are low and in addition are easily scale up [31]. Thus, we decided to use SLNs as the 
delivery system of RvD1. In this study, SLNs were synthesized using hot ultrasonication, 
avoiding the use of organic solvents. In addition, they present low cytotoxicity due to their 
lipid biodegradable and biocompatible composition recognized as safe by FDA. RvD1-
loaded SLNs with ~350nm of diameter, and negative charge (around – 37mV) were 
successfully produced. These RvD1-loaded SLNs were not cytotoxic to human 
macrophages, since a decrease in cell metabolism was not observed.    
 
Aiming to develop a new strategy to increase the half-life of RvD1 one of our main interests 
was to investigate the functional consequences of the pre-treatment induced by SLNs 
(unloaded and RvD1-loaded) prepared days before usage, in human macrophages 
stimulated with lipopolysaccharide (LPS). Here we demonstrated that RvD1-loaded SLNs 
were able to decrease the levels of the pro-inflammatory cytokines, IL- 6 and TNF-a close 
to values of cells that were treated with fresh RvD1 free solution. These results are in 
accordance with the literature since RvD1 inhibited the phosphorylation of TAK1, a key 
upstream regulatory kinase common to both MAP kinase and NF-kB pathways, decreasing 
IL-6 and TNF-a [32, 33]. No differences were observed with other cytokines, namely CCL2, 
IL-10 and IL-1b (data not shown).  
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Further studies concerning the analysis of the release profile of RvD1 would be of interest 
to validate the developed strategy.  
 
5. CONCLUSIONS 
Based on the results obtained until now, it can be concluded that we were able to optimize 
RvD1 stability and SLNs are a promising platform to deliver RvD1, since RvD1-loaded SLNs 
showed an anti-inflammatory effect, while being non-toxic to primary human macrophages. 
The results obtained until now are promising and further studies will be performed, namely 
the entrapment efficiency and release studies.  
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1. GENERAL DISCUSSION  
 
The work of this thesis was developed in view of enhancing the knowledge concerning 
macrophage response to macroscopic 3D Ch scaffolds, as well as the development of a 
new approach to modulate macrophage response to this scaffold leading to an improvement 
in tissue repair. 
 
Tissue repair is a critical biological process, essential to the survival of all living organisms. 
The immune response to tissue injury is key in defining the outcome of the healing process, 
including the degree of damaging and the restoration of tissue integrity and function [1, 2].  
 
Delayed bone healing or non-union fractures in response to traumatic injury, surgery or 
disease, has significant effect on patient´s quality of life and are a challenge in orthopedic 
practice. As a consequence of delayed fracture healing, bone-related medical treatments 
and costs increase [3]. The current “gold standard” treatment for delayed or non-union 
fractures is bone grafting, using an autograft or an allograft. This treatment has several 
drawbacks, namely the donor site morbidity and pain, the size of bone that could be 
harvested and the risk of disease [4, 5]. So, a more efficient and long-term treatment 
strategy is required. Bone grafts substitutes have been developed to facilitate the repair of 
natural tissues, namely 3D scaffolds have received wide attention in the past years due to 
their unique physical properties with controlled porosity to support bone tissue growth [6, 
7]. For a correct bone repair, scaffolds need to imitate natural bone tissue, support bone 
growth and should elicit minimal host tissue inflammation [6, 7]. One of the most promising 
strategies to improve tissue repair is the use of biomaterials that allow the modulation of the 
inflammatory response [8, 9].  
 
It is important to take in consideration that the process of biomaterial implantation results in 
damage to tissues or organs of the host. A series of events are initiated upon material 
implantation, starting with an acute inflammatory response that, when is not well resolved, 
leads to a chronic response and the deposition of a collagenous fibrous capsule around the 
implant, harming material function [10, 11]. So, it is of extreme relevance to understand how 
a specific material is recognized by immune cells.  
 
In this doctorate, we decided to use Ch, a well know biomaterial with several remarkable 
properties that offer unique opportunities to the development of biomedical applications 
[12]. The interaction between Ch-based products and immune cells has been deeply 
studied over the last years by our team and others. The results obtained showed that 
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different chemical (DA and MW) and physical (2D films, nanoparticles, 3D structures) 
properties of Ch prompts different immune responses. Oliveira et al. verified that 2D Ch 
films (DA of 11%) drives anti-inflammatory macrophage polarization [13] and also showed 
that Ch was not able to activate the MAPK pathways ERK1/2 and JNK, TLR4 downstream 
pathways [14]. Our initial work demonstrated that 3D Ch scaffolds with different DA 
stimulates different macrophage polarization phenotypes. Macrophage polarize for a M1 
pro-inflammatory phenotype in presence of 3D Ch scaffolds with higher DA (15%). On the 
other hand, implantation of 3D Ch scaffolds with lower DA (4%) leads to a M2 macrophage 
polarization [15]. Castro F et al. disclosed that Ch/poly (g-glutamic acid) (DA of 11%) 
nanoparticles promote M2-to-M1 transition of macrophage polarization [16]. Tu J. et al. 
showed that in LPS-primed Caco-2 cells Ch nanoparticles were able to reduce inflammatory 
reaction decreasing cytoplasmic IkB-a degradation and nuclear NF-kB p65 levels [17]. 
Fong et al. suggested that biodegradable Ch microparticles induce anabolic responses in 
M0 (resting macrophages) and M2 but not M1 U937 macrophages, increasing IL-10 release 
and the release of excess IL-1ra over IL-1b [18].  
 
Although immune-modulating properties of Ch have been studied for many years, 
intracellular Ch response pathways have only recently start to be clarified. The activation of 
NLRP3 inflammasome pathway by lysosomal rupture after Ch uptake, was one of the 
mechanisms described has been associated to immune response to Ch-based products 
[19-21]. Fong et al. postulated that the inflammatory response to Ch depend on prior 
immune cell activation state and Ch dose [22]. Considering that all the studies showing Ch 
a potent activator of NLRP3 inflammasome were performed with nanoscale Ch-based 
products, and since for tissue repair macroscopic materials are required, up to date, a 
question was still left open: what is the role of NLRP3 inflammasome in the macrophage 
response to macroscopic biomaterials?  
 
In this thesis, as the first main goal we attempted to answer this question by study the role 
of 3D Ch scafolds with different DA in NLRP3 inflammasome priming and activation. We 
start to assess the NLRP3 inflammasome in BMDM culture within 3D Ch scaffolds. Mouse 
bone marrow derived marocphages were plated in Ch scaffolds at day 6 of differentiation 
and primed at day 7 with LPS and subsequent NLRP3 activation was achieved after 
incubation with nigericin. One of the drawbacks for the establishment of BMDM culture into 
3D Ch scaffolds was the selection for optimal time point for cell seeding. We tried different 
approaches such as, (i) isolation of BMDM from bone marrow and plate immediately the 
cells in Ch scaffolds; (ii) isolation and differentiation for 3 days in a petri dish plate, 
detachment and cell seeding in Ch scaffolds and finally (iii) left the BMDM differentiate for 
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6 days upon isolation, detach and plate BMDM in Ch scaffolds. In (i) and (ii) approaches 
cells were not viable, so we decided to use the (iii) methodology for the all experiments.  
 
As described in Chapter III, in contrast to what is described in the literature with nanoscale 
Ch-based products, our results showed for the first time that 3D Ch scaffolds per se were 
not able to activate the inflammasome, no IL-1b release was detected with Ch scaffolds 
without stimulus and even after LPS priming [19-21]. More importantly, the release of IL-1b 
after NLRP3 inflammasome activation with nigericin was significantly decreased in BMDM 
seeded in 3D Ch scaffolds with lower DA (4%) when compared with cells in TCPS. A 
decrease in IL-1b release on cells cultured in 3D Ch with higher DA (15%) was also 
observed, although the difference was not statistically significant. Interestingly, we also 
verified that Ch scaffolds were able to modulate macrophage response to NLRP3 
inflammasome activation. The maturation and release of IL-1b after inflammasome 
activation could lead to a type of lytic cell death known as pyroptosis [23-25]. Lactate 
dehydrogenase is released by dead or dying cells during pyroptosis [26], and we measured 
the LDH in the supernatant and found a significant decrease of LDH leakage induced by 
inflammasome activation in cells within Ch scaffolds with lower DA, comparing with cells in 
TCPS. Macrophages in Ch scaffolds with lower DA presented approximately 40% less 
pyroptosis than cells cultured in TCPS. Macrophages seeded on Ch scaffolds with 15% DA 
also present less pyroptosis than cells in TCPS, although this decrease was not statistically 
significant. These findings support the results obtained with IL-1b release. The 
inflammasome activation is an incredibly controlled process and requires two signals. The 
“priming” step is responsible for the transcription of NLRP3 and pro-IL-1b through the 
activation of NF-kB pathway. The second step signal leads to the oligomerization of NLRP3 
and consequently maturation and release of IL-1b [27]. Regarding the effect of 3D Ch 
scaffolds on NLRP3 inflammasome priming we demonstrated that Ch scaffolds did not 
trigger the expression of inflammasome components, even after LPS priming. We also 
observed a highly decrease of pro-IL-1b expression following LPS priming in BMDM seeded 
on both Ch scaffolds, being the differences statistically significant for Ch scaffolds with lower 
DA. The analysis to the second step signal revealed that BMDM plated on Ch scaffolds with 
lower DA presented a significantly lower number of NLRP3 oligomers or ASC specks, 
comparing with cells in TCPS. This tendency was also observed for macrophages cultured 
in Ch scaffolds with higher DA. With these results we demonstrated that NLRP3 
inflammasome activation on BMDM is strongly down-modulated in presence of 3D Ch 
scaffolds.  
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Taking in account the results with BMDM, the next step was the study of NLRP3 
inflammasome activation in primary human macrophages cultured in 3D Ch scaffolds. 
Differently to BMDM, human macrophages were seeded in Ch scaffolds in the isolation day 
and left to differentiate until day 6. Consistently with what we found with BMDM, human 
macrophages without stimulus, were not able to induce NLRP3 inflammasome activation. 
In contrast to what was verified in BMDM, in human macrophages an increase of IL-1b 
release after LPS priming in all tested conditions was observed. It was recently described 
that human monocytes exhibit an alternative one-step pathway of NLRP3 activation in 
response to LPS alone, so it is reasonable to assume that some alternative NLRP3 
activation could account for this release [28]. Importantly, after NLRP3 inflammasome 
activation, macrophages cultured in Ch scaffolds showed a decrease of IL-1b release, being 
the differences in human macrophages statistically different for cells cultured in Ch scaffolds 
with higher DA. Concerning the role of 3D Ch scaffolds in priming step of inflammasome 
activation we observed a decrease of NLRP3 expression in cells cultured in both Ch 
scaffolds, comparing with cells in TCPS. Concerning pro-IL-1b expression by human 
macrophages cultured in Ch scaffolds we did not observed the decrease verified in BMDM. 
Instead, we detected an increase of pro-IL-1b expression after LPS priming in cells cultured 
in Ch scaffolds with lower DA. It is important to notice that the increase of pro-IL-1b 
expression did not change after NLRP3 inflammasome activation with nigericin, 
demonstrating that the maturation and release of IL-1b did not occur, as showed before. As 
verified with BMDM, 3D Ch scaffolds also down-regulate the NLRP3 inflammasome 
oligomerization in human macrophages. The results of ASC specks quantification showed 
a decrease in the number of oligomers per cell in both Ch scaffolds. Since we observed a 
significant decrease of IL-1b release with Ch scaffolds, we expected to perceive the same 
tendency with cell dead. Surprisingly, we did not observe a significant difference in the LDH 
leakage among conditions. Taking in account the results with IL-1b we expected a higher 
percentage of LDH activity in the supernatants of cells cultured in TCPS. In the literature is 
generally accepted that cell rupture is correlated with IL-1b release. So, it is expected that 
IL-1b release is directly related with cell dead. However, recently studies presented 
evidences that contradict this model. Monteleone et al. and Evavold et al., demonstrated 
IL-1b release in non-pyroptotic macrophages [29, 30] which can explain the results what we 
have obtained.  
A previous work from us, demonstrated that 3D Ch scaffolds with different DA (4 and 15%) 
hints distinctive macrophage polarization phenotype following material implantation in an in 
vivo model of inflammation. Chitosan scaffolds with higher DA induce a typical pro-
inflammatory response mediated by M1 macrophages. On the other hand, Ch scaffolds with 
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lower DA caused an inflammatory reaction characteristic of a macrophage M2 reparative 
response [15]. Following these results, we anticipated to observe clear differences in 
NLRP3 inflammasome activation in the studied scaffolds. These differences were not found, 
moreover the results on both DA were rather similar. We assume that these differences are 
related to the fact that in vivo, different cell types are present at the implant site will secrete 
different mediators that will have an influence in the fate of macrophage polarization in 
response to the implanted material. 
Overall, the findings stemming from this thesis on NLRP3 inflammasome – 3D Ch-based 
products lead us to propose that macroscopic 3D Ch scaffolds, regardless of DA impair the 
NLRP3 inflammasome activation, disturbing the priming and assembly steps both in mouse 
and human macrophages. These outcomes provide an important understanding of the 
immunological properties of 3D Ch scaffolds, which will dictate a favorable fate for 
biomaterial integration.  
Different approaches can be used to improve the healing process through 
immunomodulation [31]. The physicochemical properties of the material can be altered to 
induce different responses [15, 32], or the most common strategies reside in the delivery of 
pro-inflammatory modulators or anti-inflammatory/pro-resolving mediators [33]. A more 
complex approach is related to a sequential delivery of pro-inflammatory mediators in an 
early stage of the healing phase to trigger the inflammatory response and the clearance of 
the injured tissue, and anti-inflammatory/pro-reparative mediators in a later phase to initiate 
the repair/remodeling of the tissue. The sequential modulation employs a more 
comprehensive control throughout the tissue healing process [31]. Spiller et al., revealed 
that the sequential delivery of IFN-g and IL-4 to promote the M1-to-M2 transition, 
respectively, improve vascularization of bone scaffolds [34]. More recently Li et al. also 
showed on 5% calcium silicate/b-tricalcium phosphate scaffolds that IFN-g release in the 
early stage to induce M1 phenotype, followed by release of Si prompting the switch to M2 
polarization increase the formation of more blood vessels comparing with the control groups 
[35]. Alhamdi et al. described that the weakened and delayed bone healing is due to age-
related alterations in bone cells and in the immune system, namely a deficient resolution of 
inflammation delays healing. The authors developed a strategy for temporal M1-to-M2 
polarization transition and perform the proof of concept in macrophages from old mice, 
using biomimetic calcium phosphate coating to physically and temporally divide the pro-
inflammatory stimulus IFN-g, and the pro-reparative stimulus simvastatin. The results 
showed a sequential transition of M1 polarization to M2 phenotype in aged macrophages 
[36]. 
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As pointed by several authors, the modulation of inflammatory response to biomaterial 
implantation is key for promoting tissue healing. In this work, the modulation of inflammatory 
response in response to implanted materials was attempted to promote tissue repair. 
 
This led us to our second main aim that was the development of an immunomodulatory 
biomaterial. To achieve such purpose, we used RvD1 to modulate inflammation through M2 
macrophage polarization. Resolvin D1 is an endogenous pro-resolving mediator with 
several functions in the resolution of inflammation. In a previous work we observed that 
RvD1 was able to experimentally shift the macrophage response to the implanted Ch 
scaffolds with 15% DA [37]. As explained before we knew for previous works that 3D Ch 
scaffolds with higher DA induces a typical M1 macrophage phenotype and RvD1 prompted 
the M1-to-M2 macrophage polarization transition. So, our main goal in this part of the work 
was to develop a sequential immunomodulation strategy. Resolvin D1 was added to Ch 
scaffolds, and the scaffolds were immediately lyophilized. It has been reported that 
lyophilization increase the long-term stability of pharmaceutical formulations and it is a lipid 
stabilizer [38, 39]. It is known that RvD1 has a half-life of minutes [40], so the effect of 
lyophilization after RvD1 was critical for its effective application. The release assays 
demonstrated that the group with lyophilized RvD1 presented a delay in the release of 
RvD1, but then released higher amounts of RvD1 when compared with Ch scaffolds with 
RvD1 without lyophilization. The total amount of RvD1 was released after 72h. The 
developed material was implanted in an air pouch mouse model. Interestingly, we verified 
with the developed material a diminishment in the total number of inflammatory cells that 
were recruited to the implanted site and into the 3D Ch scaffolds, together with a general 
decrease of pro-inflammatory cytokines like, IL-6, TNF-a and IL-1b. More significantly, Ch 
scaffolds with RvD1 lyophilized diminished the percentage of F4/80+/CCR7+ cells (M1 
macrophage) and augmented the percentage of F4/80+/CD206+ cells (M2 macrophage) 
leading to an important increase in the M2:M1 ratio in the implanted site. A higher M2:M1 
ratio has been associated with an improvement in tissue repair [41].  
To our knowledge this was the first study using RvD1 incorporated into 3D Ch scaffolds as 
an immunomodulatory biomaterial that allowed the modulation of macrophage phenotype 
towards an M2 anti-inflammatory, pro-reparative phenotype. 
 
Understanding the physiology of the bone healing process is the first step in the 
development of successful scaffolds for bone repair. Fracture repair is a complex highly 
regulated process, with consecutives phases of inflammation, repair and remodeling, that 
involves the interplay of many cells and their mediators [5]. Macrophages have an important 
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role in bone healing, they are the osteoclast precursors cells [42], are fundamental for the 
osteoblasts maintenance and promote intramembranous and endochondral ossification [43, 
44] recruiting and stimulating MSCs differentiation [45]. Macrophages have been reported 
to be present throughout all bone healing phases. They are part of the acute phase 
response triggered by tissue injury, acting as phagocytic cells clearing cell debris and 
possible pathogenic invaders and secreting immune mediators that will recruit other cell 
types [46, 47]. Recently, Schlundt et al. demonstrated that a complete lack of macrophages 
in an early phase of bone healing, abolished the repair, impairing soft and hard callus 
formation leading to a complete failure in fracture repair [44]. Vi et al. showed that 
macrophages are critical for osteoblast differentiation [48]. These studies demonstrated that 
macrophages are important for the early as well for later phase of bone healing. 
Consequently, these cells represent a major target in regenerative medicine. A key element 
in tissue repair is the switch from the initially pro-inflammatory M1 macrophages to the anti-
inflammatory, pro-reparative M2 phenotype. Disturbances at any point in the process can 
lead to an anomalous repair [49]. 
 
As proof of concept for the material developed in the chapter IV an in vivo rat femoral defect 
model well established in our team was used. Therefore, the main aim of this part of the 
work, that is detailed described in Chapter V was to verify in an in vivo model of bone tissue 
injury the ability of the developed material to improve bone healing. Each animal was 
implanted in the bone defect with Ch + RvD1 or Ch alone. Bone defects were analyzed two 
months after material implantation. We verified by micro-computed tomography a slightly 
increase in new bone formation (BV/TV) in the defect region in animals that received Ch + 
RvD1, comparing with Ch alone together with a statistically significant increase of bone 
trabecular thickness (Tb.Th), a reliable indicator of bone strength [50]. It is described that 
bone strength depends not only the quantity of bone tissue but also on its quality, being the 
bone quality assessed in part by the presence of Coll type I [50]. Picrosirius-polarization 
method with analysis of birefringent fibers was used to analyze the presence of Coll type I 
and Coll type III [51]. Our data demonstrated a significant increase on Coll type I fibers, as 
well an increase of Coll I/Coll III ratio in animals with Ch + RvD1. Higher amount of Coll type 
I is characterized by the organized arrangement, giving greater stiffness when compared to 
the disorganized nature of Coll type III fibers. So, we could conclude that RvD1 has a 
positive effect in bone healing, giving rise to a new bone with a higher organization and 
strength. Even though we have obtained interesting results, they were not as significant as 
expected, since we were predicting higher bone formation. The lower amount of new bone 
formation could be related with the fact that the tissue injury performed was very extensive 
and takes several days to be resolved. As the in vitro RvD1 release studies showed that 
Chapter VII – General Discussion & Future Perspectives 
 176 
RvD1 is totally released from Ch scaffolds in 72h. We hypothesize that the amount of RvD1 
released in the bone defect was not enough to induce a higher modulatory effect, or that it 
would be necessary to maintain the release of RvD1 after the 72h.  
 
So, in the last chapter of this thesis (chapter VI) we decided to develop a new strategy to 
improve the release through the time of RvD1 together with the increase of RvD1 half-life. 
In order to achieve this objective, we decided to use SLNs as the delivery system for RvD1. 
Solid lipid nanoparticles have been described as being a rather adequate delivery system 
of hydrophobic drugs that are able to improve the physical stability and controlled release. 
Up to now we were able to optimize RvD1 stability [52, 53]. RvD1-loaded SLNs produced 
in the day before to be used in human macrophages showed an anti-inflammatory effect, 
leading to a decrease in the release of pro-inflammatory cytokines, IL-6 and TNF-a after 
LPS priming. The results obtaining until now seem to be rather promising and further 
developments in the framework of this thesis project would include the validation of the 
developed strategy with the RvD1-loaded SLNs.  
 
Overall in the scope of this thesis, we brought new insights on the role of NLRP3 
inflammasome in macrophages response to Ch, showing for the first time that macroscopic 
Ch-based products modulate NLRP3 inflammasome activation, impairing the priming step 
on primary mouse and human macrophages. We also developed, characterized and 
validate an immunomodulatory material that was able to promote the transition from M1 to 
M2 macrophage polarization in an in vivo model of inflammation. Finally, we verify in an in 
vivo model of bone repair, that RvD1 has an effect on bone healing, and we were able to 
develop a delivery system for RvD1 increasing the stability and the half-life of this pro-
resolving mediator. 
 
The work presented in this dissertation will strongly impact the community that addresses 
the macrophage response to biomaterials, and hopefully, also the clinical investigation to 
ultimately developed target materials to improve bone repair. 
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2. FUTURE PERSPECTIVES 
 
In chapter III we describe our studies regarding NLRP3 inflammasome activation in the 
presence of macroscopic 3D Ch scaffolds. Following our outcomes, we believe that it will 
be of great interest to perform in vivo studies on KO mice for NLRP3 components, to explore 
in detail the role of NLRP3 inflammasome in the in vivo immune response to implanted 3D 
Ch scaffolds. The in vivo studies could further highlight the function of NLRP3 
inflammasome in the immune response to implanted biomaterials.  
We truly believe that understanding the signaling that is elicited by inflammasomes could 
be useful to abrogate fibrosis and to improve tissue healing. Therefore, modulation of 
inflammasome activity can be an important target to develop effective strategies for 
biomaterial integration which represents one of the most important challenges in the 
biomedical research and clinical medicine. 
 
Afterwards we have developed an immunomodulatory biomaterial that is detailed described 
in chapter IV, 3D Ch scaffolds impregnated with the specialized pro-resolution mediator 
RvD1. The results obtained were rather interesting since we were able to control in vivo the 
macrophage phenotype. As the results were very promising, we consider that it would be 
of great interest to explore in detail the use of this specialized pro-resolution mediators, 
namely Maresin 1 (macrophage mediators in resolving inflammation) that act specifically on 
macrophages and have an important role in re-establishing the tissue homeostasis. We 
predict that the use of maresin 1 could give rise to interesting results concerning the 
modulation of macrophage polarization. 
 
The results obtained on the research work described in chapter V, as explained in the 
previous section, were not as significant as expected which lead us to develop the strategy 
described in chapter VI. Nevertheless, it would be important to perform the in vivo studies 
in the rat femoral defect model using higher concentrations of RvD1 to asses if better 
outcomes would be achieved.In addition, it would be also interesting to perform the studies 
at different time points to evaluate the effect of RvD1 over time and in the different phases 
of bone repair and also to try to correlate the immune response observed with bone tissue 
repair. 
 
Regarding the work described in the chapter VI, future studies to validate the use of SLNs 
as an interesting delivery system to increase the half-life and the release time of RvD1 will 
be crucial, namely the entrapment efficiency assay and release studies to verify if the 
release of RvD1 through time. Afterwards, it would be also of keen interest to verify, in vivo 
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in the model of bone tissue repair discussed in chapter V, if the RvD1-loaded SLNs have 
the ability to improve bone repair. In order to use RvD1-loaded SLNs at sites of bone injury, 
SLNs would need to be combined with Ch scaffolds, and thus allowing its implantation, 
making possible a controlled and localized release of RvD1 which, in our view, could 
improve bone healing. To achieve this purpose, we already start to explore different 
approaches to combine the SLNs with Ch scaffolds, but additional tests must be performed, 
such as, a deeply physical characterization of Ch scaffolds after the incorporation of the 
SLNs. 
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